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Role of metals in the mechanism of action of antimalarial peroxides 
Names of drugs 
 
When existing, the trivial name of antimalarial drugs is used (e.g. chloroquine, …). In other cases, 
we use either the name given by the authors (e.g. OZ277, RKA182, PA1103, …) or a systematic 
numbering. 
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Chapter 1. Alkylating properties of antimalarial 
peroxide-containing drugs: A focused review 
I. Malaria and the Plasmodium parasite 
I.1. Plasmodium species 
Malaria is due to a blood infection by protozoan 
parasites of the genus Plasmodium, which is transmitted 
from a human to another by the bites of female 
Anopheles mosquitoes. Five species of malaria parasite 
can infect humans (Table 1). Plasmodium falciparum is 
the most virulent species and is responsible for most of 
the mortality associated with malaria, especially in 
Africa.[1] 
Plasmodium was often used in the early 1930s as a 
pyretic agent for the treatment of neurosyphilis, caused 
by a thermo-sensitive bacteria.[2] The first natural 
infection of P. knowlesi in a human was reported in 
1965,[3] but it was not considered an important public 
health concern until 2004. Very recently, several fatal 
cases of P. knowlesi have been reported in Southeast Asia.[4,5] 
I.2. Malaria: Brief history and today’s world situation 
Malaria has been present since ancient times and many cases of malaria are reported in writings 
from old civilizations. Hippocrates described the various malaria fevers of man by 400 BC.[6]  
It is believed that malaria has shaped the course of history of millennia.[7] Kings, popes, and 
military leaders were struck down in their prime by malaria. Many great warriors succumbed to the 
disease after returning from the warfront and in many conflicts, more troops were killed by malaria 
than in combat.[7]  
Until the twentieth century, malaria was widespread on all continents, including Europe and North 
America.[8] After World War II, the Global Malaria Eradication Programme was launched by the 
World Health Organization (WHO), with the objective to eliminate the disease totally.  
Table 1: Species of Plasmodium that infect 
humans 
• Plasmodium falciparum: responsible of 
the most serious form of the disease, 
especially in Africa. 
• Plasmodium vivax: most geographically 
widespread but produces less severe 
symptoms than P.falciparum. 
• Plasmodium malariae: can persist in the 
blood for very long periods without 
producing symptoms. 
• Plasmodium ovale: rare and generally 
infects in Africa.  
• Plasmodium knowlesi: simian parasite, 
rare and limited to Southeast Asia but can 
be virulent and result in death. 
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Widespread use of dichlorodiphenyltrichloroethane 
(DDT) insecticide, coupled with the wide use of the 
drug chloroquine, resulted in eradication of malaria in 
Europe and North America. This initiative had 
successes but, face to the emergence of resistances to 
both DDT and chloroquine, the global eradication was 
considered impossible and then abandoned in the 
early 1970s. Since then, the burden of malaria has 
increased substantially in many parts of the world.[1]  
 
Today, malaria is curable and preventable but it is still the most important parasitic infection and 
one of the major causes of mortality. According to recent estimates by the WHO, there are 
approximately 300-500 million cases of malaria and about 1 million deaths each year, the vast 
majority of which are African children under five.[9,10] Pregnant women are also especially 
vulnerable. With more than a third of the world’s population living in endemic areas, malaria is a 
serious global health and developmental challenge in Africa, South-East Asia and the Amazon 
region of Latin America (figure 1).  
 
 
 
 
 
 
 
 
 
Figure 1: Malaria endemic regions in 2004[11] 
Global warming and other environmental factors, added to 
migration of populations, may have contributed to the 
spread of malaria into some previously malaria-free 
regions. This situation could deteriorate even more as 
available drugs are failing due to resistances.[9] 
Table 2: Nobel Prizes in malaria 
• Sir Ross, 1902: British bacteriologist, 
discovered the role of Anophele mosquitoes in 
the transmission of the disease 
• Laveran, 1907: French army surgeon, 
discovered the Plasmodium parasite 
• Wagner-Jauregg, 1927: Austrian professor in 
psychiatry, discovered the therapeutic value of 
malaria inoculation in the treatment of 
dementia paralytica 
• Müller, 1948: Swiss chemist, inventor of DDT 
Table 3: Malaria world situation[11,12] 
• 247 million malaria cases in 2006 
• About 1 million deaths in 2006, mostly 
children under 5 years 
• 3.3 billion people at risk 
• 109 countries in endemic areas in 2008 
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I.3. Life cycle of Plasmodium 
The malaria parasite has a complex life cycle[9] that requires two hosts: the intermediate human host 
for the asexual stages, and the definite Anophele mosquito host, for the sexual stages (figure 2). 
Human host: When the infected mosquito takes a blood meal, it injects saliva that contains 
sporozoites, the infectious form of the parasite, into the bloodstream of its victim. The sporozoites 
migrate to the liver where they multiply in the hepatocytes and develop into schizonts. After 
approximately one week, the mature schizonts burst out and release merozoites that return to the 
bloodstream and invade the erythrocytes. Once in the erythrocytes, the merozoites develop into 
ring forms, then trophozoites (feeding stage) and form schizonts again. The schizonts mature, 
rupture the cell, and release merozoites to the bloodstream, where they invade other red blood cells 
(RBCs) to achieve a new asexual cycle. The synchronous rupture of RBCs (each 48 or 72 h 
depending on the parasite species) is associated with the rythmic fever accesses and other symptoms 
of malaria. Some of the newly formed merozoites do not develop into schizonts but change to the 
sexual stage called gametocytes.  
 
Figure 2: Life cycle of Plasmodium (adapted from[13])                                                                                                         
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Mosquito host: Gametocytes do not develop in humans but are extracted by a mosquito during 
another blood meal. Inside the mosquito stomach, gametocytes produce male and female gametes. 
The fertilization then produces oocytes filled with sporozoites. When the oocytes mature, they burst 
out and sporozoites migrate to the salivary glands of mosquitoes, where the cycle can start over 
again when the mosquito bites its next victim. 
The initial liver stage of malaria infection is asymptomatic. As the rupture of infected RBCs and 
reinvasion in responsible for the symptoms, many efforts have dealt with the erythrocytic stage of 
the parasite. As a result, most of antimalarial drugs are active on this stage. 
I.4. Clinical features of malaria 
For most people, symptoms begin 10 days to 4 weeks after infection, although a person may feel ill 
as early as 8 days or up to 1 year later. Clinical attacks of malaria normally begin with influenza-
like symptoms, fever often accompanied by a headache, muscle stiffness and shaking, sometimes 
also vomiting and diarrhoea. Severe malaria includes anemia, organ failure, and cerebral malaria. If 
untreated, severe malaria lead to coma and death.[14] 
I.5. Vaccine 
No vaccine is currently available to prevent malaria. However, many vaccine candidates are in 
development, the most advanced to date being the RTS,S vaccine, developed by the pharmaceutical 
company GlaxoSmithKline (GSK) in partnership with Malaria Vaccine Initiative (MVI).[15] RTS,S 
has been designed to prevent from the pre-erythrocytic parasites i.e. invasion of the blood. Results 
of RTS,S in endemic areas are very promising so far, as it reduces the risk of clinical malaria, 
delays time to new infection, and reduces episodes of severe malaria for at least 18 months. RTS,S 
has recently entered Phase III clinical trials.[16] 
I.6. Host hemoglobin digestion and heme detoxification by Plasmodium  
Once in the red blood cell, Plasmodium needs amino acids to synthesize its own proteins. A major 
source of amino acids is provided by the digestion of the host hemoglobin.[17] Hemoglobin is one of 
the major components of the erythrocyte with a concentration of 5 mM, corresponding to a 
concentration of iron-heme of 20 mM (ferroprotoporphyrin IX, FePPIX). The malaria parasite 
degrades up to 65% of the hemoglobin in the host cell, both for its development and to create space 
with the digestive vacuole.[18,19] This digestion by protease enzymes releases peptides, degraded to 
amino acids,[20] and a high concentration of free iron(II)-heme as a by-product. Like for every living 
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cell, iron(II)-heme is toxic to the parasite at micromolar concentration, i.e. several orders of 
magnitude below the total heme concentration in the red blood cells, as it can reduce molecular 
oxygen and generate reduced oxygen species (O2•- and H2O2) that produce HO•.[21] In order to 
inhibit the toxic effect of heme, Plasmodium crystallizes it into hemozoin, an inert and insoluble 
aggregate (also called malaria pigment, figure 3).[22,23]  In hemozoin, iron is in oxidation state III, 
i.e. no more able to reduce molecular oxygen.  
 
Figure 3: Host hemoglobin degradation pathway and hemozoin formation 
The exact mechanism of hemozoin formation, although still unclear, involves histidine-rich protein 
II (HRPII),[24-26] a protein secreted by the parasite and mainly constituted of histidine residues 
(34%).[26] Kannan et al. reported that HRPII can bind 17 molecules of heme in vitro at pH 5, the 
pH of the parasite food vacuole, and up to fifty molecules at pH 7. This binding, probably by 
coordination of histidine residues of HRPII as axial ligand of iron atom of heme, should result in 
local concentration of heme favorable to initiate heme polymerization. The growing of chains is 
then independent on the presence of HRPII, which is consequently not a true “polymerase”. 
 
The structure of hemozoin has been a topic of debate for years. It has been finally reported that its 
spectroscopic properties are identical to synthetic β-hematin, formed by polymerization of heme 
under controlled conditions (pH, salt concentration, …). Structure determination using X-ray 
powder diffraction by Pagola et al. has revealed that hemozoin is constituted by heme dimers, 
interacting through hydrogen bonding.[27,28] Within the dimer, the heme units are linked to each 
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other by an iron-carboxylate bond: the propionate carboxylate side chain of one heme is coordinated 
to the iron atom of the next heme (figure 4). Each heme then contains a pentacoordinated iron(III), 
with no possibility to be reduced. Any perturbation of this heme detoxification process is expected 
to have a drastic impact for the parasite survival. 
 
Figure 4: Two unit cells of the crystal structure of β-hematin dimers from Pagola et al.[27] 
Because of their importance for the parasite survival, the hemoglobin degradation and hemozoin 
formation processes are effective targets for therapeutic intervention.  
Other processes of the asexual blood stage of the parasite have been identified (folate biosynthesis, 
protein synthesis in the apicoplast, electron transport in the mitochondrion, etc). However in this 
review we will only focus on drugs that target heme and interfere with its detoxification process.    
II. Quinoline-based drugs:  Over a century of use 
II.1. Conventional treatment 
Quinoline-containing drugs have been the mainstay of malaria treatment for the past 50 years. 
Among them, quinine, chloroquine (CQ), and mefloquine (MQ) are the most widely used 
clinically.[29] This part summarizes the current knowledge on their common mechanism of action, 
with a focus on the role of heme in the antimalarial activity of these three quinolines. [30,31]  
 
Figure 5: Structures of quinoline drugs 
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It should be mentioned at this point that quinine, chloroquine, and mefloquine contain one or more 
stereogenic centers. Only quinine, a natural product, is clinically used as a single optic isomer. 
Chloroquine is used as a racemate and mefloquine, which contains 2 stereogenic centers, is also 
used as a racemic mixture (11S,12R and 11R, 12S). Enantiomers of chloroquine and mefloquine 
exhibit the same antimalarial activity, in the limits of experimental variability.[32]  
a. Quinine 
Quinine, an aryl-amino alcohol (figure 5), is the oldest agent used for the treatment of malaria. It is 
extracted from the bark of the Cinchona tree, which was first imported into Europe from Peru for 
antimalarial use in the seventeenth century.[33] Since then, quinine has been the treatment of choice 
for intermittent fever throughout the world. In 1820, the French pharmacists Pelletier and Caventou 
isolated quinine from cinchona bark, and its first total synthesis was reported in 1944 by Woodward 
and Doering, but this claim has been a matter of debate until very recently (see Appendix 1). 
Approximately 300–500 tons/year are produced commercially by extraction of the bark from 
various cinchona species that are now widely cultivated. About 40% of the quinine goes into the 
production of pharmaceuticals, while the remaining 60% is used by the food industry as the bitter 
principle of soft drinks, such as bitter lemon and tonic water.[33] 
Quinine has been widely used until the 1930s, when other synthetic drugs like chloroquine 
appeared. However, quinine is still employed for the treatment of severe malaria,[34,35] although 
there are reports on declining efficacy in South America and Africa.[36,37]  
The mechanism of action of quinine is still not fully elucidated, but it has been established that this 
quinoline interacts with heme in the food vacuole of the parasite.[38,39] This mechanism, common to 
chloroquine, is further detailed in the next section. 
b. Chloroquine 
Chloroquine (CQ, figure 5) is a 7-chloroquinoline ring substituted by a N,N-diethyl-1,4-pentane 
diamine in para position of the quinoline hydrogen. Thanks to its excellent properties, chloroquine 
has been the drug of choice for more than forty years (1940s – 1980s): it is easy and cheap to 
produce, well tolerated, safe for use by pregnant women and children, and used to be highly 
effective against the blood stages of Plasmodium.[40]  
Chloroquine, usually prepared as a diphosphate salt of the racemate, is a diprotic weak base (pKa1 
= 8.1 cycle, pKa2 = 10.2 chain) that mainly exists in both mono- and di-protonated forms within the 
biological pH. The neutral (CQ) and mono-protonated (CQH+) chloroquine species may enter in 
the cytoplasm of the parasite (pH ∼ 7) and diffuse across the membranes to reach the acidic food 
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vacuole (pH ∼ 5).[41] In the food vacuole, the equilibrium is completely shifted toward the di-
protonated species CQH22+. The drug is then “trapped” in this compartment, where it rapidly 
accumulates, potentially reaching millimolar concentrations (figure 6).[42]  
 
Figure 6: Chloroquine accumulation in the food vacuole of the parasite 
The total concentration of heme released in the food vacuole by hemoglobin digestion has been 
estimated at 400 mM.[43] Chloroquine is thought to exert its antimalarial effect in the food 
vacuole by binding heme and interfering with its detoxification process.[38,39] The ability of 
chloroquine to inhibit hemozoin formation has been shown both in vitro and with P. falciparum 
cultures.[44,45] Several studies, including modeling experiments, showed that the complex 
chloroquine-heme is based on an energetically favorable pi-pi stacking interaction between the 
quinoline heterocycle of CQ and the metalloporphyrin ring of hematin dimer.[31,38,46]  Sullivan and 
co-workers suggested that the chloroquine-heme complex incorporates into the growing hemozoin 
crystal to terminate chain extension, blocking further sequestration of toxic heme.[43] The heme-
chloroquine complex itself has been shown to be toxic to the parasite.[47] 
Unfortunately, massive use of chloroquine has resulted in the emergence of resistant P. falciparum 
strains in the 1960s and their widespread in nearly every endemic region throughout Asia and then 
Africa.[48] Today, more than 80% of field isolates of Plasmodium falciparum are resistant to CQ.[49] 
The mechanism whereby P. falciparum becomes resistant to chloroquine is complex. Fitch and co-
workers showed that accumulation of CQ in resistant parasites is less important than in sensitive 
strains.[29,50] This lower accumulation is due to a higher efflux of chloroquine: resistant parasites 
have been found to release CQ up to 50 times more rapidly than the susceptible parasites.[51]   
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The resistance is associated with mutations (K76T) in the Chloroquine Resistance Transporter 
(PfCRT), a protein located on the membrane of the parasite digestive vacuole.[52-54]  
c. Mefloquine 
Mefloquine (MQ, figure 5) belongs to the 4-methanolquinolines subclass and is structurally related 
to quinine. It was introduced in the 1980s to treat chloroquine-resistant malaria. Today, mefloquine 
is used for prophylaxis (eg Lariam®) and to treat uncomplicated malaria, in combination with other 
drugs. Mefloquine displays high activity against chloroquine-resistant strains.[55] However, 
resistance to mefloquine is spreading.[56] In addition, mefloquine is quite expensive, then 
unaffordable for many patients in Africa, and it is well established to be neurotoxic, for a review see [57] 
and associated with psychiatric side effects, probably due to the presence of the (-)-erythro 
diastereoisomer in the mixture. Clinical studies are ongoing with the pure (+)-erythro 
diastereoisomer, to determine whether it has a better safety profile.[58]  
As for chloroquine, MQ was shown to interact with heme, but it has also been proposed that 
phospholipids are a second target for this quinoline.[59] 
II.2. Old pharmacophore for new drugs: N-tert-butyl Isoquine and 
Ferroquine 
Because of the widespread of quinoline resistances, there is an urgent need of new antimalarial 
drugs. One possibility is to re-design quinoline-based drugs and prepare chloroquine derivatives 
that are still able to interact with heme by pi-stacking, but can escape drug resistances.[60]  In this 
purpose, several chloroquine analogues with a shorter side chain have been prepared. They are 
active against P. f. chloroquine-resistant strains (IC50s below 15 nM against CQR strains).[61] 
However, the main drawback with these compounds is that they readily undergo metabolic N-
dealkylation in vivo, producing metabolites that are less potent than the parent drug.[62] For these 
compounds, the in vitro activity is not translated into good in vivo activity. Other analogues with 
metabolically more resilient side chain have been prepared. These second-generation compounds 
display good activity both in vitro and in vivo.[63] 
Another strategy is to develop drugs with modified quinoline structures. Several synthetic 
quinoline-based drugs have been produced. The most important of these were amodiaquine (1951), 
primaquine (1952), halofantrine (1966) and, in the past 30 years, piperaquine and lumefantrine. All 
of these drugs interfere with the detoxification of heme, although there are important differences in 
their activities. We report here the synthesis and pharmacological properties of two new promising 
4-aminoquinoline derivatives: N-tert-butyl isoquine and ferroquine. 
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a. N-tert-butyl Isoquine (GSK369796) 
O’Neill, Ward and co-workers have designed and prepared a series of promising 4-aminoquinolines 
antimalarials. Among them is the drug candidate N-tert-butyl isoquine (NTBI, figure 8). NTBI is 
currently developed in a public/private partnership between GSK pharmaceuticals, Medicines for 
Malaria Venture (MMV), and the University of Liverpool. This compound has completed 
preclinical evaluation and entered phase I clinical trial in April 2008.[64] 
NTBI is related to amodiaquine (AQ, figure 7), a drug active against chloroquine-resistant strains 
of P. falciparum, but associated with potential cardiotoxicity and hepatotoxicity.[65] This toxicity 
results from the P-450-catalyzed oxidation of the 1,4-aminophenol ring and the formation of 
reactive quinine-imine (figure 7).[66]  
 
Figure 7: Oxidation of amodiaquine to a reactive quinine-imine metabolite 
In a first attempt to prevent this metabolism-dependent toxicity, the positions of the hydroxyl and 
the diethylaminomethyl residue at the phenyl ring have been interchanged. The resulting 1,3-
aminophenol isoquine (IQ, figure 8) does not form quinine-imines and exhibits good oral in vivo 
activity (ED50 = 3.7 mg/kg vs. P. berghei ANKA compared to amodiaquine ED50 = 7.65 mg/kg).[67] 
Subsequent metabolism studies in the rat model demonstrated that isoquine does not undergo in 
vivo bioactivation. However, a drawback of isoquine is its low oral bioavailability in animal 
models, due to extensive metabolism of the N-diethylamino side chain. Further studies in this area 
have revealed that replacement of the diethylamino moiety by a tert-butylamine avoids too rapid 
biotransformation.  
 
Figure 8: Structures of amodiaquine, isoquine and N-tert-butyl isoquine 
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The resulting N-tert-butyl isoquine displays potent in vitro and in vivo activity (ED50 = 2.8 mg/kg 
and ED90 = 4.7 mg/kg against P. berghei ANKA).[68] Detailed study of drug metabolism and 
pharmacokinetics (DMPK), in four animal species including primates, showed that NTBI has a 
safer profile than chloroquine. In addition, no cross resistance with any clinically used antimalarial 
drug has been observed so far.[69]  
Synthesis of NTBI has been optimized and allows the preparation of the drug with fairly good yield 
(57%) from the readily available 4,7-dichloroquinoline.[70] Molecular modeling of the interaction of 
the NTBI with heme showed that, in the most 
favorable complex, the aromatic quinoline ring is 
parallel to the edge of the hematin, consistent with a π-
π stacking interaction. There is also a favorable 
hydrogen-bonding network between the carboxylate 
groups of the hematin and both the alcohol and 
protonated amine of the Mannich side chain.  
          Model of the most favorable hematin-NTBI complex. 
For clarity, only hydrogens involved in hydrogen bonds are 
shown.[68] 
b. Ferroquine (SSR97193) 
Inspired by work of Jaouen’s group on ferrocene-containing tamoxifen analogues,[71,72] Brocard and 
co-workers have prepared several derivatives of antimalarial drugs, bearing a ferrocene 
(dicyclopentadienyl iron (II), Fc) in their side chain.[73] Ferroquine (FQ, figure 9), a 4-
aminoquinoline linked to a ferrocenyl moiety, was selected from a first screening and is currently in 
phase IIb clinical trials by Sanofi-Aventis.[74] 
 
Figure 9: Structure of ferroquine 
Ferroquine is active against various chloroquine-sensitive and chloroquine-resistant laboratory 
strains (IC50 = 11 - 22 nM)[75] as well as various field isolates (IC50 = 0.4 - 47.0 nM).[76-81] In a 
mouse model, ferroquine is curative at 10 mg/kg.[75]  
Synthesis of ferroquine is simple from relatively inexpensive materials.[73,82] FQ exhibits planar 
chirality inherent to the 1,2-substitution of the ferrocene cyclopentadienyl ring. Both the (1’R)-FQ 
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and (1’S)-FQ enantiomers have been prepared using bio-catalysis and tested against P. falciparum. 
They exhibit the same activity in vitro and a slightly different activity in vivo, believed to be due to 
different pharmacokinetic properties.[75] The overall close properties of the two enantiomers allow 
ferroquine to be formulated as a racemic mixture for its development. 
Investigations of the physicochemical properties showed that FQ is more lipophilic than CQ at 
vacuolar pH, suggesting that its accumulation in the food vacuole is less significant than CQ.[83] 
In vitro inhibition assays showed that the drug candidate FQ is a strong inhibitor of β-hematin 
formation, in a higher extent than CQ.[83] These data suggest that the two drugs share a similar 
mechanism of action e.g. inhibition of hemozoin formation by interaction with intra-vacuolar heme. 
Furthermore, EPR and spin trapping experiments in the Fenton conditions put into evidence the 
generation of hydroxyl radicals from the oxidation of the ferrocene into ferricinium.[84] In vivo, 
radical concentration would be high enough to induce significant damage on the parasite 
membranes.  
It was also reported that FQ generates HO• in the presence of H2O2 and this redox activity of the 
ferrocene moiety was suggested to be “a possible discriminating property from CQ in the 
antimalarial activity” of the two drugs.[84] However, concentrations as high as 1 mM – i.e. 5 to 7 
order of magnitude above the steady-state of H2O2 in living cells (10-7 to 10-9 M) - were required for 
a hydroxyl radical production of 0.5 µM (calculated yield: 0.017%). In addition, at so low 
concentration of hydroxyl radicals, a contamination by iron salts cannot be excluded.  
Ruthenocene analogues of ferroquine have also been synthesized. First results showed similar in 
vitro antimalarial activity, suggesting that the physical properties of ferroquine may be more 
prevalent than the chemical reactivity of the metallocene moiety.[85]  
As expected, the major metabolic pathway of ferroquine by P450s is demethylation of the side 
chain amine leading to the mono- and the di-demethylated derivatives.[86] Interestingly, this 
metabolites are still more active than CQ.[80] 
Ferroquine exhibits good therapeutic index and did not show cross resistance with chloroquine.[75,87] 
Because of the lipophilic ferrocenyl moiety, authors proposed that ferroquine does not fit into the 
substrate binding site of the chloroquine resistance transporter (PfCRT). The mutational status of 
the pfcrt gene did not influence the compound activity. 
Using a strategy similar to the design of ferroquine, ferrocene conjugates of quinine and mefloquine 
have been prepared, as well as artemisinin and atovaquone conjugates. However, the biological 
activities of the new compounds were lower than that of the parent drugs.[88-91] 
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III. From the natural artemisinin to new synthetic peroxide-
containing drugs: A new era in malaria chemotherapy 
The discovery of artemisinin and its derivatives is another milestone in the history of antimalarial 
drug research since the discovery of quinine. After a brief introduction on the chemistry and 
pharmacological aspects of artemisinin and other peroxide-containing drugs, we will focus this 
review on the radical chemistry and alkylation properties of artemisinin and synthetic peroxides. As 
we will see, a good knowledge of the basis of mechanism of action of artemisinin and derivatives 
allowed the rational design of new active compounds.  
III.1. Artemisinin (Qinghaosu): a natural peroxide drug from the Chinese 
traditional medicine 
Artemisinin (figure 10) has a structure that differs from the classical quinoline-based drugs. In 
1972, isolation and characterization of artemisinin revealed that the main structural feature of this 
natural tetracyclic compound is the unusual 1,2,4-trioxane cycle.[92] Artemisinin, also called 
qinghaosu, is extracted from the leaves of the Chinese wormwood Artemisia annua (Qing hao).[93] 
This herb was specifically recommended for fevers in the Zhou Hou Bei Ji Fang, a Chinese 
handbook of prescriptions published in 341 AD. Thereafter qing hao appears in several standard 
Chinese texts as a treatment for febrile illnesses.[94] In a research effort apparently prompted by the 
requests of Ho Chi Minh to the Chinese minister Zhou EnLai for antimalarial drugs to protect his 
Vietnamese troops, the scientists identified the active antimalarial principle, characterized its 
physicochemical properties, conducted in vitro and in vivo studies.[95] 
It is known that the peroxide bond of artemisinin is essential for its antimalarial activity as 
deoxyartemisinin (figure 10), for which the peroxide bond is replaced by an ether bridge, is totally 
inactive.[92]  
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Figure 10: Artemisinin, Artemisia annua, C10-derivatives and inactive derivatives of artemisinin. In vitro activity 
against the P.f. chloroquine-resistant strains K1 or W2 is reported 
Artemisinin is the fastest acting antimalarial and kills all Plasmodium species that infect humans. In 
particular, it is highly active against both chloroquine sensitive- and resistant-strains of P. 
falciparum in the nanomolar range.[92,96] More important, artemisinin is active against all 
erythrocytic stages of Plasmodium, including young rings and gametocytes, the sexual form of the 
parasite.[97-99] Effect on young-ring stages prevent their development to the more pathological 
parasites, while activity on gametocytes is important for the control of transmissibility. Indeed, the 
introduction of artemisinin derivatives in routine treatment has been associated with a reduction in 
the subsequent incidence of P. falciparum of 47% in Thailand.[98]    
In addition of its strong antimalarial efficacy, artemisinin exhibits also some activity against 
Schistosoma, although the required doses in infected mice are prohibitive for use in monotherapy 
(200 to 400 mg/kg).[92,100] Artemisinin has been also shown to be potent against specific breast and 
prostate cancer cell lines.[101] 
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Total chemical synthesis of artemisinin is possible and several stereoselective methods have been 
reported since 1983.[102-104] However, synthesis requires many intermediate steps (>10 steps) that 
would make this approach too expensive for endemic countries. 
In healthy volunteers, orally administrated artemisinin is mainly metabolized during the first hepatic 
pass into inactive metabolites such as deoxyartemisinin and deoxydihydroartemisinin. This high 
first pass clearance is responsible for the moderate oral bioavailability of the drug (32%) compared 
to intramuscular oil.[105] 
III.2. Artemisinin semi-synthetic derivatives and ACTs 
In order to improve the solubility of artemisinin, C10-modified derivatives have been prepared. 
Their semi-synthesis starts with the reduction of artemisinin lactone carbonyl at C10 with NaBH4 to 
produce the lactol dihydroartemisinin (DHA, figure 10). DHA, itself highly active, is next used for 
the preparation of the clinically used artemether and artesunate, obtained by methylation and 
acylation with succinic acid, respectively (figure 10). Both compounds are more potent than 
artemisinin but have short plasma half-lives (c.a. 40-60 min) and are rapidly metabolized to DHA, 
which can then be eliminated in urine as a glucuronide metabolite.[106] These short half-lives can be 
associated to high recrudescence levels. 
Artemisinin and derivatives have proved to be well tolerated and safe drugs. Based on animal 
studies, a concern that has been raised was the possible neurotoxicity of artemisinin and 
derivatives.[107,108] However, no significant toxicity has been reported in patients, although 
artemisinin and derivatives have been extensively used in various formulations for years.[109-111] 
There is evidence that artemisinin is safe for pregnant women; however the drug is not 
recommended in the first trimester of pregnancy, except in severe malaria.[95] 
Artemisinin and its derivatives are active against malaria parasites at nanomolar concentrations, but 
micromolar concentrations are required for toxicity to mammalian cells. One reason for this 
selectivity is the enhanced uptake of the trioxane drug by the parasite; P. falciparum infected 
erythrocytes concentrate [3H]-dihydroartemisinin and [14C]-artemisinin to a >100-fold higher 
concentration than do uninfected erythrocytes.[112,113]  
Extensive work has been carried out to improve the pharmacokinetic properties of the first 
generation analogues of artemisinin and several compounds, resulting from modifications on the C-
10 position, have emerged as potential next-generation artemisinin derivatives. [114-117] Among these 
derivatives, artemisone (figure 10) has completed phase II clinical trials with Bayer and MMV.[118] 
Chapter 1: Alkylating properties of antimalarial peroxide-containing drugs: A focused review 
16 
 
The compound was not found to be dramatically superior to artemisinin.[119] However, artemisone 
gave good results on patients who had showed longer parasite clearance times with artemisinin.[120] 
Artemisinin Combination Therapy (ACT): To prevent the development of further resistances to 
antimalarial drugs, the World Health Organization guidelines recommend the use of artemisinin in 
combination with a more slowly eliminated antimalarial drug (ACT).[12]  
The rationale for ACTs (3 days regimen) is that the short-acting but highly potent artemisinin 
derivative delivers a rapid reduction in parasite biomass (reduction by a factor ∼ 108 in parasite 
number), with the remaining parasites (up to 105) being removed by the less active but more slowly 
eliminated partner drug, structurally unrelated to artemisinin.[121] Distinct modes of action of 
artemisinin derivatives and partner drugs should, in theory, enable the combination to kill parasites 
that manifest decreased sensitivity to one agent alone, and thus avoid or delay emergence of 
resistances.[9] The first ACT to be evaluated was artesunate-mefloquine, but the fixed-dose 
artemether-lumefantrine combination (Coartem, Novartis) represents 75% of the ACT market 
today. Other used combinations are artesunate-amodiaquine (Coarsucam, Sanofi-Aventis), 
artesunate-sulfadoxine-pyrimethamine, artesunate-mefloquine.[12,122]  
Despite the high efficacy of ACT, a major obstacle to large-scale use of ACTs is their cost; they are 
up to twenty times more expensive than monotherapy (artemether-lumefantrine costs around US$ 
0.9-1.4 for a child and US$ 2.4 per adult treatment dose, compared to US$ 0.34 for 
chloroquine).[123,124] The use of artemisinin and derivatives has been limited: the only source of 
artemisinin is the plant Artemisia, with short and unreliable supply. As already mentioned, the total 
synthesis of the parent drug artemisinin is not an option as it would make them too costly for 
developing countries. Studies are ongoing to improve and sustain artemisinin supply. They include 
maximization of artemisinin production by genetic modification of the plant[125] and production of 
the artemisinic acid precursor in engineered yeast.[126]  
In addition to their cost, a decline of artesunate-mefloquine ACT efficacy against P.falciparum has 
been observed in the Thai-Cambodian border region, the historical source of resistance to 
antimalarial drugs (chloroquine, …). This reduced susceptibility might be due to high-level of 
mefloquine resistance, as the drug was used for monotherapy long before the introduction of 
ACT.[127] However, a more worrying decline of in vivo susceptibility to artesunate in the same 
region, along with prolonged parasite time clearance, has been recently reported.[128-130] Although it 
is not clinically relevant yet - no artemisinin-resistance isolate has been characterized - resistance of 
P. falciparum to artemisinin derivatives appears to be a real threat.  
Chapter 1: Alkylating properties of antimalarial peroxide-containing drugs: A focused review 
17 
 
Toward synthetic peroxide drugs. 
The disadvantage of all of the semisynthetic compounds described is that their production requires 
artemisinin as starting material. To circumvent this problem, a number of groups have attempted to 
produce totally synthetic peroxide analogues that are fast acting, highly potent against asexual blood 
stage infections, non-toxic, and affordable to residents of endemic regions. Some of these 
compounds demonstrate promising results. These include endoperoxide analogues such as arteflene, 
simplified 1,2,4-trioxanes, the dispiro-trioxolanes and dispiro-tetraoxanes, and trioxaquines.  
III.3. Synthetic peroxide-containing drugs 
Mechanism-based rationale drug design has allowed the synthesis of numerous peroxides over the 
last three decades. We will discuss here about the most advanced in terms of development and 
knowledge of their reactivity. After a rapid presentation of their pharmacological activity, we will 
focus on their common reactivity toward iron and heme.  
 
Figure 11: Structures of peroxide-containing antimalarial drugs. In vitro activity against the P.f. chloroquine-
sensitive (3D7) and -resistant strains FcB1, K1 or W2 is reported 
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a. Arteflene 
Arteflene (figure 11) is a stable analogue of Yingzhaosu A, a natural endoperoxide extracted with 
putative antimalarial properties isolated from the traditional Chinese herb, Yingzhao (Artabotrys 
uncinatus L).[131] Arteflene contains the 2,3-dioxabicyclo[3.3.1]nonane core of Yingzhaosu 
A.[132,133] It is active in vivo (ED50 = 2.6 mg/kg against P. berghei) and has lower rate of 
recrudescence and a longer plasma half-life than artemether and artesunate.[133] Arteflene was 
selected in the 1990s as the clinical candidate by Hoffman-LaRoche but has been discontinued after 
phase III trials because of high production cost and lack of evident advantages over artemisinin 
derivatives.[134] 
b. Trioxanes 
Several compounds were designed to see whether the tetracyclic framework in artemisinin is really 
essential for its biological activity. Results of this structure-activity relationship suggested that (i) 
small structural changes around the peroxide bond can have a significant effect on the activity,[135] 
and (ii) neither the peroxide function, nor the 1,2,4-trioxane ring alone, are sufficient for maximum 
efficacy.[136] However, (iii) ring A and lactone ring D are not essential for antimalarial activity of 
artemisinin (see figure 10, p 14).[137]  
Based on this observation, Jefford et al. have prepared a large series of cis-fused cyclopenteno-
1,2,4-trioxanes. They showed good activity on chloroquine-resistant Plasmodium strains. Among 
them, the racemate Fenozan BO7 (figure 11) had the most promising activity profile and was 
chosen for further development. The p-fluoro substitution of BO7 has been shown important for its 
in vivo activity: BO7 is as equally active as artemether when administered by oral route (ED90 = 6.0 
mg/kg).[138] 
A series of tricyclic trioxanes was also synthesized by Posner et al. (figure 11).[139] Many of these 
compounds were highly efficacious in vivo, against multidrug-resistant P. falciparum in Aotus 
monkeys, confirming that the lactone ring of artemisinin is not essential for antimalarial activity. On 
the basis of mechanistic observations (vide infra), new trioxanes for which the C3-methyl (trioxane 
1 series) was replaced by a C3-phenyl were prepared by enantioselective synthesis (trioxane 2 
series).[140,141] Among them, 3-fluorophenyltrioxane (figure 11) showed promising in vitro and in 
vivo antimalarial activity.   
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c. Trioxolanes 
Identification of the trioxolane OZ277 (RBx-11160, also called arterolane, figure 11), by 
Vennerstrom and co-workers was a significant breakthrough in antimalarial drug development 
efforts during the past decade.[142,143] The key pharmacophore of OZ277 is the 1,2,4-trioxolane 
cycle (secondary ozonide). Preliminary structure-activity relationship clearly showed that the 
antimalarial activity of dispiro-1,2,4-trioxolanes decreases when the peroxide bond is too exposed 
(3,5-bis-cyclohexane 3, figure 12), or sterically inaccessible (3,5-bis-adamantane 4). A middle 
ground has been met with compound 5, for which one side of the trioxolane cycle is sterically 
hindered by the adamantane moiety, shown to bring stability, while the other side leaves the 
peroxide bond more accessible.[144]  
 
Figure 12: Stability and activity of dispiro-trioxolanes 
A large family of potent trioxolanes has been prepared using the Griesbaum coozonolysis reaction 
with the symmetrical O-methyl 2-adamantanone oxime.[145] However, most of the first trioxolanes 
had limited oral bioavailability due to poor aqueous solubility and high first pass metabolism.[146]  
As the spiroadamantane trioxolane pharmacophore is inherently lipophilic, the polarity of 
trioxolanes was adjusted by addition of an amine or amide side chain.[146] OZ277 has the best 
combination of physic-chemical properties (lipophilicity, aqueous solubility), pharmacological 
properties (metabolism) and antimalarial activity.[142,147] 
OZ277 has in vitro and in vivo activity superior to artemether and artesunate, and completely cures 
malaria-infected mice treated via oral route at 10 mg/day. Its half-life in plasma after intravenous 
injection in the rat is 3 times longer than that of artesunate (1.4 h and 0.47, respectively). Equally 
important is its low susceptibility to metabolic degradation by P450 monooxygenases that give a 
biopharmaceutical profile better than that of artemisinin derivatives.[142] 
Clinical development of OZ277 began in 2003 through collaboration between the University of 
Nebraska, MMV, and Ranbaxy Laboratories Ltd., India.[143] Unfortunately, MMV stopped funding 
the project in 2006, but Ranbaxy is still developing OZ277/arterolane and the trioxolane is 
advancing through phase III in India, Africa and Thailand. MMV is currently supporting the 
development of the next-generation trioxolane OZ439 (figure 11).[119,148]  
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d. Tetraoxanes 
While impressive activity profiles have been observed with the 1,2,4-trioxolane class, it has been 
shown in parallel that the achiral 1,2,4,5-tetraoxane template is more stable compared to ozonides. 
This prediction was confirmed by the observation that 3,5-dicyclohexyl trioxolane (3, figure 13) are 
inactive and unstable, whereas the close tetraoxane 6 is relatively stable and expresses good 
antimalarial activity.[142,149] Tetraoxanes are cyclic peroxides originally used for the production of 
macrocyclic hydrocarbons and lactones.[150,151]  
 
Figure 13: Rationale for dispiro-tetraoxanes 
Work by the Vennerstrom’s group in the early 90’s showed that symmetrical dispiro-1,2,4,5-
tetraoxanes such as WR148999 possess high in vitro antimalarial activity.[152] 
However, despite being more potent than artemisinin in vitro, these compounds 
did not show a good activity when tested orally, probably because of an 
extensive first-pass metabolism.[153]  
Given the observation that introduction of adamantane group is capable of stabilizing the 
endoperoxide 3,[154] O’Neill and co-workers explored 1,2,4,5-tetraoxanes that also incorporate this 
stabilizing motif (7, figure 13). They have designed unsymmetrical dispiro-tetraoxanes, easily 
prepared from inexpensive materials via acid-catalyzed cyclocondensation of bis(hydroperoxides) 
with various ketones. Incorporation of water-soluble and polar functionalities via amide coupling 
produces several simple and achiral analogues.[155] These analogues exhibit remarkable antimalarial 
activities in vitro (IC50 1.5 – 29.4 nM against 3D7) and preliminary in vivo evaluation demonstrates 
that they also have promising oral activities.[154,156]  
From a library of over 150 tetraoxanes, RKA182 has been selected as candidate for full formal 
preclinical development. RKA182 has outstanding in vitro and in vivo activity against P. 
falciparum and shows improved pharmacokinetic characteristics compared to other peroxide drugs 
(see Appendix 2). 
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e. Trioxaquines 
Using a covalent bitherapy approach, Meunier’s 
group has designed and synthesized a family of 
chimeric molecules named trioxaquines (figure 11). 
In this approach, two pharmacophores of known 
modes of action are linked covalently to create a new 
drug with the expectation of achieving a net increase 
in therapeutic efficacy.[157] Trioxaquines combine a 
1,2,4-trioxane, like in artemisinin, and a 4-
aminoquinoline, known from quinoline-based drugs 
to facilitate penetration within infected red blood 
cells and interaction with intra-vacuolar heme.[158]  
The first synthesized trioxaquines were found highly 
active in vitro on both chloroquine-sensitive and 
resistant strains of P. falciparum with IC50 values ranging from 8 to 40 nM, depending on the 
trioxane substituent. As an example, trioxaquine DU1102 was found to be very active in vitro on 
field isolates (IC50 mean value = 43 nM).[159] Trioxaquines have also shown promising results on P. 
berghei and P. vinckei in vivo.[158,160] Like artemisinin, trioxaquine are active against all erythrocytic 
stages of Plasmodium, including gametocytes.[161]  
 
Trioxaquines are currently developed by Palumed S.A. (www.palumed.fr). Among the 120 
trioxaquines that have been prepared and tested so far, PA1103 (figure 11) was selected for further 
development in January 2007 and is currently in pre-clinical trials in association with Sanofi-
Aventis.[162]  
IV. Fe(II)-mediated reactivity of antimalarial peroxides and 
possible drug targets 
IV.1. Reactivity with inorganic salts 
The development of previously described peroxide-containing drugs required knowledge of the 
bases about the mechanism of action of artemisinin at a molecular level. In this part, we review the 
results of biomimetic studies of artemisinin and synthetic derivatives, with ferrous iron. Similar 
mechanistic issues are discussed with synthetic antimalarial peroxides. 
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a. Oxidative stress and lipid peroxidation 
Since peroxides may lead to the production of free radicals, it was first suggested that artemisinin 
might kill the parasite by generation of activated oxygen species such as superoxide O2-• and 
hydroxyl •OH radicals, known to cause cell damage.[163,164] Few studies have reported lipid 
peroxidation and membrane thiol oxidation after membranes were treated with artemisinin or 
artesunate.[163,165,166] However, the peroxidation products were observed only at very high 
concentrations of the drugs (> 100 µM) while the effective concentration of artemisinin is in the 
low nanomolar range, i.e. ∼10,000-fold lower. This observation implies that artemisinin and 
derivatives must have a more selective toxic effect to kill the parasite, rather than random cell 
damage caused by free radicals.[112]  We will see below that this selectivity may be due to alkylation 
of cell components and alter processes that are vital for the parasite.  
b. Reactivity with ferrous salt 
In the early 1990s, Meshnick and co-workers showed that iron, in the form of heme, catalyzes the 
reductive decomposition of artemisinin and dihydroartemisinin in vitro.[167] It has been proposed 
that free intraparasitic heme, released during hemoglobin digestion, might play an important role in 
the selective toxicity of artemisinin toward the parasite.[168] Since then, Posner, Jefford and co-
workers have contributed in a major way to the comprehension of artemisinin chemistry and its 
reductive activation by ferrous iron, used as models of biological iron sources.[169-174]  
The reaction of artemisinin with iron(II) is a reduction reaction via single electron transfer 
from the metal to the antibonding orbital σ* of the peroxide bond. This reductive cleavage of a 
peroxide by a low-valent transition metal ion/complex is a well known reaction of peroxides 
chemistry, by which oxy radicals (O-centered) are generated.  
Since artemisinin is an unsymmetrical peroxide, two different pathways are possible, according to 
the oxygen atom of the peroxide bond (O1 or O2) coordinated on the metal (figure 14):  
 Route 1: Coordination of Fe(II) on O1 provides the complexed oxy radical 8 (O2-centered) 
that readily rearranges via C-C β-scission to the primary carbon-centered radical 9 (seco-
radical). In the absence of alkylable target (vide infra), intramolecular rearrangement of this radical 
leads to the formation of the ring-contracted tetrahydrofuran 10, with expulsion of Fe(II) (figure 
14). This rearrangement is energetically favored by the formation of the acetate group.[175] 
Formation of a C-centered radical by cleavage of the adjacent C–C bond has also been evidenced by 
Jefford, using BO7 as substrate (vide infra).[172]   
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 Route 2: Alternatively, coordination on O2 provides the oxy radical 11 (O1-centered), that 
produces the secondary carbon-centered radical 12 via a 1,5-H shift.[170] Route 2a leads to 4α-
hydroxy-deoxoartemisinin (14, figure 14) with formation of the intermediate 3,4-epoxide 13, first 
postulated[176] and later isolated in low yield (1%).[177] 
 
Figure 14: Fe-mediated activation of artemisinin 
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The 1,5-H shift proposition called into question because the distance between the H-C4 and O1 
(2.478 – 2.803 Å)[173] was suspected to exceed the critical distance for 1,5-H abstraction (2.1 
Å).[174,178] However, qualitative evidence for the formation of both the primary and secondary 
carbon-centered radicals was provided by spin-trapping and EPR analysis.[177,179,180] Interestingly, 
all the attempts to trap the intermediate oxy radicals fail, confirming that the rearrangement of these 
species proceeds extremely rapidly (with a rate constant greater than that of typical reaction of 
alkoxy radical with DMPO).  
In some particular conditions, deoxyartemisinin (15, figure 14) was also identified as the major 
product. Its formation was proposed to involve the electrophilic high-valent iron-oxo species 
(Fe(IV)=O, route 2b).[115,171,181-183] However, the groups of Jefford[173,174] and Meunier have 
contested this chemical mechanism on the basis that (i) the reported Raman resonance spectra 
exhibited a signal/noise ratio for the Fe-O vibration below 2,[183] while a S/N up to 20 is expected 
for well-characterized metal-oxo species;[184,185] (ii) no epoxidation of electron-rich olefin (such as 
cyclohexene), characteristic of the presence of a metal-oxo species, have been observed;[172,186] and 
(iii) formation of deoxyartemisinin 15 can be achieved without generation of ferryl-oxo species 
(route 2c).   
The ratio of Fe-mediated activation products has been found to be highly dependent of reaction 
conditions (iron salt, solvent, …): route 1 is preferred when artemisinin is activated by FeCl2 in 
acetonitrile while route 2 becomes significant when FeBr2 is used in THF.[176]  
Despite the accumulation of evidence supporting the radical 
pathways, Haynes and co-workers proposed that artemisinin acts 
as a masked source of hydroperoxides, which would be generated 
via iron-induced heterolytic cleavage of the O2-C3 bond at low 
pH (SiO2/H2SO4 in CH2Cl2).[187-189] However, according to a 
report by Robert et al., artemisinin peroxide bond is stable at pH 
2.1.[190] In addition, the dissociation energy of the O-O bond 
being very low, the homolytic cleavage of this bond is more 
likely to occur, rather than a heterolytic C-O bond cleavage.  
The formation of alkyl radicals is common to all active artemisinin derivatives that have been 
tested. Reaction of artemisone with ferrous acetate in presence of the alkyl radical spin trap 4-oxo-
2,2,6,6-tetramethyl-1-piperidine-1-oxyl (oxo-TEMPO)[191,192] provided a drug-TEMPO adduct by 
trapping of the artemisone-derived seco-radical (figure 15).[193]  
 
Table 4: Bond dissociation energy 
(For information)  
• RO-OR:  36 – 38 kcal/mol 
• HO-OH: 51 kcal/mol 
• HOO-H: 90 kcal/mol 
• tBuO-H: 88 kcal/mol 
• RC-O: 65 - 67 kcal/mol 
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Figure 15: Spin-trapping of artemisone-derived radical by oxo-TEMPO 
 
In the case of trioxane BO7, ferrous iron(II) induces the rupture of the peroxidic bond to form the 
radical anion 16, that may be complexed on Fe(II) and which quickly isomerizes to radical 17 
(figure 16).[172] The alkyl radical 16 was trapped in the presence of a thiol to afford the pentanoate 
18. The intermediate radical 17 is completely analogous to the artemisinin-derived radical 9 (figure 
14) produced in similar conditions.  
 
Figure 16: Fe-mediated decomposition of trioxane BO7. Adapted from [172] 
In a similar fashion than artemisinin, reaction of arteflene with ferrous chloride provides the alkoxy 
radicals that further rearrange or fragment to produce the diol derivative 21 and enone 22. The 
arteflene-derived secondary C-centered radical 23 was trapped and characterized by EPR analysis 
(figure 17).[194,195]  
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Figure 17: Fe-mediated activation of arteflene and radical spin-trapping.  
The biomimetic Fe(II)-mediated reactivity of antimalarial dispiro-trioxolanes has been also 
studied.[196,197] Reaction of trioxolane 3 with ferrous bromide produced lactone 30, bromoacid 31 
and unsaturated acid 32 (figure 18) resulting from coordination of Fe(II) on O1 and subsequent C-C 
β-scission of the adamantane to form the secondary radical 28. The reaction also produced 6-
bromohexanoic acid 29 resulting from coordination of Fe(II) on O2 and β-scission of 
spirocyclohexanone. The reaction is strongly regioselective with a yield ratio of the products from 
coordination of O1 vs. O2 of 73/3. The preferential coordination of Fe(II) is likely due to lower 
steric hindrance around O1.[197]  
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Figure 18: Fe-mediated activation of trioxolane 1.[197] 
Formation of the secondary radical 28 was put into evidence by spin-trapping with nitroxide free 
radical oxo-TEMPO to form the corresponding aminoxy acid 33 (figure 18). As expected by the 
regioselectivity of the reaction, only adduct resulting from trapping of the secondary radical has 
been isolated. Formation of TEMPO-adducts suggests that trioxolane-derived radicals survive long 
enough to react with other molecules.[142,197] 
The reaction of antimalarial tetraoxanes with iron has been less studied but the formation of C-
centered radicals has been reported in the literature.[198,199] In chapter 4, we further studied the Fe-
mediated reactivity of potent dispiro-1,2,4,5-tetraoxanes prepared by O’Neill’s group and 
confirmed the formation of carbon-centered radicals. It should be also noted that Opsenica et al. 
recently reported the spin trapping and EPR analysis of alkoxy radicals generated from steroidal 
tetraoxanes.[200]  
c. Reactivity with other transition metals ions 
The reactivity of artemisinin with transition metal ions other than Fe is not as well documented as 
with ferrous salts. Wu and co-workers studied the reaction of artemisinin with several low valent 
transition metal salts, including copper salt - the only biologically relevant metal of the series. As 
expected, these metals salts induce the reductive cleavage of artemisinin peroxide and all reactions 
produced the same products as reported with Fe2+, despite in lower yields.[201,202]  
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The Fe-mediated reactivity of artemisinin and synthetic peroxides depends on the same 
mechanism, namely (i) reductive homolytic cleavage of the peroxide bond, (ii) formation of 
oxy radicals and (iii) subsequent rearrangement to thermodynamically more stable carbon-
centered radicals. 
All the reactions reported above have been carried out with iron/metals salts as models of possible 
biological reactions and the results provided major insights in the mechanism of activation of 
peroxide drugs. However, these models have a limited validity as “free” iron ions do not exist in 
biological aerobic conditions. Due to the highly insoluble structure of [Fe(OH)3]n (Ks ∼ 10-39), iron 
is indeed complexed in vivo, likely by proteins (ferritin, transferrin, heme proteins, …). 
A more relevant iron complex to study the reactivity of proxide drugs is heme as (i) it is the most 
abundant iron complex in the red blood cells (20 mM) and (ii) it is involved in a detoxification 
process specific to Plasmodium.  
IV.2. Reactivity with iron(II)-heme and biological targets:  
There is no doubt that Fe-mediated reduction of artemisinin and synthetic antimalarial peroxides 
generate carbon-centered radicals. How do these reactive species interact with biomolecules and 
what are the implications for their antimalarial mechanism of action?  
Extensive work has shown that heme could play a major role in the antimalarial activity of 
artemisinin and other peroxide-containing drugs, both as activator and target. In this part, we review 
results on heme alkylation by artemisinin and synthetic antimalarial peroxides. We also review the 
alkylation/inhibition of parasitic proteins and enzymes that have been proposed as target for 
artemisinin. 
 
Figure 19: Bio-activation of artemisinin 
a. Heme as target for artemisinin and peroxide-containing antimalarials 
Alkylation of heme by artemisinin was first suggested by Meshnick after identification of heme-
drug adducts by mass spectrometry, both in solution and in parasite cultures treated with radio-
labeled artemisinin, but no structures were proposed for these adducts at that time.[203]   
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After these first reports on the heme alkylation, Meunier and co-workers studied the reaction of 
artemisinin and heme in vitro in order to identify the adducts proposed by Meshnick and investigate 
the mechanism of this reaction. 
In a preliminary study, the group used the synthetic manganese(II) tetraphenylporphyrin (MnIITPP) 
to confirm the formation of adducts. MnTPP was first chosen as a simple heme model for its fourth-
order symmetry and eight equivalent β-pyrrolic positions that are possible alkylation sites. Another 
practical reason was Mn porphyrins are easier to demetalate than their iron analogues.  
Reaction of artemisinin with [MnIII(TPP)Cl], in the presence of borohydride to generate MnIITPP in 
situ, gave the covalent porphyrin-drug adduct 37. This adduct is the result of alkylation by the 
artemisinin-derived primary radical at the β-pyrrolic positions of the porphyrin cycle (figure 
20).[204,205] Its formation can be explained by the mechanism proposed in figure 20.  
 
Figure 20: Formation of the H2TCP-artemisinin adduct 
 
The reductive activation of the artemisinin peroxide bond by MnIITPP produced the alkoxy radical 
8 which quickly rearranged by homolytic cleavage of the C3–C4 bond to the non-sterically hindered 
C-centered radical 9. The intramolecular addition of alkyl radical 9 on a β-pyrrolic carbon of the 
porphyrin ring allowed the generation of the radical 35 on the adjacent β-pyrrolic position and then 
the carbocation 36 by intramolecular electron transfer to Mn(III). The attack of borohydride at this 
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position led to the dihydropyrrole ring. Borohydride also mediated the reduction of the drug 
fragment and the loss of the acetate function at C12 to provide the covalent manganese 
tetraphenylchlorin (MnTPC) adduct. Further Mn removal under mild acidic conditions 
(transmetalation from Mn(II) complex to its Cd(II) analogue, followed by in situ demetalation of 
the cadmium complex) allowed full characterization of the resulting chlorin-type H2TPC adduct 
37.[205]  
It should be noted that the chlorin structure of this adduct is due to the use of borohydride and the 
reduction by the latter of one of the pyrrole cycles. Borohydride here not only acts as a one-electron 
reducing agent to reduce the Mn center, but also as a hydride donor toward the cation 36. Reaction 
with other reducing agents leads to the porphyrin analogue of 37. The mechanistic issues of this 
reaction have been discussed by the authors.[204]  
Similar adducts have been prepared with artemether and the synthetic trioxane BO7.[186,206-209] To 
investigate the importance of alkylation for the antimalarial activity of peroxide drugs, two other 
synthetic peroxides prepared by Posner’s group were also used: trioxane 38 is highly active against 
Plasmodium while its epimer 39 is totally inactive (figure 21).  The difference between 38 and 39 is 
the configuration at C4: in trioxane 39, the methyl substituent is on the same side than the peroxide 
(with respect to the drug mean plane).  
 
Figure 21: Activation of trioxanes 37 by an inner-sphere electron transfer: possible correlation between 
pharmacological activity and alkylating properties 
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No alkylation of MnTPP was observed with trioxane 39 while covalent adducts were characterized 
with the epimer 38, suggesting that the methyl substituent at C4 prevents close interaction between 
the metal and the peroxide, necessary for the reductive activation step. These data confirmed that (i) 
drug activation occurs through an inner-sphere electron transfer from the low valent metal to the 
peroxide bond, and (ii) more important, the alkylation ability correlates with the antimalarial 
activity. Such a correlation has been shown for several other synthetic antimalarial peroxides.[190]  
Artemisinin alkylates iron(II)-heme 
Further investigations with iron(II)-heme showed the same reactivity of the peroxide as with 
MnTPP. In few minutes at room temperature, reaction of artemisinin with iron(II)-heme led to the 
formation, in excellent yield (>85%), of covalent heme-drug adducts Fe-40 (m/z 898.3 M+) and Fe-
41 (m/z 838.4 [M-CH3COOH]+). These adducts were formed by addition of the artemisinin-derived 
C4-radical on the four α, β, δ, and γ  meso-positions of the porphyrin, without regioselectivity 
(figure 22).[210] The demetalation of the heme moiety allowed full NMR characterization of the 
meso regioisomers.[210,211]  
 
Figure 22: Alkylation of heme by artemisinin. For clarity, only the β regioisomers are depicted. 
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It should be also mentioned that a docking molecular modeling study that supports heme as a target 
for artemisinin was reported. Results showed that in the most stable configuration, the endoperoxide 
bridge of artemisinin is in close proximity to the iron center of heme.[212]  
b. The role of heme in the antimalarial activity of artemisinin in vivo evidenced by the 
identification of heme-artemisnin adducts in malaria-infected mice.  
Plasmodium vinckei-infected mice were treated with artemisinin by both oral (doses: 20, 50, or 100 
mg/kg) and i.p. routes (doses: 100 or 200 mg/kg).[213] Mice were sacrificed 2 h after treatment, 
organs were collected and extracts were analyzed by LC-MS, along with urine. The heme-drug 
adducts Fe-40 and Fe-41, already known from in vitro reaction, were detected in the spleen 
extracts. Spleen is the main organ involved in the elimination of damaged red blood cells. 
Glucuroconjugated derivatives of these adducts were also detected in urine, indicating that these 
compounds were metabolized in the liver (figure 23). Adducts were absent in non-infected mice 
treated in the same conditions, indicating that alkylating ability of artemisinin in vivo is triggered by 
the presence of the parasite. There is then a clear correlation between in vivo antimalarial 
activity and heme alkylation. 
 
 
Figure 23: Alkylation of heme by artemisinin within P. vinckei-infected mice[213] 
Alkylation of heme within hemoglobin. Artemisinin is pharmacologically active on the early ring 
stages of Plasmodium, when hemoglobin is not yet extensively degraded by the parasite. Meunier 
and co-workers investigated the reactivity of artemisinin with intact human ferrous hemoglobin A0 
(oxyHb) in order to see whether alkylation of heme within the protein can be related to its efficacy 
Chapter 1: Alkylating properties of antimalarial peroxide-containing drugs: A focused review 
33 
 
against young ring parasites. The group reported that the heme co-factor of the protein was 
efficiently alkylated by artemisinin and heme-drug adducts have been identified by comparison with 
previously characterized adducts.[214] No alkylation was observed with ferric Met-hemoglobin 
alone, while adducts were identified when a reducing agent was added, confirming the crucial role 
of ferrous iron in artemisinin reactivity. 
How heme-alkylation by artemisinin may induce the parasite death? 
Artemisinin and derivatives form adducts with heme. Loup et al. reported that (i) heme-artemisinin 
adducts inhibit the formation of β-hematin in vitro, in a better extent than chloroquine, and (ii) do 
not dimerize themselves in the conditions of β-hematin formation.[215] A reasonable proposal for 
this absence of dimerization is that the bulky artemisinin residues prevent the close stacking of the 
porphyrin macrocycles. Heme-artemisinin adducts are then likely to accumulate in the food vacuole 
of the parasite. Just like “free” heme, they contain a redox active iron and may generate oxidative 
stress, and be responsible for the parasite death. 
c. Heme-mediated reactivity of trioxolanes  
Vennerstrom and co-workers studied the iron(II)-heme mediated reactivity of antimalarial 
trioxolanes and reported that iron(II)-heme quickly reacts with the peroxide bond of these drugs. 
The secondary alkyl radical 43 has been shown to form a covalent bond with the heme porphyrin on 
the meso-positions and heme-drug adducts Fe-43 were characterized by LC-MS (figure 24).[216] A 
correlation was found between the extent of heme alkylation and in vitro antimalarial activity, 
suggesting that heme alkylation may be related to the mechanism of action for these 
trioxolanes.[216,217]  
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Figure 24: Formation of heme-trioxolane adduct Fe-43. For clarity, only regioisomer δ  is depicted 
 
d. Heme-mediated reactivity of trioxaquines 
As trioxaquines have been designed to combine the advantages of quinolines (accumulation in the 
food vaccuole) and trioxane (alkylation), Meunier and co-workers evaluated the heme alkylating 
ability of trioxaquines in vitro. Reaction of DU1301 with iron(II)-heme led to the formation of two 
covalent heme-trioxaquine adducts Fe-47 and Fe-48, the second resulting from ester hydrolysis of 
Fe-47 and loss of the terpene moiety (figure 25). These adducts were isolated, demetalated and fully 
characterized.[218]  
The evidence of heme alkylation by the trioxaquine DU1301 in malaria-infected mice is 
reported in chapter 5. 
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Figure 25: Alkylation of heme by trioxaquine DU1301. For clarity, onlyβ  regioisomers are depicted. 
 
Trioxaquines are active mainly against young erythrocytic stages of P. falciparum. Like for 
artemisinin, this efficacy may be due to the alkylation ability of the drug, as chloroquine is mainly 
active on the late stages.[161]  
 
Loup et al. reported that trioxaquines inhibit β-
hematin formation in vitro by pi-stacking with the 
porphyrin. Taking together, these data confirm 
the dual mode of action of these hybrid drugs. 
Trioxaquines are able to interact with heme via 
two different mechanisms:  
 Chloroquine-like route: disruption of 
hemozoin bio-crystallization, a vital process for 
the parasite 
 Artemisinin-like route: heme alkylation 
and formation of redox active adducts. 
Both processes may lead to the build-up of 
toxic oxygen species in the parasite food 
vacuole. 
Figure 26: Dual mode of action of trioxaquine DU1301 
Chapter 1: Alkylating properties of antimalarial peroxide-containing drugs: A focused review 
36 
 
IV.3. Proteins as possible targets for artemisinin 
a. GSH as enzyme active site model 
The heme alkylation is an intramolecular reaction, which would explain its high efficiency. To 
study the possible alkylation of cysteine residues, Wu and co-workers presented a system where the 
drug was activated with an iron-glutathione complex (γ-Glu_Cys-Gly). In these conditions, the 
artemisinin-derived radicals reacted also in an intramolecular reaction with the thiyl radical of 
amino acid chelates. Artemisinin-glutathione adducts were then identified.[199,202]  
The alkylation of a protein via formation of a thioether bond is a plausible reaction for the 
artemisinin.  
b. Alkylation of parasite proteins 
Protein alkylation was first reported by Meshnick in vitro with human serum albumin using 
[14C]artemisinin and [3H]dihydroartemisinin. Mass spectrometry revealed that two molecules of 
artemisinin where covalently attached to the protein.[219]  
Later, the same group showed that when P. falciparum-infected erythrocytes are incubated with 
[3H]dihydroartemisinin (DHA), [3H]arteether and [14C]arteflene, besides heme, several malarial 
proteins were covalently labeled.[220]  
One of the major alkylated proteins was the translationally controlled tumor protein (TCTP), a 25 
kDa parasitic protein that binds heme.[221] In P. falciparum, this protein – of which the function is 
unknown - appears to be associated with food vacuolar membranes.[222] The covalent linkage 
between DHA and the protein has been confirmed in vitro, with recombinant P. falciparum 
TCTP.[221] It is dependent on the presence of heme and of the single cysteine residue in the TCTP 
sequence. 
c. PfATP6 inhibition 
In addition to heme alkylation, an alternative mechanism of action for artemisinin has been 
suggested. It involves PfATP6, a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) orthologue 
of P. falciparum and homologous to the mammalian SERCA1a. In 2003, Krishna and co-workers 
reported that artemisinin inhibits PfATP6 overexpressed in Xenopus oocytes (Ki = 150 nM).[223] 
Inhibition was also observed with artemisone (Ki = 1.7 nM)[224] and an antagonistic interaction was 
also reported between artemisinin and thapsigargin (TG, figure 27), a specific mammalian SERCA 
inhibitor,[225,226] although the antagonistic effect was not confirmed in a more recent publication.[227]  
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Figure 27: Structures of artemisinin and thapsigargine 
Additional studies in Xenopus oocytes suggest that mutations in position 263 can modulate the 
affinity of artemisinin for PfATP6.[224] Mutation S796N was also proposed to be related to 
decreased sensitivity of the parasite to artemether, an artemisinin derivative.[228] However, no 
mutations were found in atp6 genes of laboratory artemisinin-resistant P. falciparum and P. 
chabaudi strains,[229] or in isolates of P. falciparum from Western Cambodia that showed a decrease 
of susceptibility to artesuante in vivo.[128]  
Krishna and coll. also reported that the inactive deoxyartemisinin, chloroquine and quinine do not 
inhibit PfATP6 activity. Effect of artemisinin on PfATP6 was attenuated by the iron chelator 
desferrioxamine, suggesting an iron-dependent activation mechanism, however no alkyation has 
been proven with PfATP6. Trioxolane OZ277 showed poor inhibition of PfATP6 overexpressed in 
Xenopus oocytes (Ki = 7700 nM).[230] 
Although several reports do not support the direct implication of the protein in the mechanism of 
action of artemisinin, the inhibition of PfATP6 has been relayed in a plethora of articles – the article 
of Krishna and coll. in Nature 2003[223] is 7th most cited article of 2837 articles using “artemisinin” 
as key-word on Web of science, accessed on 21/01/10 – and is often presented as the definite target 
of artemisinin. 
In order to provide information on the possible role of the PfATP6 calcium pump in the mechanism 
of action of artemisinin and related compounds, we performed a docking study of a series of 
structurally different antimalarial drugs into the thapsigargin-binding cleft of a PfATP6 
model. In contrast to a recent report,[231] our study was not limited to artemisinin derivatives, but 
included other peroxide- and quinoline-based antimalarial agents. Our objective was to determine 
whether the binding affinity of the studied drugs to PfATP6 can be significantly correlated to their 
in vitro antiplasmodial activity. The results of this study are reported in chapter 6. 
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V. Conclusion and scope of the thesis  
Alkylation of both heme and proteins has been reported to occur in vitro and/or in vivo. More work 
is still needed to know which of these processes is the most relevant for artemisinin antiparasitic 
effect. However, it is likely that both play a role in the impressive antimalarial activity of 
artemisinin and derivatives. 
In the following chapters, we confirm the alkylation properties of antimalarial peroxides toward 
heme by studying the in vitro reactivity of artemisone and the new class of dispiro-tetraoxanes 
(chapter 2 and 4, respectively).  
We also confirmed the alkylation of heme by trioxaquine in infected mice (chapter 5).  
In order to explore the possibility of reductive activation of artemisinin by other redox active metal 
present in vivo, we have studied the alkylation ability of artemisinin with copper complexes 
presenting possible alkylable sites (chapter 3). 
Finally, we carried out a modeling study of PfATP6 with various antimalarial drugs and analogues, 
to see whether the inhibition of protein observed in vitro is translated in terms of drug/protein 
affinity in silico.   
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Résumé en français de la publication : 
The antimalarial artemisone is an efficient heme 
alkylating agent 
F. Bousejra-El Garah, B. Meunier, and A. Robert, European Journal of Inorganic Chemistry 2008, 
2133-2135.  
L’artémisone, antipaludique dérivé de l’artémisinine, est un agent alkylant 
efficace de l’hème. 
L’artémisone est un dérivé hémi-synthétique de l’artémisinine, plus précisément de la dihydro-
artémisinine qui est substituée en position C-10α par un groupement thiomorpholine-1,1-dioxyde 
(figure ci-dessous). Comme pour l’artémisinine, la liaison peroxyde de l’artémisone peut être 
réduite par le fer(II) et former des radicaux alkyles qui ont été piégés par 4-oxo-TEMPO.[1] Compte-
tenu du rôle de l’hème dans le paludisme, nous nous sommes intéressés à la réactivité de 
l’artémisone vis-à-vis de l’hème, d’autant que, selon des travaux publiés,  l’artémisone et tous les 
dérivés en C-10α de l’artémisinine, seraient incapables d’alkyler le cycle porphyrinique de 
l’hème.[2]  
Nous avons donc fait réagir l’artémisone avec l’hème-fer(II) généré in situ par réduction de l’hème-
fer(III) en présence de dithionite. Lors de cette réaction, 93% de l’hème de départ est converti en 1 
h. L’analyse par LC-MS a permis de caractériser les produits de couplage covalent hème-drogue 6 
et 7, l’un et l’autre issus de réarrangements de l’adduit hème-artémisone 5 (figure ci-après) et 
présents sous la forme de 4 régio-isomères, dus à la substitution du fragment artémisone en position 
α, β, γ et δ de la porphyrine de l’hème. L’adduit 6 (m/z 957.5 M+) est issu du couplage covalent 
entre l’hème et un radical alkyle dérivé de l’artémisone après réarrangement. Ce même radical avait 
précédemment été piégé par 4-oxo-TEMPO.[1] 
Ce résultat montre que la substitution en C-10α de la dihydro-artémisinine par le groupement 
thiomorpholine-1,1-dioxyde n’affecte pas les propriétés alkylantes de ce peroxyde très actif. 
L’artémisone, comme tous les dérivés actifs de l’artémisinine, est un alkylant efficace de l’hème et 
cette réactivité pourrait être liée à son mécanisme d’action antipaludique. Le caractère alkylant de 
l’artésunate, de la 10-déoxoartémisinine et de la 10α-(4-benzylpiperazinyl)artémisinine qui est un 
autre dérivé de l’artémisinine substitué en C10α, avait précédemment été décrit.[3] 
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The reductive activation by iron(II)-heme of artemisone, a C-
10 substituted derivative of the antimalarial artemisinin, gen-
erates covalent heme-drug adducts in high yields. This result
confirms that the substitution at C-10 of artemisinin does not
Togetherwith AIDS and tuberculosis, malaria is one of
the three main causes of mortality by infectious diseases
in the world. The naturally occurring artemisinin, and its
semisynthetic derivatives artemether and artesunate are
nowadays the most efficient and rapidly acting antimalarial
drugs. Despite a wide use for more than 30 years, no clini-
cally relevant parasite resistance to these drugs has been
reported up to now.[1–3]
The peroxide function of artemisinin (1; Figure 1) and
synthetic trioxanes is known to play a key role in their anti-
malarial activity. The possible formation of alkylating spe-
cies after reductive activation of the O–O bond by heme-
or non-heme-iron species was early suspected.[4,5] The full
characterization of a covalent porphyrin-artemisinin adduct
after reductive activation with a heme model confirmed the
strong alkylating ability of artemisinin.[6,7] Covalent heme-
artemisinin adducts were also isolated and characterized.[8]
Furthermore, these heme-drug adducts have been detected
in the spleen and the urine of malaria-infected mice,
whereas they are absent from healthy mouse organs treated
under the same conditions. This experimental fact indicates
that alkylation of heme by artemisinin is triggered by the
presence of the parasite within erythrocytes.[9] In fact, the
reductive activation of peroxide-containing antimalarials to
produce heme-drug adducts has been found to correlate
well with their biological efficacy.[10,11] The active semisyn-
thetic derivatives of artemisinin substituted at C-10 are also
efficient heme-alkylating agents,[12,13] despite a claim by
R. K. Haynes et al. to the contrary.[14]
Artemisone (3; Figure 1) is a promising artemisinin de-
rivative substituted at the C-10α position by a thiomorpho-
line 1,1-dioxide residue.[15] This compound was recently re-
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alter the alkylating ability of artemisinin derivatives when
activated by a redox-active metal center.
(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2008)
Figure 1. Synthesis of artemisone 3; (a) TMSBr, 25 min, 0 °C; (b)
thiomorpholine 1,1-dioxide, 1,1,1,3,3,3-hexafluoropropan-2-ol
(HFIP), 75 min, 0 °C. TMS = trimethysilyl.
ported to extensively react with iron(II) salts. This reaction
produced a C-4-centered radical which has been trapped by
4-oxo-TEMPO in a rather low yield [10% when activation
occurred in the presence of Fe(OAc)2].[16] For this reason,
the authors considered that “the structural flexibility of the
C radicals from artemisinins allows facile extrusion of Fe2+
and collapse to benign isomerization products”. Then, they
rule out the possible importance of these radicals for the
antimalarial activity, and state that “as an explanation for
the antimalarial activity of artemisinins (...) the C-radical
hypothesis is not feasible”. In fact, under the conditions
used by Haynes et al. (activation by an iron salt), the experi-
mental mixture does not contain any component that could
be considered as a putative biological target of the C-cen-
tered radical.
Therefore, we decided to evaluate the alkylating capacity
of artemisone in the presence of a potential target such as
heme. We found that the alkylation of iron(II)-heme by art-
emisone is indeed achieved in high yield as reported below.
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A patent reports the large-scale synthesis of artemisone
(3) by using gazeous HCl.[17] In ref.[15b] is also reported the
laboratory-scale synthesis and the characterization of this
compound. However, we prepared artemisone from dihy-
droartemisinin using the route that we chose for the prepa-
ration of the 10α-benzylpiperazinyl derivative of artemisi-
nin.[12] The 10β-trimethylsilyl ether derivative 2 was first
prepared by reaction of chlorotrimethylsilane with dihy-
droartemisinin in pyridine as solvent. Reaction of bromotri-
methylsilane (1.2 mol-equiv.) with compound 2 in dichloro-
methane for 25 min, followed by addition of thiomorpho-
line 1,1-dioxide (10 mol-equiv.) in the presence of
1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) at 0 °C provided
artemisone 3 (Figure 1). After purification by chromatog-
raphy and recrystallization (from ethyl acetate and hexane),
the yield of 3 was 40% with respect to dihydroartemisinin,
close to the reported value (44%).[15b] Elimination product
4 was also isolated in 19% yield. The (R) configuration at
C-10 of artemisone was assessed by the 1H NMR coupling
constant 9-H,10-H (J = 10.3 Hz).[18]
Iron(II)-heme, generated in situ by reduction of its
iron(III) analogue with sodium dithionite, reacted quickly
with artemisone (3) to provide the covalent heme-drug ad-
duct 5 (heme/3/dithionite = 1:1:5 molar ratio, room temp.,
DMSO). As previously described for artemisinin, reductive
activation of the peroxide bond produces an alkoxy radical
centered at O-2. Rapid and subsequent C-3–C-4 β-scission
leads to the alkyl radical centered at C-4. This radical
quickly alkylates the meso positions of the porphyrin
macrocycle by an intramolecular reaction. The reaction was
monitored by high-pressure liquid chromatography (C18
RP column). After 1 h, the conversion of heme monitored
by HPLC was 93% (Rt = 18.2 min, λmax = 398 nm). Seven
Figure 2. Alkylation of iron(II)-heme by artemisone. The oval stands for the protoporphyrin-IX macrocycle. Inset: adduct between artemi-
sone and 4-oxo-TEMPO, reported in ref.[16]
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resolved peaks were detected with retention times between
23 and 26 min, and λmax = 405–407 nm. These peaks can
be assigned to the four regioisomers of the two different
heme-drug adducts, resulting from the alkylation of the four
meso positions of heme without regioselectivity (eight peaks
expected, but two peaks overlapped; Figure S2, Supporting
Information). The crude reaction product was analyzed by
ESI+-MS after dilution with acetonitrile. The complete ad-
duct 5 (Figure 2) was not detected; however, its formation
was assessed by the detection of adducts 6 and 7. Com-
pound 6 (Figure 2; at m/z = 957.5) is generated by re-
arrangement of the artemisone-derived moiety of 5. The
drug-derived fragment of adduct 6 has been previously
trapped using 4-oxo-TEMPO (Figure 2, inset), and a path-
way has been proposed for its formation.[16] Adduct 7, de-
tected at m/z = 840.3, arose from the hydrolysis of the C-
12–O bond of 5, followed by the intramolecular attack of
the hydroxy function at C-12 onto the C-10 and the release
of the thiomorpholine dioxide residue (Figure 3). As an ad-
ditional identification of compound 7, dilution with meth-
anol caused hydration of the aldehyde at C-12 and methyl-
ation of the alcohol function at C-10 (m/z = 872.5, com-
pound 8; Figure 2). These analytical results are fully consis-
tent with those reported for the adducts between heme and
other artemisinin derivatives (higher retention times than
heme itself, and a bathochromic shift of absorbance due
to the substitution at the meso position of the porphyrin
macrocycle).[8,12] In particular, the alkylation of heme with
another C-10-substituted artemisinin derivative also led to
adduct 7 after release of the C-10 substituent.[12] To confirm
these results, a similar reaction was carried out by using
heme dimethyl ester instead of heme. Under these condi-
tions, covalent heme-drug adducts were detected at m/z =
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985.5, 868.4, and 900.5, corresponding to the dimethyl ester
analogues of adducts 6, 7, and 8, respectively. From HPLC
and mass spectra, the yield of heme-drug adducts was rang-
ing from 80 to 90% with respect to starting heme.
Figure 3. Mechanism of rearrangement of the covalent heme-arte-
misone adduct 5.
There is no doubt that the substitution of dihydroartemi-
sinin by the thiomorpholine dioxide moiety at C-10α does
not prevent the reductive activation of the peroxide bond
of artemisone by iron(II)-heme, leading to the alkylation of
the four meso positions of heme. Artemisone, as all the
other active artemisinin derivatives (artemether, artesunate,
...) is a very efficient alkylating agent toward heme. This
property of artemisone is an experimental fact that should
be taken into consideration in discussions about possible
mechanisms of action of this antimalarial drug.
Supporting Information (see footnote on the first page of this arti-
cle): Experimental conditions of the alkylation reaction and
characterization of the heme-drug adducts 6, 7, and 8 by mass spec-
trometry; 13C NMR spectrum of 3 (Figure S1), and HPLC moni-
toring of the alkylation reaction (Figure S2).
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of C-12a, at the junction of four cycles, was detected at δ =
80.18 ppm. The article by Haynes et al. does not report any
signal at this chemical shift.
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Alkylation of heme by artemisone 
To a solution of Fe(PPIX)Cl (16.16 mg, 24.8 μmol) and artemisone (10.26 mg, 25.6 μmol, 1 mol. 
equiv.) in DMSO (0.5 mL), was added Na2S2O4 (21.7 mg in 40 μL of water, 124.6 μmol, 4.3 mol. 
equiv.). 
At t = 0 (just before addition of Na2S2O4) and t = 1 h, an aliquot of the reaction mixture (20 μL) was 
withdrawn and diluted with 980 μL of methanol/water/trifluoroacetic acid, 70/30/0.05, v/v. This 
solution was then diluted 100 x in the same solvent, and 100 μL of this latter diluted solution were 
injected for HPLC analysis on a 5 μm C18 Nucleosil column. The eluent gradient was from 
methanol/water/trifluoroacetic acid, 70/30/0.05, v/v to methanol/water/trifluoroacetic acid, 
100/0/0.05, v/v. The flow was 0.5 mL/min, and detection at 400 and 410 nm with a diode array 
detector. 
After 1 h, the peak of heme (Rt = 18.2, λmax = 398 nm) was decreased by 93% with respect to its 
intensity at t = 0. The major products were detected as seven peaks having Rt = 23.1, 23.8, 24.1, 
24.6, 25.0, 25.5, and 25.9 min. All these peaks have λmax = 405-407 nm, and the sum of their 
intensities corresponds to ca. 80-90% of those of the heme derived material (Figure S2). 
ESI+-MS after dilution of the crude reaction mixture in acetonitrile: m/z (relative intensity): 957.5 
(6, M+, 13), 862.5 (7, MNa+, 14), 858.3 (hydrate derivative of 7, M+, trace), 840.3 (7, M+, 100), 
616.2 (unreacted heme, M+, 16). 
ESI+-MS after dilution in methanol: m/z (relative intensity): 950.5 (8•DMSO, M+, 100), 918.4 
(7•DMSO, M+, 24), 872.5 (8, M+, 100), 840.5 (7, M+, 14), 694.5 (unreacted heme•DMSO, M+, 73). 
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Figures 
S1 13C (125.7 MHz, CDCl3) NMR spectrum of artemisone 3 
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 S2. HPLC chromatogram of heme alkylation by 3. 
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Résumé en français de la publication : 
Alkylating ability of artemisinin after Cu(I)­induced 
activation 
F. Bousejra-El Garah, M. Pitié, L. Vendier, B. Meunier, and A. Robert Journal of Biological 
Inorganic Chemistry 2009, 14(4), 601-610. 
Capacité alkylante de l’artémisinine après réduction par le cuivre(I) 
Les érythrocytes contiennent environ 20 µM de cuivre, principalement sous la forme de SOD 
Cu/Zn.[1] La digestion de cette SOD par Plasmodium libère du cuivre qui pourrait être utilisé par le 
parasite.[2] Comme le fer, le cuivre est un métal oxydo-réducteur biologique, capable de catalyser la 
formation de radicaux par la réaction de Fenton. C’est pourquoi nous avons étudié l’activation de 
l’artémisinine par ce métal, bien que sa concentration dans les globules rouges soit environ mille 
fois moins importante que celle du fer contenu dans l’hème.  
Pour étudier la réactivité de l’artémisinine vis-à-vis du cuivre, nous avons utilisé des complexes de 
cuivre(I) dont les ligands présentent des sites susceptibles d’être alkylés par les radicaux de 
l’artémisinine. Ainsi, des ligands peptidiques, Clip-Phen,[3] et dipyrrine ont été utilisés.  
1. Activation de l’artémisinine par un sel de cuivre(I) 
Il a été montré que des sels de métaux de transition autres que le fer peuvent réduire le peroxyde de 
l’artémisinine pour donner les mêmes produits de dégradation que ceux générés en présence de sels 
de fer(II).[4,5] Dans un travail préliminaire, nous nous sommes donc intéressés à l’activation de 
l’artémisinine en présence de chlorure de cuivre(I). L’analyse des produits de réaction a montré la 
formation de la déoxyartémisinine 4 et du dérivé furane-acétate 5, également générés en présence 
de fer(II). Le composé 6 a également été caractérisé, sous la forme de deux épimères. A notre 
connaissance, la formation de ce composé n’a pas été décrite dans la littérature. Un mécanisme de 
sa formation est proposé dans la publication ci-après.  
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Activation de l’artémisinine en présence de cuivre(I) et produits de réarrangement 
2. Activation de l’artémisinine par le cuivre(I) en présence de glutathion (γ­Glu­Cys­Gly, 
GSH) 
L’activation réductrice de l’artémisinine a pu être réalisée avec le complexe cuivre(I)-glutathion 
généré in situ. L’analyse par spectrométrie de masse du mélange réactionnel a permis de 
caractériser les adduits artémisinine-glutathion 7, 8 et 9 provenant de la liaison covalente entre le 
radical thiyl du glutathion et le radical alkyle issu de l’artémisinine. Ce résultat est en accord avec 
ceux décrits pour la réaction avec le fer(II) en présence de glutathion.[6] 
 
Adduits covalents GS-artémisinine  
3. Activation de l’artémisinine par le complexe CuI(Clip­Phen) 
Le complexe CuII(2-Clip-Phen)Cl2, synthétisé dans notre équipe,[3] contient deux groupements 
phénanthroline, reliés par un pont 2-amino-1,3-propanediol. Après réduction in situ par le 
dithionite, nous avons utilisé le complexe CuI(Clip-Phen) à la fois comme activateur et cible 
potentielle de l’artémisinine. Un produit de masse m/z 791.3, correspondant à un produit de 
couplage covalent entre le complexe Cu(Clip-Phen) et l’artémisinine, a été caractérisé par 
spectrométrie de masse. La masse et la figure isotopique de cet ion sont compatibles avec les 
structures proposées ci-dessous. En effet, la masse de cet ion correspond à la somme des masses du 
complexe Cu(Clip-Phen) et de l’artémisinine. Par ailleurs, la répartition isotopique de cet ion est 
caractéristique de la présence d’un atome de cuivre dans sa structure.  
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Propositions de structure pour l’adduit Cu(Clip-Phen)-artémisinine 
4. Activation de l’artémisinine par le complexe CuI(dipyrrin)2 
L’artémisinine étant capable de former des adduits avec la tétraphénylporphyrine (TPP) de 
manganèse,[7] utilisée comme modèle de l’hème, nous avons dans un premier temps utilisé la 
tétraphénylporphyrine de cuivre pour activer l’artémisinine. Cependant, compte-tenu de 
l’impossibilité de réduire le cuivre dans le ligand porphyrinique plan-carré rigide, nous avons 
ensuite utilisé le ligand meso-phényldipyrromethène (dipyrrine), plus souple, pour chélater le 
cuivre. Le choix de ce ligand, qui peut être vu comme une demi-TPP, permet en effet la 
coordination tétrahédrique requise pour le cuivre(I).  
La réactivité de l’artémisinine vis-à-vis du complexe CuI(dipyrrine)2  a été 
étudiée, et comparée à celle vis-à-vis du complexe FeII(dipyrrine)3. Dans les deux 
cas, l’adduit covalent dipyrrine-artémisinine 14 (m/z 503.2, MH+) – démétallé 
dans les conditions analytiques - a été identifié par spectrométrie de masse. 
D’après les résultats obtenus avec MnTPP, on s’attend à ce que l’alkylation ait 
lieu sur les positions pyrroliques. 
Bien que la formation de l’adduit 14 ait été mise en évidence avec les deux 
complexes Cu(dipyrrine)2 et Fe(dipyrrine)3, les rendements obtenus indiquent que 
la réactivité de l’artémisinine est meilleure avec le fer(II) qu’avec le cuivre(I).  
5. Conclusion 
Ce travail nous a permis d’explorer une voie nouvelle dans le mécanisme d’action de l’artémisinine, 
mettant en jeu le cuivre contenu dans les érythrocytes.  
En présence de complexes de cuivre(I), l’activation réductrice de l’artémisinine a lieu. La formation 
de produits d’alkylation a été mise en évidence avec tous les complexes étudiés. Toutefois, nous 
avons également observé que, en présence de complexes de cuivre, le réarrangement intra-
moléculaire des radicaux de l’artémisinine, qui est observé avec un sel de cuivre, est 
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systématiquement favorisé par rapport à la formation d’adduits, et que l’alkylation du ligand reste 
un phénomène minoritaire.  
De plus, la formation d’adduits en présence de dipyrrine de fer indique qu’un complexe de fer non 
héminique peut également être activateur et cible de l’artémisinine. 
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Abstract The reductive activation of artemisinin by
copper(I)-dipyrrin or copper(I)-(2-Clip-Phen) complexes
generates an artemisinin derived alkylating species leading
to covalent artemisinin–copper complex adducts. The
reactivity of the peroxide function of artemisinin toward
Cu(I) complexes is similar to that of Fe(II) analogues, even
though the reaction is more sluggish and product distri-
bution slightly different.
Keywords Alkylation ! Artemisinin ! Copper !
Malaria ! Non-heme complexes
Introduction
Faced with the burden of malaria, efforts to control the
disease are currently based on anti-vector measures asso-
ciated with drug combinations containing an artemisinin
derivative [1]. The recent success of these measures in a
few specific areas of Africa, such as KwaZulu-Natal in
South Africa, Eritrea, and the Tanzanian island of Zanzi-
bar, prompted renewed calls for global eradication [2].
Artemether and artesunate, now recommended by the
WHO, are semi-synthetic derivatives of artemisinin 1
(Fig. 1), a 1,2,4-trioxane extracted from Artemisia annua.
Although the exact mechanism of action of artemisinin
and its derivatives is still a matter of debates, it is known
that the key pharmacophore of this highly efficient anti-
malarial is its 1,2,4-trioxane unit, and in particular its
peroxide bond [3]. Peroxides are known to react with
transition metals of low valency such as iron(II) [4]. In
particular, the crucial role of iron(II)-heme in the diges-
tion/polymerization process in infected erythrocytes has
led to investigations of its possible interaction with
artemisinin.
Since the initial work of Meshnick and coworkers [5] on
the heme-catalyzed reductive activation of artemisinin and
on the alkylation of heme and specific parasite proteins by
artemisinin [6, 7], the radical chemistry of this antimalarial
drug has been investigated. In the same period, Posner,
Jefford and coworkers have also reported the chemical
decomposition of artemisinin by simple iron(II) salts, and
have pointed out the importance of an artemisinin derived
alkyl radical centered at C4 [8, 9]. In the presence of iro-
n(II), the peroxide bond of artemisinin is cleaved, leading
to the formation of oxy-radicals that rapidly rearrange via
either hydrogen abstraction or b-scission to form carbon-
centred radicals [10, 11]. These latter radicals are able to
alkylate biomolecules such as heme or specific parasitic
proteins. Covalent adducts between artemisinin and heme
have been characterized both in vitro and in malaria-
infected mice [12, 13]. On the basis of artemisinin reac-
tivity, many synthetic peroxides have been synthesized as
potential antimalarial drugs (one of them, trioxaquine
PA1103, is currently under pre-clinical development
[14, 15]) and the possible interaction of heme with the
peroxide function of the drugs has been investigated
[16–20]. Like artemisinin, the alkylating ability of the
trioxaquine DU1301 on heme has been observed in vivo
[21]. In addition, the in vitro alkylating ability of several
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1,2,4-trioxolanes (family of OZ277) has been correlated
with their antimalarial activity [22].
Moreover, the artemisinin-induced inhibition of two
parasitic proteins, a TCTP (translationally controlled tumor
protein) homolog [23] and the calcium-dependent ATP-ase
PfATP6 (Ca-ATP-ase of Plasmodium falciparum) [24],
was clearly reported as being iron-dependent. Alkylation is
possible, although adducts between artemisinin and these
proteins have never been identified in the biological
models.
Like iron, copper is a biologically relevant metal which
can catalyze peroxide reduction, and thus participate in
the free-radical-producing Fenton reaction [25]. Many
copper–sulfur proteins participate to in vivo electron
transfer reactions. For example, one of the four copper
atoms of ascorbate oxidase has an environment quite
similar to that of plastocyanins, chelated by two nitrogen
and two sulfur atoms (contained in methionine and cys-
teine). Human erythrocytes contain about 20 lM copper,
of which 70% is found in the Cu/Zn superoxide dismutase
(SOD). During the hemozoin formation process in the
food vacuole of Plasmodium, toxic ferrous heme is oxi-
dized to the ferric state. This oxidation reaction results in
the generation of reduced oxygen species, a major source
of oxidative stress that can be fatal for the parasite. To
counter this, Plasmodium has an anti-oxidant defense that
is not completely understood. Nevertheless, it seems that
Plasmodium concentrates the host Cu/Zn SOD in its
digestive vacuole, and may use it to convert superoxide
radical to hydrogen peroxide [26]. The H2O2 is then
cleaved by a catalase activity whose origin and location
are unknown [27]. Like hemoglobin, this Cu/Zn SOD is
Fig. 1 Reductive activation of
artemisinin 1 by CuCl2/
Na2S2O4, giving rise to
rearrangement products 4, 5,
and 6 (isolated yields are
indicated)
602 J Biol Inorg Chem (2009) 14:601–610
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also digested inside the parasite food vacuole, a process
that may be one of the possible sources of copper for the
Plasmodium [28].
To date, few studies have mentioned the reaction of
artemisinin with copper(I) salts [29]. The aim of the
present study was to induce the copper(I) reductive acti-
vation of the artemisinin peroxidic bond and examine the
possible alkylation of copper complexes. Beyond the
characterization of artemisinin rearrangement products, we
expected to detect possible covalent adducts by formation
of C–C or C–heteroatom bonds between artemisinin and
copper complexes.
Results and discussion
After checking the reductive activation of artemisinin by
copper(I) salts, we then studied the reaction of artemisinin
with copper(I) complexes of (1) amino acids or peptides,
(2) 2-Clip-Phen ligand, and (3) meso-diphenyldipyrro-
methene (dipyrrin for short). In these three cases, we
detected covalent adducts between artemisinin derived C4
radical and the ligand of copper, either through a C–S or a
C–C bond.
Activation of artemisinin by copper(I) salt
Wu and coworkers reported that, in acetonitrile/water,
copper sulfate and other non-iron transition metal salts
induce the cleavage of artemisinin to produce the rear-
rangement products that have already been reported with
Fe2? ions [29, 30]. In our hands, reaction of artemisinin
with copper(II) chloride reduced in situ by sodium
dithionite in dimethylsulfoxide mainly produced deox-
yartemisinin 4 in 57% yield with respect to the starting
amount of artemisinin (Fig. 1). Compound 4 resulted
from initial coordination of Cu(I) on O2 and homolysis of
the peroxide to generate an alkoxy radical on O1 2a. It
has been proposed that 2a rearranged via a stereospecific
1,5-H shift from H4a, leading to the secondary alkyl
radical 3a [8]. From 3a, deoxyartemisinin 4 might then be
formed by capture of H! from the DMSO used as solvent,
and release of CuII–OH. However, the formation of 4
could also occur from 2a via capture of H! to generate an
hydroxyl function at C12a, followed by release of CuII–
OH, without involving the secondary alkyl radical 3a. In
fact, the initial alkoxy radical 2a is better at abstracting a
hydrogen atom from an external source than the alkyl
radical 3a (this has been evidenced in autoxidation reac-
tion). In addition, the distance for the H-atom transfer
from C4 to O1 probably exceeds the critical limit distance
of 2.1 A˚ for such a migration [31]. Direct formation of
4 from 2a is then more probable.
Compound 5 was also obtained in 9% yield. This
compound was produced by homolysis of the peroxide
bond after initial coordination of Cu(I) on O1, followed by
C3–C4 bond cleavage and subsequent ring closure. Char-
acterisation of 4 and 5 was consistent with data reported in
references [32] and [33], respectively. These two reaction
pathways, resulting of the coordination of a reduced metal
either on O1 or on O2 of the peroxide bond, have already
been reported after activation of artemisinin by iron(II) salt
[18, 34, 35]. In Wu’s conditions (water/acetonitrile, 1/1),
compound 4 was only obtained in 1 or 2% yield with
stoichiometric FeII or CuI, respectively, whereas the tetra-
hydrofurane derivative 5 was the major product (41%)
[30]. Other reports suggest a small preference for attack of
Fe(II) on the nonketal peroxide oxygen atom of artemisinin
(O1) [36]. Anyway, as already pointed out with iron, data
obtained with copper suggest that the formation of the
alkoxy radical either on O1 or on O2 (Fig. 1, pathways (a)
and (b), respectively), and subsequent product distribution,
may depend on the reaction conditions [37].
In the present study, compound 6 (Fig. 1) was also
isolated in 6% yield. To our knowledge, this compound had
never been isolated from artemisinin degradation up to
now. It was characterized by 2D NMR as a mixture of two
epimers at C12a (A:B = 60:40). A significant difference in
the chemical shifts (up to 0.6 ppm in 1H-NMR and
7.7 ppm in 13C-NMR) was observed for the two stereo-
isomers, indicating two markedly different conformations,
keto-butyl at C5a and hydroxyl at C12a being either cis- or
trans-substituents with respect to the cyclohexyl ring. A
possible intramolecular H-bonding between O=C3 and
HO–C12a giving rise to an eight-membered ring (for the
trans isomer), or the sterically hindered free rotation of the
keto-butyl chain (for the cis isomer) result in diastereotopic
behavior of the C4 and C5-methylene groups. A possible
pathway for the formation of 6, by homolysis of the C3–
O13 bond of the alkoxy radical 2b, is proposed in Fig. 1. In
principle, compound 6 can exist as a cyclic form 60.
However, we failed to isolate 60, and the ‘‘open’’ structure
of 6 was confirmed by the 13C chemical shift of carbonyl
C3, detected at 208.8 and 212.6 ppm for epimers A and B,
respectively.
The studies described above, focused on copper ions,
allowed only the characterisation of artemisinin rear-
rangement products. To explore the possible alkylation
reaction between artemisinin and a putative target, it is
more favorable to have an alkylable target in the close
vicinity of the metal center. In fact, an intramolecular
alkylation reaction (as in the case of alkylation of heme by
artemisinin) should occur rather than an intermolecular
reaction. For this purpose, we used redox-active copper
chelates, with ligands having an alkylable position in the
close vicinity of the metal center.
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Activation of artemisinin by copper in the presence
of glutathione
We activated artemisinin with copper complexes of cys-
teine-containing peptides. In particular, glutathione (c-Glu-
Cys-Gly, GSH) is a physiological reducing agent occurring
in high concentrations in red blood cells (5 mM). The
coordination of sulfur onto the metal center would place (1)
the reduced metal, (2) artemisinin, and (3) the peptide
target in close proximity, thus increasing the probability of
peptide alkylation. So, the peptide may play the role of
both the reducing agent of the metal center, and the alky-
lable target.
When artemisinin reacted with copper (I), generated in
situ from copper(II) chloride and glutathione, we detected
by mass spectrometry minor amounts of a ‘‘complete’’
covalent adduct between glutathione and artemisinin, that
retains the full fragments of glutathione and artemisinin.
In fact, the exact mass of this compound (589) corresponds
to the addition of the masses of glutathione (307) and
artemisinin (282). This adduct may be formed by recom-
bination of the S-centered radical of glutathione with the
C4-centered primary radical of artemisinin 3b, giving rise
to a thioether bond (GS-artemisinin adduct 7, Fig. 2,
m/z = 590.3 and 612.3 for MH? and MNa?, respectively).
In fact, the production of the thiyl radical is also supported
by the detection of oxidized glutathione GS–SG (m/z =
613.4, MH?). In addition, the formation of compound 10
(m/z = 285.4, MH?), resulting from the capture of H! by
radical 3b confirms the possibility of homolytic cleavage of
the thiol function.
Compound 8, resulting from the hydrolysis of the lac-
tone in 7 and loss of an acetic acid unit, was also detected
(m/z = 548.2, MH?) along with the 5-membered lactone
(9, m/z = 530.2, MH?). A similar reactivity of the lactone
ring of the drug-derived fragment has been reported for
heme-artemisinin adducts [12, 13]. Compounds 4, 5 and 6
were also detected.
A similar alkylation reaction occurred when h-cysteine
was used instead of glutathione, giving rise in low yield,
to the adduct between h-cysteine and artemisinin
(m/z = 418.4, MH?, see ‘‘Materials and methods’’).
Compound 8 was isolated by Wu and coworkers in the
presence glutathione and Fe2? [38]. The same research
group also reported the formation of a cysteine–artemisinin
adduct in the presence of FeSO4 [39]. These authors carried
out a similar reaction with copper salt. However, the yield
reported for the cysteine–artemisinin adduct in the latter
case (as high as 37%) was not reliable, being only ‘‘esti-
mated from missing amounts’’ of products in 1H-NMR
spectrum of the crude product mixture [29]. On the con-
trary, our experience indicates that the yield of this C–S
coupling reaction is probably very low (\1%).
Activation of artemisinin by CuI(2-Clip-Phen)
Bis-phenanthroline ‘‘2-Clip-Phen’’ complexes, containing
two phenanthroline units linked by a serinol bridge in the
ortho position of a phenanthroline nitrogen, have been
designed as redox copper chelates with nuclease activity
[40–42]. In the present study, the copper complex of
2-Clip-Phen was used both as an activator of artemisinin
and its putative alkylation target. The metal center of
the CuII(2-Clip-Phen)Cl2 complex (11-Cu
II, Fig. 3) was
reduced in situ by sodium dithionite under an argon
atmosphere and the formation of the diamagnetic copper(I)
complex was followed by 1H-NMR. Artemisinin was then
added. After 1 h, TLC monitoring showed the disappear-
ance of artemisinin. 1H-NMR of the reaction mixture
suggested the presence of compounds 4 and 5, their H12
resonances being detected as sharp singlets at 5.86 and
6.51 ppm, respectively, in DMSO-d6. The presence of 5
was confirmed by the resonance of the methylene group at
C4 (4.73 and 3.83 ppm). A modication of the –O–CH2–
signal of the 2-Clip-Phen ligand was also observed
(4.66 ppm compared with 4.95 ppm for the starting 11-CuI
complex). However, all NMR signals of the phenanthroline
residue were broadened, as already described for cuprous
Clip-Phen complexes, which consist of mixtures of species
in rapid exchange at the NMR time scale [41]. In addition,
the region of aliphatic protons was very complicated due to
the overlapping of several artemisinin-derived fragments.
Therefore, the characterisation of a 2-Clip-Phen–artemisi-
nin adduct could not be achieved by NMR. However, the
Fig. 2 Alkylation of
glutathione by artemisinin 1 in
the presence of copper(I), giving
rise to GS-artemisinin covalent
adducts 7, 8, and 9
604 J Biol Inorg Chem (2009) 14:601–610
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mass spectrum of the crude reaction mixture indicated the
presence of a new compound with m/z = 791.3, along with
compounds 4, 5 and 6 as major products. This peak at
791.3 is the exact mass of Cu(2-Clip-Phen) (510.1) plus the
mass of artemisinin (282.2) minus one hydrogen atom (1).
Thus, a compound with this mass strongly suggests cova-
lent coupling between Cu(2-Clip-Phen) and artemisinin
without loss of a moiety. The MS isotopic pattern showed
the presence of one copper atom (M ? 2 due to 65Cu,
Fig. 3). When a similar reaction was made using Cu(phe-
nanthroline)2Cl2 (lacking the serinol bridge) instead of 11-
Cu, only rearrangement products 4, 5, and 6 were detected.
This result suggests that alkylation of 11-Cu by artemisinin
may occur on the serinol linker, rather than on the phe-
nanthroline part.
The structure proposed in Fig. 3 (12-Cu) is consistent
with these results. As an alternative, a free hydroxyl
function at C12 and coordination of the deprotonated ali-
phatic amine on copper cannot be ruled out (120-Cu). We
tried to clarify the alkylation position of the 2-Clip-Phen
ligand. As mentioned above, 1H-NMR analysis of the crude
reaction mixture allowed the detection of methylene groups
H2C1
0, with a correct integration value with respect to
the phenanthroline protons. In contrast, HC20 was not
Fig. 3 Alkylation of Cu(2-
Clip-Phen) by artemisinin 1.
ESI?-MS characterisation and
proposed structure of the
Cu(2-Clip-Phen)–artemisinin
covalent adduct 12-Cu
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unambiguously detected. In addition, the possible radical
alkylation at the a-position of aliphatic amines has been
reported [43], whereas radical N-alkylation has not. It can
therefore be proposed that the coupling between the 2-Clip-
Phen and the artemisinin fragments occurred through
C20–C4 bonding.
On the basis of the mass spectrometry of the crude
reaction mixture (triplicate), the relative intensity of the
adduct 12-Cu with respect to the total amount of products
4 ? 5 ? 6 ? 12-Cu was c.a. 2%.
Activation of artemisinin by CuI(dipyrrin)
As artemisinin efficiently reacts with iron(II)-heme and
manganese(II) tetraphenylporphyrin, at meso- or b-pyrrole
positions, respectively, we first tried to activate artemisinin
with copper tetraphenylporphyrin (CuTPP) or with the
copper analogue of heme (CuPPIX). These complexes are
stable Cu(II) species, and their cuprous analogues must be
generated in situ to induce artemisinin activation. How-
ever, we failed to generate CuITPP or CuIPPIX. In fact, the
most preferable coordination environments of Cu(II) and
Cu(I) are different. The d9 Cu(II) complexes generally
adopt Jahn-Teller distorted six-coordinate or five-coordi-
nate geometries which fit well with the porphyrin ligands
when a solvent molecule or a counter-ion ligation is
included. The d10 Cu(I) complexes generally prefer lower
coordination numbers such as four-coordinate tetrahedral
environments, which is an unfavorable situation for the
rigid square planar structure of porphyrins. Indeed, it has
been reported that the first one-electron reduction of Cu(II)
porphyrins usually occurs at the ligand, resulting in the
formation of the p-radical anion of Cu(II) porphyrins
[44–46]. The relatively good fit of Cu(II) into the porphyrin
hole, compared to the large radius of Cu(I), may also
explain the lack of any Cu(I) porphyrin complexes [47].
Copper porphyrins were therefore not suitable to induce
artemisinin activation.
We then used meso-phenyldipyrromethene (dipyrrin, for
short) as ligand. This kind of ‘‘half-porphyrin’’ is expected
to have a similar reactivity to that of TPP at b-pyrrole
positions; but a non-square planar geometry should be
allowed for a coordinated metal ion and dipyrrin should
then be able to coordinate Cu(I). Then, we prepared di-
pyrrin ligand [48] and its corresponding copper complex
Cu(dipyrrin)2, 13-Cu (Fig. 4) [modification from reference
49]. The reactivity of artemisinin with 13-Cu was then
investigated in the presence of 2,3-dimethylhydroquinone
as reducing agent. In comparison, a similar reaction was
made with the iron analogue Fe(dipyrrin)3 13-Fe [50]. In
both cases, a compound with a molecular peak at m/
z = 503.2 was detected by ESI?-MS, along with the
molecular peak of the dipyrrin ligand at m/z = 221.1. The
exact mass of this new compound (502) corresponds to the
mass of dipyrrin (220) ? the mass of artemisinin (282). It
is therefore consistent with the presence of a dipyrrin–ar-
temisinin covalent adduct obtained after substitution of one
proton of dipyrrin by the drug residue (14, Fig. 4). The
alkylation site was not determined, however the reaction is
expected to occur in the same fashion as with Mn-TPP, e.g.
at b-pyrrolic positions [11]. In this regard, the structure
proposed for adduct 14 is the most probable. It should be
mentioned that mass spectrometry of the crude reaction
mixtures did not allow the detection of the iron or copper
complexes of the dipyrrin–artemisinin adduct. In a similar
way, when Fe(dipyrrin)3 13-Fe and Cu(dipyrrin)2 13-Cu
were analyzed by ESI?-MS, demetallation occurred in the
spectrometer and only the dipyrrin ligand was detected.
Beside adduct 14, compounds 4, 5, and 6 were also formed
as by-products of the reaction.
On the basis of mass spectrometry, the relative ratio of
the covalent dipyrrin–artemisinin adduct (m/z = 503.2)
with respect to the total amount of dipyrrin (e.g.
221.1 ? 503.2) was 47 and 18% when starting from the
iron and copper dipyrrin complexes, respectively. Mass
spectrometry is not, strictly speaking, a quantitative tech-
nique. However, this result indicates that the alkylation
yield of Cu(dipyrrin)2 by artemisinin, although moderate, is
probably the highest yield reported up to now with a copper
complex. In the presence of Fe(dipyrrin)3, a yield of 47%
Fig. 4 Alkylation of
Cu(dipyrrin)2 and Fe(dipyrrin)3
by artemisinin 1, giving rise to
the dipyrrin–artemisinin
covalent adduct 14. ORTEP
view of Cu(dipyrrin)2
606 J Biol Inorg Chem (2009) 14:601–610
123
80
of dipyrrin–artemisinin adduct 14 was obtained after 4.5 h
at 38 "C, which is comparable to the yields reported for the
alkylation of Mn(TPP) by artemisinin (25% after 80 min)
or several other antimalarial peroxides [51]. This result
indicates that the extended conjugation of the porphyrin
macrocycle is not required for an efficient alkylation
reaction by the artemisinin-derived C4-radical entity.
Conclusion
In the presence of copper(I) ions and chelates, the
reductive activation of the peroxidic bond of artemisinin
is observed. In all cases, the intra-molecular collapse of
the radicals generated by artemisinin reduction was
favored with respect to the alkylation of metal ligands.
Nevertheless, this study documents the alkylation of a
target by an artemisinin-derived radical in the vicinity of
the reduced copper center, with formation of C–C or C–S
bonds. In addition, the intra-erythrocytic concentration of
copper being 1,000 times lower than that of iron, in vivo
activation of artemisinin by copper should be considered
as a minor reaction pathway compared to the activation
by heme.
The Fe(dipyrrin)3 complex was also alkylated by arte-
misinin, in significantly higher yield than Cu(dipyrrin)2.
The formation of a covalent adduct between the Fe(di-
pyrrin)3 complex and artemisinin indicates that non-heme
iron complexes are able to activate artemisinin, leading to
covalent adducts between the drug and the iron ligand.
Such a reaction may occur with biomolecules containing
non-heme iron sites. Note that parasitic proteins such as
TCTP or PfATP6, both reported as putative artemisinin
targets, are inhibited by artemisinin in an iron-dependent
manner [23, 24].
Materials and methods
Chemicals
Artemisinin was supplied from Sigma-Aldrich. CuCl2!
2H2O and Cu(CH3COO)2!H2O were purchased from Fluka;
DMSO 99.9% and Na2S2O4 were from Acros. Chelex
#
100, 100–200 mesh, was purchased from Bio-Rad.
Dichloromethane and hexane were supplied by Fluka and
had a low content of evaporation residue (B0.0005%).
Unless noted, all solvents and reagents were purchased
from commercial suppliers and used without further
purification. Solvents were freshly vacuum degassed and
purged with argon to remove oxygen prior to use. All
alkylation reactions were carried out under an argon
atmosphere.
Instrumentation
1H- and 13C-NMR spectra were recorded on Bruker
Avance 500 or Avance 300 instruments. Significant
1H-NMR data are written following the order: multiplicity
(b, broad; s, singlet; d, doublet; t, triplet; q, quartet; m,
multiplet), number of protons, coupling constants in Hertz,
assignment. Chemical shifts are expressed in ppm (d)
relative to tetramethysilane as external reference. Mass
spectrometry was performed on a QTrap Applied Biosys-
tems or on an LCT Waters mass spectrometer, by direct
injection and detection in ESI or DCI/NH3 mode. Analyt-
ical TLC was performed on aluminium sheets precoated
with silica gel (Merck). Visualization was accomplished
using phosphomolybdic acid. Elution conditions were
hexane/AcOEt, 70/30, v/v, unless otherwise indicated.
X-ray crystallographic analysis
Data were collected at low temperature (180 K) on a
Bruker Kappa Apex II diffractometer using graphite-
monochromated Mo-Ka radiation (k = 0.71073 A˚) and
equipped with an Oxford Cryosystems Cryostream Cooler
Device. The final unit cell parameters were obtained by
means of a least-squares refinement performed on a set of
2,557 well measured reflections. The structures were
solved by direct methods using SIR92 [52], and refined by
means of least-squares procedures on an F2 with the aid of
the program SHELXL97 [53] included in the software
package WinGX version 1.63 [54]. The atomic scattering
factors were taken from International Tables for X-Ray
Crystallography [55]. All hydrogen atoms were located
geometrically, and refined by using a riding model. All
non-hydrogen atoms were anisotropically refined, and in
the last cycles of refinement a weighting scheme was used,
where weights were calculated from the following formula:
w = 1/[r2(Fo
2) ? (aP)2 ? bP] with P = (Fo
2 ? 2Fc
2)/3.
Molecules were drawn with the program ORTEP32 [56]
with 30% probability displacement ellipsoids for non-
hydrogen atoms.
Crystallographic data (without structure factors) for the
structure of Cu(dipyrrin)2 13-Cu were deposited with the
Cambridge Crystallographic Data Centre (CCDC) as sup-
plementary publication no. CCDC-706790. Copies of the
data can be obtained free of charge from the CCDC (12
Union Road, Cambridge CB2 1EZ, UK; e-mail: depos-
it@ccdc.cam.ac.uk; Web site: http://www.ccdc.cam.ac.uk.
Reaction of artemisinin with copper(I) salt
A solution of artemisinin (51 mg, 181 lmol, 1.0 equiv),
CuCl2!2H2O (31 mg, 182 lmol, 1.0 equiv) and Na2S2O4
(44 mg, 2.26 lmol, 1.4 equiv) in 1.0 mL of degassed
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DMSO was left to stir at 37 "C under argon atmosphere.
Reaction of artemisinin was complete after 1 h (TLC
monitoring). Water (15 mL) was then added and extraction
was achieved with CH2Cl2 (3 9 15 mL). The organic layer
was washed with 15 mL of water to remove traces of
DMSO, dried on Na2SO4, filtered and concentrated. The
crude mixture of products was separated by flash chro-
matography on silica (eluent: hexane/ethyl acetate, 80/20
to 0/100, v/v). Yields: 57% of 4, 9% of 5 and 6% of 6.
Analyses for 4
1H-NMR (CDCl3, 500 MHz) d (ppm) 5.72 (s, 1H, H12),
3.20 (dq, 1H, J = 7.3 and 4.7 Hz, H9), 2.03 (dt, 1H,
J = 13.1 and 4.5 Hz, H8a), 1.94 (m, 2H, H5eq and H8eq),
1.81 (m, 2H, H4eq and H7eq), 1.65 (m, 1H, H4ax), 1.55 (s,
3H, 3-CH3), 1.30 (m, 3H, H5ax, H5a and H6), 1.22 (d, 3H,
J = 7.2Hz, 9-CH3), 1.11 (m, 1H, H7ax), 1.02 (m, 1H,
H8ax), 0.93 (d, 3H, J = 6.0 Hz, 6-CH3).
13C-NMR (CDCl3,
125 MHz) d (ppm): 171.8 (C10), 109.2 (C3), 99.7 (C12),
82.4 (C12a), 44.7 (C5a), 42.5 (C8a), 35.4 (C6), 34.0 (C4),
33.5 (C7), 32.8 (C9), 24.0 (3-CH3), 23.5 (C8), 22.0 (C5),
18.6 (6-CH3), 12.6 (9-CH3). MS (ESI
?) m/z 267.4 (MH?),
289.3 (MNa?). MS (DCI/NH3) m/z 267.4 (MH
?), 284.3
(MNH4
?).
Analyses for 5
1H-NMR (CDCl3, 500 MHz) d (ppm): 6.67 (s, 1H, H12),
4.24 (bt, 1H, H4eq), 3.96 (bq, 1H, H4ax), 3.19 (qd, 1H,
J = 7.6 and 4.6 Hz, H9), 2.18 (s, 3H, CH3–CO), 2.06 (m,
1H, H5eq), 2.02 (m, 1H, H7eq), 1.96 (m, 1H, H8eq), 1.90 (dt,
1H, J = 4.6 and 12.9 Hz, H8a), 1.75 (m, 1H, H6), 1.61 (m,
1H, H5ax), 1.49 (ddd, J = 8.2, 9.5 and 17.1 Hz, H5a), 1.24
(d, 3H, J = 7.2Hz, 9-CH3), 1.09 (qd, 1H, J = 2.5 and
6.1 Hz, H7ax), 1.01 (d, 1H, J = 6.0 Hz, 6-CH3).
13C-NMR
(CDCl3, 125 MHz) d (ppm) 171.7 (C10), 168.5 (C3), 93.0
(C12), 79.4 (C12a), 69.3 (C4), 54.8 (C5a), 426.7 (C8a),
35.0 (C9), 34.6 (C7), 30.9 (C6), 27.7, (C5), 24.3 (C8), 21.2
(CH3–COO), 20.4 (6-CH3), 12.5 (9-CH3). MS (ESI
?) m/z
283.4 (MH?), 305.3 (MNa?). MS (DCI/NH3) m/z 283.4
(MH?), 300.3 (MNH4
?).
Analyses for 6
The two epimers A and B were not separated. 1H-NMR
(CDCl3, 500 MHz) d (ppm) 6.86 (s, 1H, OH B), 3.40 (qt,
1H, H9 B), 2.91 (m, 1H, H9 A), 2.82 (m, 1H, H4eq B),
2.68–2.62 (m, 2H, H4ax B and H8a A), 2.57 (m, 1H, H4eq
A), 243–2.39 (m, 1H, H4ax A), 2.21–2.27 (m, 2H, H5eq B
and H8a B), 2.23 (s, 3H, CH3CO B), 2.20–2.12 (m, 2H,
H5a A and H8eq A), 2.15 (s, 3H, CH3CO A), 1.94–1.91
(m, 1H, H7eq A), 1.90–1.84 (m, 1H, H5eq A), 1.82–1.78 (m,
2H, H5ax A and H7eq B), 1.74 (m, 1H, H8eq B), 1.64 (m,
1H, H6 A), 1.59–1.51 (m, 4H, H7ax A, H5a B, H8ax A and
H5ax B), 1.38–1.34 (m, 1H, H6 B), 1.24 (bd, 3H,
J = 6.7 Hz, 9-CH3 A), 1.14 (bd, 3H, J = 9.0 Hz, 9-CH3
B), 1.12 (bd, 3H, J = 6.0 Hz, 6-CH3 A), 1.09–0.95 (m, 2H,
H7eq B and H8ax B), 0.98 (bd, 3H, J = 6.6 Hz, 6-CH3 B).
13C-NMR (CDCl3, 125 MHz) d (ppm) 212.6 (C3 B), 208.8
(C3 A), 179.9 (C10 A), 179.8 (C10 B), 56.64 (C5a A),
53.67 (C8a A), 50.87 (C5 B), 46.13 (C8a B), 43.12 (C4 B),
41.09 (C4 A), 40.55 (C6 A), 39.31 (C9 B), 38.53 (C9 A),
35.68 (C6 B), 34.34 (C7 A), 32.50 (C7 B), 30.05 (C8 A),
29.99 (CH3CO A), 29.91 (CH3CO B), 24.97 (C8 B), 21.12
(C5 B), 20.51 (6-CH3 A), 20.05 (C5 A), 19.82 (6-CH3 B),
14.79 (9-CH3 A), 8.85 (9-CH3 B). MS (ESI
?) m/z 255.4
(MH?), 277.3 (MNa?). MS (DCI/NH3) m/z 255.4 (MH
?),
272.4 (MNH4
?).
Reaction of CuCl2 with artemisinin in the presence
of glutathione
To a solution of CuCl2!2H2O (4.4 mg, 26 lmol, 1 equiv)
and artemisinin (20.7 mg, 72 lmol, 3 equiv) in degassed
DMSO (1 mL), was added glutathione (26.7 mg, 87 lmol,
3.4 equiv) as a solid. The solution was stirred at 38 "C
under argon for 32 h. Water (3 mL) was then added, and
the reaction mixture was extracted with CH2Cl2 (2 mL).
The aqueous phase was diluted with CH3OH (1/1) and
treated overnight in the presence of Chelex# 100, 100–
200 mesh.
The organic phase was diluted with methanol and ana-
lyzed by ESI?-MS: m/z (relative intensity) 267.4 (4, MH?,
21), 277.3 (6, MNa?, 12), 289.3 (4, MNa?, 100), 305.4 (5,
MNa?, 35), 307.3 (10, MNa?, 43).
The aqueous phase was diluted with methanol contain-
ing 10 vol% formic acid, and analyzed by mass
spectrometry. ESI?-MS m/z 530.2 (9, MH?), 548.2 (8,
MH?), 590.3 (7, MH?), 612.3 (7, MNa?), 613.4 (GS–SG).
ESI--MS m/z 588.2 [7, (M-H)-].
Reaction of CuCl2 with artemisinin in the presence
of h-cysteine
To a solution of CuCl2!2H2O (3.1 mg, 18 lmol, 1 equiv)
and artemisinin (20.2 mg, 71 lmol, 4 equiv) in degassed
CH3CN (1 mL) and H2O (0.5 mL), was added h-cysteine
(10.0 mg, 35 lmol, 2 equiv) as a solid. The solution was
stirred overnight at 38 "C under argon. Only a small por-
tion of the starting artemisinin was converted (\10%). The
crude reaction mixture was diluted in methanol for ESI?-
MS analysis: m/z 418.4 (MH? for the h-cysteine–artemis-
inin adduct, trace amount).
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Reaction of artemisinin with CuI(2-Clip-Phen)
2-Clip-Phen ligand was prepared according to reference 41.
Preparation of CuI(2-Clip-Phen)
A solution of CuCl2!2H2O (2.08 mg, 12 lmol, 1 equiv),
2-Clip-Phen (5.42 mg, 12 lmol, 1 equiv) in 0.6 mL
DMSO-d6 was left to stir at 38 "C under argon. Na2S2O4
(10.82 mg, 62 lmol, 5 equiv) was then added, and the
color of the reaction mixture shifted instantaneously from
green (CuII complex) to red (CuI complex). After 45 min of
reaction, the mixture was transferred to an NMR tube under
argon for 1H-NMR analysis.
1H-NMR (300 MHz, DMSO-d6) of Cu
I(2-Clip-Phen) d
(ppm): 9.04 (dd, 2H, J = 1.7 and 4.4 Hz, H900), 8.49 (dd,
2H, J = 1.7 and 8.2 Hz, H700), 8.45 (d, 2H, J = 8.7 Hz,
H400), 7.97 (d, 2H, J = 8.8 Hz, H600),7.88 (d, 2H,
J = 8.8 Hz, H500), 7.75 (dd, 2H, J = 4.4 and 8.2 Hz, H800),
7.31 (d, 2H, J = 8.7 Hz, H300), 4.95 (4H, d, J = 3.8 Hz,
H2C1
0), 4.22 (m, 1H, HC20).
Reaction of CuI(2-Clip-Phen) with artemisinin
A solution of CuCl2!2H2O (2.12 mg, 12 lmol, 1 equiv)
and 2-Clip-Phen (5.48 mg, 12 lmol, 1.0 equiv) in
0.5 mL DMSO-d6 was left to stir at 38 "C for 10 min
under argon to generate the CuII complex of 2-Clip-Phen
Artemisinin (10.43 mg, 37 lmol, 3 equiv) was the added,
followed by Na2S2O4 (10.67 mg, 61 lmol, 5 equiv). The
color of the solution changed from green to red. The
reaction mixture was stirred at 38 "C for 45 min and
then transferred in an NMR tube under argon. 1H-NMR
analysis shows that the 2-Clip-PhenCuI complex was
modified after reaction with artemisinin. Deoxyartemisi-
nin 4 and the tetrahydrofurane derivative 5 were also
identified by their H12 protons.
1H-NMR (300 MHz, DMSO-d6, selected data): d (ppm)
9.91 (s, 0.5H, exchangeable H), 9.60 (bs, 0.5H,
exchangeable H) 9.05 (2H, H900), 8.47 (d, 2H, J = 8.0 Hz,
H700), 8.41 (d, 2H, J = 8.5 Hz, H400), 7.91 (2H, H600), 7.82
(2H, H500), 7.72 (dd, 2H, J = 4.3 and 8.4 Hz, H800), 7.25
(d, 2H, J = 8.4 Hz, H300), 6.50 (s, H12 of 5), 5.87 (s, H12
of 4), 4.66 (m, 4H, H2C1
0), 4.12 and 3.83 (H2C4 of 5).
Ratio 2-Clip-Phen/4/5 = 55/38/7. ESI?-MS m/z 791.3
(11-Cu, M?).
Reaction of artemisinin with copper- and iron
complexes of dipyrrin
Dipyrrin was prepared as already published [48] and
analyses were compliant.
Preparation of Cu(dipyrrin)2
The Cu(dipyrrin)2 complex 13-Cu was prepared by modi-
fication of reference [49] as follows: To a solution of
dipyrrin (91 mg, 41 lmol, 2.2 equiv) and Cu(OAc)2!H2O
(41 mg, 21 lmol, 1.1 equiv) in methanol (5 mL), was
added 0.5 mL of NH4OH. The complex precipitated
instantaneously as a dark solid. The crude product was
purified on a short chromatography column (SiO2, dichlo-
romethane/hexane, 1/1, v/v). The first bright orange band
was collected and evaporated to dryness to give 91 mg of
complex as a dark green crystalline solid (yield: 88%).
Red-green dichroic single crystals of Cu(dipyrrin)2 were
grown by slow evaporation of a solution of the complex in
dichloromethane/methanol, and analyzed by X-ray dif-
fraction. Anal. calcd for C30H22CuN4: C, 71.77; H, 4.42; N,
11.16. Found: C, 71.70; H, 4.33; N, 11.07. The solid state
structure of this complex shows the metal center to possess
a highly distorted square planar geometry which is typical
of bis(dipyrrin) metal complexes. This distortion has been
attributed to a steric clash between the a-pyrrole protons on
opposing ligands [57].
Reaction of artemisinin with Cu(dipyrrin)2
A solution of 13-Cu (9.0 mg, 18 lmol, 1 equiv), artemisinin
(10.1 mg, 35 lmol, 2 equiv) and 2,3-dimethylhydroquinone
(43.0, 311 lmol, 17 equiv) in degassed dichloromethane
(4 mL) was left to stir under an argon atmosphere at 38 "C
for 24 h. The reaction mixture was diluted in CH2Cl2 and
analyzed by mass spectrometry. ESI?-MS m/z 503.3 (14,
MH?), 221.1 (dipyrrin ligand, MH?). Intensity: 503.3/
(503.3 ? 221.1) = 0.18.
Preparation of Fe(dipyrrin)3
The Fe(dipyrrin)3 complex 13-Fe was prepared according
to reference 49. Anal. calcd for C45H33FeN6: C, 75.74; H,
4.66; N, 11.78. Found: C, 75.67; H, 4.86; N, 11.80.
Reaction of artemisinin with Fe(dipyrrin)3
A solution of 13-Fe (24.3 mg, 34 lmol, 1 equiv),
artemisinin (30.0 mg, 106 lmol, 3 equiv) and 2,3-dim-
ethylhydroquinone (16.6, 106 lmol, 3 equiv) in degassed
dichloromethane (1 mL) was left to stir under an argon
atmosphere at 38 "C for 4.5 h. The reaction mixture was
diluted in CH2Cl2 and analyzed by mass spectrometry.
ESI?-MS m/z 503.3 (14, MH?), 221.1 (dipyrrin ligand,
MH?). Intensity: 503.3/(503.3 ? 221.1) = 0.47.
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Résumé en français de la publication en cours de rédaction : 
Reactivity of antimalarial dispiro­1,2,4,5­
tetraoxanes with Fe(II), heme and phospholipids: 
Implications for their mode of action 
F. Bousejra-El Garah, R.K. Amewu, S. Muangnoicharoen, S.A. Ward, and P.M. O’Neill 
Réactivité de tétraoxanes antipaludiques avec un sel de fer(II), l’hème ou 
les phospholipides : Relation avec leur mode d’action 
Dans la recherche de nouvelles molécules synthétiques pour le traitement du paludisme, les dispiro-
1,2,4,5-tétraoxanes (ensuite dénommés tétraoxanes) se sont révélés très prometteurs. Le groupe du 
Pr. O’Neill a mis au point une série de tétraoxanes stables, achiraux, peu coûteux à synthétiser et 
très actifs.[1,2]  
Nous nous sommes intéressés à la réactivité de ces peroxydes avec le fer (II) en présence du radical 
2,2,6,6-tetramethyl-1-piperidine 1-oxyl (TEMPO) d’une part, et de phospholipides d’autre part. 
Nous avons comparé cette réactivité à celle de trioxolanes analogues, qui sont également des 
antipaludiques actifs. Nous nous sommes ensuite intéressés à la réaction des tétraoxanes avec 
l’hème, principale source de fer dans les érythrocytes infectés.   
Ce travail a été effectué au sein de l’équipe du Pr O’Neill, à l’Université de Liverpool, lors d’un 
stage doctoral de 12 mois (de octobre 2008 à septembre 2009).  
Reactivité  des  tétraoxanes  avec  le  sulfate  de  fer  en  présence  de  TEMPO  et  de  la 
phosphatidylcholine 
Réactivité avec un sel de Fe2+ : Piégeage des radicaux alkyles par TEMPO 
Afin de mieux comprendre le mécanisme de la réaction des tétraoxanes avec le fer (II) et de 
confirmer la formation de radicaux, nous avons étudié cette réaction en présence du piège de 
radicaux alkyles TEMPO. Comme attendu et comme dans le cas de l’artémisinine, la coordination 
du fer (II) sur l’oxygène O2 induit la rupture homolytique de la liaison peroxyde, et conduit à la 
formation du radical alkoxy 10, qui se réarrange par β-scission pour donner le radical alkyle 
secondaire 12. Ce radical a été piégé par TEMPO pour former l’adduit 8 (figure ci-dessous). De la 
même façon, la coordination du fer sur O1 génère le radical alkoxy 11, qui se réarrange en radical 
alkyle primaire 13, également piégé par TEMPO pour former l’adduit 9. Les adduits 8 et 9 ont été 
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caractérisés par spectrométrie de masse. Une réaction analogue avec des trioxolanes également 
actifs conduits à des résultats similaires.[3] 
La formation de radicaux alkyles indique que cette réactivité est un caractère général des peroxydes 
antipaludiques testés jusqu’à présent. 
 
Activation réductrice du tétraoxane 2 et formation des adduits TEMPO-drogue 8 et 9 
Réactivité avec un sel de Fe2+ en présence de phosphatidylcholine (PC) 
Nous nous sommes intéressés à la réaction des tétraoxanes dans les conditions de Fenton en 
présence de phosphatidylcholine, utilisée comme modèle de phospholipides. Nous avons également 
comparé cette réactivité avec celle de trioxolanes analogues. Les résultats nous ont montré que ces 
deux familles de peroxydes étaient capables d’induire l’oxydation de PC et plusieurs produits 
d’oxydation ont été identifiés par spectrométrie de masse. Ce résultat confirme celui obtenu 
récemment avec des tétraoxanes hydrosolubles.[4] Cette réactivité des tétraoxanes et trioxolanes 
diffère de celle de l’artémisinine, pour laquelle aucun produit de dégradation de PC n’a été détecté.      
Réactivité des tétraoxanes avec l’hème­fer(II) : mise en évidence de la formation 
d’adduits hème­tétraoxanes 
La réactivité des trioxanes ou trioxolanes antipaludiques vis-à-vis  de l’hème a été bien étudiée et, 
dans plusieurs cas, des adduits hème-drogue ont été caractérisés.[5-8] Nous nous sommes donc 
intéressés à l’étude de la réactivité des tétraoxanes avec l’hème.  
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La réaction de différents tétraoxanes antipaludiques, tous très actifs in vitro, avec l’hème-fer(II), 
généré in situ par réduction de l’hème-fer(III), a été réalisée et suivie par analyse LC-MS. Comme il 
vient d’être décrit pour un sel de fer (II), nous montrons que l’hème-fer(II) induit la coupure 
homolytique de la liaison peroxyde des tétraoxanes pour former une espèce radicalaire qui alkyle le 
ligand porphyrinique en positions meso. Ainsi, l’adduit (15, m/z 783.2) issu du couplage covalent 
entre la porphyrine et le radical alkyle secondaire dérivé des tétraoxanes (figure ci-dessous) a été 
caractérisé par LC-MS. 
 
Mécanisme de formation des adduits hème-tétraoxanes. Seul le régio-isomère issu de l’alkylation en position δ est 
représenté. Les adduits en position α, β et γ sont également présents. 
Des produits de couplages avec les porphyrines FeTPP et MnTPP ont également été identifiés, ce 
qui confirme les propriétés alkylantes des tétraoxanes antipaludiques.  
Une étude comparative de deux tétraoxanes et de leurs analogues trioxolanes a montré que ces deux 
familles de molécules antipaludiques ont des réactivités similaires vis-à-vis de l’hème. 
Conclusion 
La formation de radicaux alkyles après activation des tétraoxanes par le fer (II) a été mise en 
évidence par la caractérisation d’adduits avec TEMPO, avec l’hème et avec des métalloporphyrines 
synthétiques.  
Les tétraoxanes présentent une réactivité avec le fer qui est semblable à celle des trioxolanes ; ces 
deux familles de molécules peuvent induire l’oxydation de phospholipides modèles.  
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Les tétraoxanes antipaludiques sont capables de se lier à l’hème de façon covalente. Cette 
caractéristique est commune à tous les peroxydes actifs étudiés. 
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Abstract  
Dispiro-1,2,4,5-tetraoxanes are an attractive class of synthetic antimalarial peroxides due to their 
structural simplicity, good stability, and impressive activity. We investigated the reactivity of a 
series of potent tetraoxanes with FeSO4/TEMPO, FeSO4/phosphatidylcholine and heme to gain 
knowledge on their possible mechanism of action. Spin trapping experiments showed that Fe(II)-
mediated peroxide reduction gives a pair of primary and secondary alkyl radicals. Reaction with 
unsaturated phosphatidylcholine under Fenton reaction conditions showed that tetraoxanes and 
trioxolanes share a common reactivity in phospholipid oxidation that differs with that of 
artemisinin. The implication in terms of mechanism of action is discussed. The tetraoxane-derived 
secondary radical was also showed to quickly react with porphyrins and coupling products were 
identified by LC-MS analysis as regio-isomers of the alkylated heme adduct. This alkylating ability 
was confirmed with FeTPP and MnTPP. Results for tetraoxanes are consistent with previous reports 
on trioxanes or trioxolanes Fe(II)/heme-mediated reactivity and the heme alkylation is a process 
that may be involved in the mechanism of action of this promising class of antimalarials.  
Introduction 
According to the World Health Organization (WHO), more than one million people die of malaria 
every year, most of them in African countries where children and pregnant women are especially at 
risk.[1] The spread of chloroquine and sulfadoxine-pyrimethamine resistances have been implicated 
in the re-emergence of malaria in areas where the disease had been eradicated. In order to control 
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the burden of malaria, artemisinin-based combination therapies are now recommended as first-line 
treatment in many endemic regions.[2] 
Artemisinin (figure 1), a sesquiterpene lactone extracted from the Chinese herb Artemisia Annua, is 
highly active against both chloroquine sensitive- and resistant-strains of Plasmodium falciparum, 
the most dangerous form of the parasitic agent responsible for malaria.[3]  
It is known that the key pharmacophore of this highly efficient antimalarial is its 1,2,4-trioxane unit, 
and in particular its peroxide bond.[3] It is also well established that iron(II) salts reduces the 
peroxide bond of artemisinin leading to the formation of a pair of oxy-radicals that rapidly 
rearrange via either hydrogen abstraction or β-scission to form more stable carbon-centered 
radicals.[4-6] These alkyl radicals may be formed in vivo by reaction of artemisinin with iron(II)-
heme, the most abundant source of iron in Plasmodium.[7,8] They are able to interact with vital 
cellular components such as specific parasitic proteins,[9,10] heme, and other targets[11] that may 
result in the parasite death (figure 1). 
 
Figure 1: Fe-mediated activation of artemisinin 
Heme, in particular, seems to play a role in the mechanism of action of the drug since heme-
artemisnin adducts were chemically prepared and isolated,[12-14] but were also detected in malaria-
infected mice, treated with artemisinin.[15] Although artemisinin and clinically used derivatives 
artemeter and artesunate are very potent antimalarials, they also exhibit high extraction costs and 
poor pharmacokinetic properties. These drawbacks have driven the development of synthetic 
antimalarials that incorporate the key peroxide pharmacophore.[16,17] Among them are found 
dispiro-1,2,4,5-tetraoxanes, a promising class of antimalarials.  
Tetraoxanes are cyclic peroxides originally used for the production of macrocyclic hydrocarbons 
and lactones.[18] Work by the Vennerstrom group in the early 90’s showed that dispiro-tetraoxanes 
possess high in vitro antimalarial activity.[19] More recently, we have designed and prepared simple, 
94 
 
 Chapter 4: Reactivity of antimalarial tetraoxanes with Fe(II), heme and phospholipids: Implications for mode of action 
achiral and highly potent dispiro-tetraoxanes that incorporate the adamantyl group, known to bring 
stability to the endoperoxide motif.[20,21]  
The first aim of this study was to investigate the radical pathway after reductive activation of highly 
potent tetraoxanes with inorganic iron(II). In fact, formation of C-centered radicals with tetraoxanes 
has been reported,[22,23] but Opsenica et al. also reported that steroidal tetraoxanes generate RO• that 
do not undergo any further rearrangements.[24] These two contradicting observations call for further 
investigation into intermediates that might be responsible for the antimalarial activity of these 
endoperoxides. We were also interested to know whether the oxidative degradation of 
phospholipids, recently reported for water soluble tetraoxanes,[25] was observed with adamantane 
functionalized tetraoxanes 1-5 (figure 2) and trioxolane analogues. Finally, we investigated the 
heme-mediated reactivity of tetraoxanes to determine whether the reaction with heme may be 
related to their impressive antimalarial activity. 
 
Figure 2: Structures of antimalarial tetraoxanes 1-5 with their in vitro activities vs. 3D7 
Results and Discussion 
Antimalarial activity 
The in vitro antimalarial activity of tetraoxanes 2 and 3 was measured versus the chloroquine-
sensitive 3D7 strain of Plasmodium falciparum. Both tetraoxanes are very potent in vitro with IC50 
of 1.35 nM and 0.44 nM, respectively. 6, the trioxolane equivalent of 2, was also tested against the 
same strain and was found to be slightly less active than 2, with an IC50 of 13.24 nM.  
Reactivity with Fe(II) and TEMPO spin trapping 
Since tetraoxanes contain a peroxide bond like artemisinin, we were interested in the reaction 
pathway of these peroxides with iron (II) and compare this reactivity with trioxolane analogues.  
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In order to confirm the proposition of carbon-centered free radical intermediates, we performed 
spin-trapping experiments with the nitroxide free radical 2,2,6,6-tetramethyl-1-piperidine 1-oxyl 
(TEMPO). Tetraoxane 2 was allowed to react with 2 equiv. of FeSO4 and 1.5 equiv. TEMPO in 
aqueous acetonitrile for 24 h. LC-MS analysis of the crude mixture showed the presence of the two 
TEMPO adducts 8 (m/z 324.3 MH+, figure 3) and 9 (m/z 454.5 MH+). Similar experiments were 
carried out with tetraoxanes 1 and 5 in the presence of FeBr2 in THF. From these experiments, the 
adduct 8 was also identified in the crude mixture. The adducts 9’ and 9’’, analogues of the adduct 9, 
were also characterized after trapping of the primary radical derived from 1 and 5, respectively 
(figure 3b). Similar adducts were previously reported by Tang et al. with trioxolanes and 
FeBr2/oxoTEMPO.[26] In the case of tetraoxanes, coordination of Fe(II) on O2 led to the formation 
of the oxy-radical 10 (figure 3). Ring-opening via β-scission gave the secondary C-radical 12 which 
was trapped with TEMPO to give the adduct 8, along with the keto-amide 14 (m/z 281.3 MH+). 
Alternatively, coordination on O1 led to the formation of the oxy radical 11 which rearranged to the 
primary C-radical 13, also trapped with TEMPO to give the product 9.  
 
 
Figure 3: a) Fe-mediated activation of 2 and TEMPO spin trapping and b) structures of adducts 9’ and 9’’ 
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The identification of the two TEMPO adducts 8 and 9 provided evidence of the formation of two 
carbon-centered radicals after iron(II) activation of tetraoxanes. This result is not in accordance with 
a previous report where the RO• generated by steroidal tetraoxanes did not undergo any further 
rearrangements.[24] It should be noted that only the secondary radical has been trapped with 
trioxolanes like OZ277. The formation of alkyl radicals from tetraoxanes is a common feature with 
artemisinin, although their reactivity is quite different in the sense that the high energy primary 
carbon centered radical of artemisinin has been trapped whereas the secondary C-radical has not 
(vide infra). 
Fe(II)-mediated reactivity: tetraoxane vs. trioxolanes 
We prepared the trioxolane analogues of 2 and 3 to compare the stability and reactivity of the 
1,2,4,5-tetraoxane pharmacophore to the ozonide core in the presence of iron (II) using standard 
conditions (figure 4).  
 
Figure 4: Tetraoxanes 2 and 3, and their trioxolanes analogues 6 and 7, respectively with their IC50 vs. 3D7 
Tetraoxanes and trioxolanes were subjected to 20 equiv. of ferrous sulfate in aqueous acetonitrile 
under nitrogen, for a 7 h period of time. Iron-mediated decomposition was observed for all the 
tested compounds. The time-dependent degradation studies, conducted by monitoring the loss of 
parent endoperoxide by LC-MS, showed a linear decrease of tetraoxanes concentration (figure 5). 
Similar reaction profiles were observed for tetraoxanes and trioxolanes, indicating that the stability 
of the two classes of drugs with inorganic Fe(II) is comparable. 
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Figure 5: Time-dependence profile for the decomposition of peroxides by 20 equiv. of FeSO4 in aqueous 
acetonitrile 
Reactivity of tetraoxanes with Fe(II) and phosphatidylcholine (PC) 
The radicals produced after tetraoxanes activation may react in vivo with cell components such as 
lipids of the membrane bilayer, a well known target for ROS, leading to cell damage and death. 
Kumara and coll. have recently reported that water soluble tetraoxanes can induce olefins oxidative 
degradation in a phospholipid model in the presence of a Fe(II) salt.[25] Several phosphatidylcholine 
degradation products were identified, while they were absent when artemisinin was used.  
We studied the reactivity of tetraoxanes 2 and 3 with phosphatidylcholine, in the Fenton reaction 
conditions, and we compared this reactivity with that of trioxolane analogues, 6 and 7, respectively. 
2-linoleoyl-1-palmitoyl-sn-phosphatidylcholine (PC) is composed of a phosphocholine polar head 
linked to the glycerol moiety with palmityl acid, a saturated fatty acid chain at the sn-1 position and 
linoleic acid, an unsaturated fatty acid chain at the sn-2 position (figure 6).  
 
Figure 6: Structure of 2-linoleoyl-1-palmitoyl-sn-phosphatidylcholine (PC) 
Reactions of PC with 8 equiv. of tetraoxanes and FeSO4 were carried out in H2O/ethanol (2:1) at 
38°C, for 24 h under N2 atmosphere. The crude mixture and the organic extract were analyzed by 
ESI-MS and LC-MS. Reaction with 2 and 3 gave several peaks other than the native PC, observed 
at M+ (m/z 758) and [MNa]+ (m/z 780). The predominant degradation products were found at m/z 
622.4, 666.4, 788.6 (810.5), and 808.5. All these ions, expect m/z 808.5, were detected by 
Kumura.[25] The structures proposed by the authors for the PC oxidation products are depicted in 
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figure 7. The bis-allylic hydrogen at C11 of the linoleic acid is more likely to be abstracted by the 
tetraoxane-derived radicals.[27] The degradation products are the result of subsequent β-cleavage 
and lipid peroxidation.  
 
Figure 7: Proposed mechanism for tetraoxane-mediated lipid peroxidation with structures suggested in ref 25  
The reaction with PC was carried out with trioxolanes 6 and 7 in the same conditions. Product 
analysis indicated that the reaction pathway observed for trioxolanes was qualitatively the same 
than for tetraoxanes. The same PC degradation products were observed, in a slightly higher extent, 
indicating that in these conditions, the two classes of antimalarials exhibit the same reactivity 
towards phospholipids. 
After reaction with artemisinin in the same conditions, the native PC was found intact, confirming 
that this natural peroxide is not responsible for phospholipid oxidation in these conditions. In fact, 
artemisinin was showed to enhance the heme-mediated lipid membrane damage[28] but does not 
affect PC in our heme-free conditions. This difference of reactivity between artemisinin and 
tetraoxanes/trioxolanes here is likely due to the difference of stability of the generated radicals. The 
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artemisinin-derived radicals are very reactive and the intramolecular rearrangement of these radicals 
is too rapid. The adamantane-derived secondary radical derived from trioxolanes/tetraoxanes, stable 
enough to be trapped with TEMPO, would abstract the bis-allylic hydrogen and initiate the lipid 
peroxidation process of PC.  
Reactivity of tetraoxanes with heme 
We studied the reactivity of tetraoxanes with heme, a more biologically relevant source of iron. 
Several studies have showed that iron(II)-heme quickly reacts with the peroxide bond of various 
antimalarial trioxanes and trioxolanes. The pathway is the same as described with ferrous ions and 
the generated C-centered radicals were shown to bind to the porphyrin macrocycle and form heme-
drug adducts. Such adducts were isolated and/or characterized with artemisinin[12,13,15] and 
derivatives,[29,30] hybrid drugs trioxaquines[31,32] and more recently with trioxolanes derivatives.[33]  
We investigated the heme-mediated reactivity of tetraoxanes 2 and 3 to provide further insight into 
the mechanism of action for this promising class of antimalarials. We next compared this reactivity 
with that of their trioxolane analogues.  
Tetraoxanes were allowed to react with iron(III)-hemin, in presence of an excess of dithionite to 
generate iron(II)-heme in situ, in ACN/NaOH 0.1 M (50/50). In these conditions, iron(II)-heme 
quickly reacts with the tetraoxanes. In the case of 2, HPLC analysis of the crude mixture showed 
that most of the starting heme has reacted within 30 min, giving at least 3 products with higher 
retention times than heme itself (figure 8a), and a maximum absorption of the Soret band at 430 nm, 
instead of 398 nm for heme. A blue-shift of the Soret band has been also observed with artemisinin, 
although to a lower extent.[13]   
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Figure 8: a) UV-Vis trace and b) extracted ion chromatogram at m/z 783.2 of reaction of heme with tetraoxane 2 
LC-MS analysis showed that these three compounds exhibit a m/z 783.2 (M+), which is consistent 
with a coupling product between heme (mass 616) and the tetraoxane-derived fragment previously 
trapped with TEMPO (mass 167).  
Both the maximum absorbance and the m/z ratio strongly suggest that these compounds result from 
the covalent bonding of the tetraoxane-derived secondary C-centered radical 12 and the heme 
porphyrin (15, figure 9). The same alkylated heme adducts have been reported with trioxolanes in 
similar conditions by Creek et al.[33] The extracted ion chromatogram at m/z 783.2 showed four 
peaks (figure 8b), expected to be the four possible regio-isomers of the alkylated heme adduct 15, as 
reported by Robert et al. for heme-artemisinin adducts.[34] 
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Figure 9: Proposed mechanism for the alkylation of heme (Fe(II)-PPIX) by tetraoxane 2, adapted from [33] 
Similar results were obtained with all the active antimalarial tetraoxanes tested, including 3 and 4 
(results not shown). The ketoamide, a co-product of the reaction, was also detected in all cases.  
Using a LC-MS calibration, we monitored the conversion of heme during the reaction (figure 10). 
As a control, the reaction was carried out without drug, to estimate the loss of heme due to 
degradation by residual oxygen. Reaction with artemisinin showed that c.a. 70% of the starting 
heme was converted within 15 min. Reaction with tetraoxanes 2 and 3 was also rapid, and resulted 
in conversion of the starting heme of 53% and 38%, respectively after 5 min only. Concentration-
time profiles of heme showed that the reaction is complete within 15 min, as the absorbance of the 
Soret band remains constant beyond. 
 
Figure 10: Time-dependence profile for the conversion of heme with peroxides 
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Reaction of trioxolanes with heme in the same conditions showed a very similar profile and the 
same coupling products were identified (figure 11). However, the adduct formation appeared to be 
more rapid with trioxolane 6 and the peak ratio is different. 
 
Figure 11: LC trace of reaction mixture of tetraoxane 2 (top) and and trioxolane 6 (bottom) with heme 
Due to their low stability, quantification of the adducts was not possible. However, estimated yield 
of adducts after 15 min for 2 is 34%, which is about half of the yield observed with 6 in the same 
conditions (71%).[35] No significant differences were observed between 3 and 7 (data not shown). 
As reported with artemisinin, we also studied the alkylating activity of tetraoxanes with iron (II) 
tetraphenylporphyrin and manganese (II) tetraphenylporphyrin, two symmetrical synthetic 
porphyrin, to confirm results observed with heme.[36] Tetraoxane 2 was allowed to react with 
MnIITPP in CH2Cl2 for 3h, in presence of tetrabutylammonium borohydride as a reducing agent. 
Analysis by LC-MS of the crude mixture showed the presence of a porphyrin-drug adduct with m/z 
835.10 (M+), consistent with a chlorin-type adduct (16), which result from alkylation on one of the 
eight β-pyrrolic positions of the macrocycle[36] by the tetraoxane-derived secondary radical. The 
same chlorin-type adduct was identified after reaction with FeIITPP. After work-up and Mn 
removal,[36] the demetalated adduct (17, figure 12) was also identified (m/z 783.19, MH+).  
These results with the tetraphenylporphyrins confirm the alkylating capacity of antimalarial 
tetraoxanes observed with heme.   
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Figure 12: Expected structures of MnTCP- and H2TCP-tetraoxane adducts 16 and 17 
One can note that, although the primary and the secondary radical can possibly be generated after 
reduction by Fe2+ salt, only the tetraoxane-derived secondary radical (12) was generated in the 
presence of heme or tetraphenylporphyrins. In the case of artemisinin and trioxaquines, only 
adducts resulting from the primary radical were reported.[12,13,32] This could be explained by the 
relative positions of the peroxide bond and the porphyrin ligand. Contrary to “free” iron which can 
coordinate both oxygen atoms, iron in the heme porphyrin would less easily coordinate O1, which 
is close to the bulky adamantane group. However, we cannot rule out the possibility that the 
primary radical is also formed, but does not react with the porphyrin. To confirm this hypothesis, a 
modeling study of the interaction between heme and the peroxide bond of tetraoxanes would be 
useful to predict which oxygen (O1 or O2) is the most favorable for association with iron in heme. 
The reaction with heme occurs much faster than reaction with ferrous sulfate. Indeed, all 
tetraoxanes were degraded in few minutes, while reaction with inorganic iron needs several hours. 
This increased reaction rate, also observed with trioxanes[32] and trioxolanes, was discussed by 
Creek et al.[33] 
Conclusion 
Iron(II)-mediated activation of tetraoxanes results in the formation of a primary and a secondary C-
centered radical. Stability of tetraoxanes with ferrous sulfate was shown to be comparable with that 
of their trioxolane analogues. Both classes of drugs react with phosphatidylcholine to give 
peroxidation products after reductive activation by Fe2+. 
All the tetraoxanes used in this study were shown to rapidly react with Fe(II)-heme. The major 
reaction products are alkylated heme adducts, resulting from addition of the adamantane-derived 
secondary radical intermediate.  
The high reactivity with heme and the formation of covalent heme-drug adducts is a feature shared 
by all tested active trioxanes, trioxolanes and tetraoxanes derivatives. 
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Experimental section 
LC-MS analysis 
Mass spectrometry analysis was performed on a Thermo TSQ Quantum Access triple quadrupole 
mass spectrometer connected to LC device Thermo Accela high pressure pump, auto sampler and 
PDA detector. Analytical separation were performed on a 150 x 3 mm Thermo Hypersyl 
HyPURITY® C18 column (5 µm). Data were captured in full MS scan mode and proceeded using 
Xcalibur software (version 2.0.7) and Thermo Quan browser (version 2.0.7). 
Chemistry 
All reagents were purchased from Sigma Aldrich UK and were used without purification. NMR 
spectra were recorded on a Brucker AMX 400 (1H, 400 MHz; 13C, 100 MHz) spectrometer. 
Chemical shifts are described in ppm (δ) downfield from an internal standard of trimethylsilane. 
Tetraoxanes 1, 4 and 5 were prepared according the procedure reported by Amewu et al. 
Synthesis of tetraoxanes 2 and 3 
Preparation of adamantane-2-spiro-3'-9'-[1-(2-methylpropyl)piperazino]-1',2',4',5’-
tetraoxaspiro[5.5]undecane (2): To a solution of adamantane-2-spiro-3'-9'-(carboxymethyl)-
1',2',4',5’-tetraoxaspiro[5.5]undecane (0.50 g, 1.48 mmol) in dry dichloromethane (50 mL), were 
added anhydrous triethylamine (0.4 mL, 3.0 mmol, 2 equiv.) and methyl chloroformate (0.11 mL, 
1.48 mmol, 1 equiv.). The mixture was stirred under N2 atmosphere at 0°C for 1 h. 1-(2-
methylpropyl)piperazine (0.21 mL, 1.48 mmol, 1 equiv.) was added, and the mixture was allowed 
to stir at 0°C for 30 min and at room temperature for further 90 min. The reaction mixture was 
diluted with water (60 mL) and extracted with dichloromethane. (3 x 60 mL). The organic layers 
were combined, washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. The crude product was purified by flash chromatography to give 145 mg of 2 as a white 
solid (21%). 
1H NMR (400 MHz, CDCl3) δ 3.62 (t, 2H, J = 4.7 Hz, NCH2), 3.45 (t, 2H, J = 4.7 Hz, NCH2), 2.35 
(t, 4H, CH2N), 2.27-2.20 (m, 2H, NCH2), 2.08 (d, 2H, J = 7.4 Hz, CH2CO), 2.04-1.90 (m, 6H, CH), 
1.86 bs, 2H, CH2), 1.84-1.50 (m, 14H, adamantylidene/CH2), 1.36-1.17 (m, 2H, adamantylidene), 
0.89 (m, 6H, J = 6.5 Hz, CH3); 13C NMR (100 MHz, CDCl3), δ 170.7, 110.8, 108.2, 67.2, 54.2, 
53.7, 46.3, 42.1, 39.4, 37.3, 34.4, 33.5, 27.4, 25.8, 21.2; HRMS calculated for C26H43O5N2: 
463.3172, found 463.3187. Elemental analysis C: 67.62, H: 9.18, N: 6.09 (required values C: 67.50, 
H: 9.15, N: 6.06). 
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Preparation of adamantane-2-spiro-3'-9'-[1-methyl-4-(4-piperidino)piperazino]-1',2',4',5’-
tetraoxaspiro[5.5]undecane (3): To a solution of adamantane-2-spiro-3'-9'-(carboxymethyl)-
1',2',4',5’-tetraoxaspiro[5.5]undecane (0.3 g, 0.89 mmol) in dry dichloromethane (20 mL), were 
added anhydrous triethylamine (0.18 mL, 1.34 mmol, 2 equiv.) and ethyl chloroformate (0.08 mL, 
0.89 mmol, 1equiv.). The mixture was stirred for 1 h at 0°C. 1-methyl-4-(4-piperidino)piperazine 
(163 mg, 0.89 mmol, 1 equiv.) was added, and the mixture was allowed to stir at 0°C for 30 min 
and at room temperature for further 90 min. The reaction mixture was diluted with water (30 mL) 
and extracted with dichloromethane. The organic layers were combined, washed with brine, dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude product was purified by 
flash chromatography to give 397 mg of 3 as a white solid (86%). 
1H NMR (400 MHz, CDCl3) δ 4.65 (d, 2H, J = 13.4 Hz, CH2), 3.90 (d, 2H, J = 11.0 Hz, CH2), 3.00 
(t, 2H, J = 11.1 Hz, CH2), 2.36-2.68 (m, 7H, CH/CH2), 2.28 (s, 3H, NCH3), 2.23 (bs, 2H, CH2), 
1.20-2.07 (m, 27H, CH/CH2). 13C NMR (100 MHz, CDCl3), δ 170.5, 110.8, 108.2, 62.1, 55.7, 49.5, 
46.4, 45.5, 41.5, 39.4, 37.3, 34.4, 33.5, 29.6, 28.6, 27.5. MS (ESI+), [M+H ] + (100) 504.4. HRMS 
calculated for C28H46O5N3: 504.3437; found 504.3426. Elemental analysis C: 66.44, H: 9.06, N: 
8.34 (required values C: 66.77, H: 9.04, N: 8.30). 
Synthesis of trioxolanes 6 and 7 
cis-adamantane-2-spiro-3’-8’-(carboxymethyl)-1’,2’,4’-trioxaspiro[4.5]decane was prepared 
according to a reported method.[37] 
Preparation of cis-adamantane-2-spiro-3'-8'-[1-(2-methylpropyl)piperazino]-1',2',4'-
trioxaspiro[4.5]decane 6: To a solution of cis-adamantane-2-spiro-3’-8’-(carboxymethyl)-1’,2’,4’-
trioxaspiro[4.5]decane (0.5 g, 1.55 mmol) in dry CH2Cl2 (50 mL) at 0°C, were added Et3N (0.44 
mL, 3.10 mmol, 2 equiv.) and methyl chloroformate (0.12 mL, 1.55 mmol, 1 equiv.) under N2. The 
mixture was stirred at 0°C for 1 h and 1-(2-methylpropyl)piperazine was added (0.22 mL, 1.55 
mmol, 1.0 equiv.). The reaction mixture was stirred at 0°C for 45 min and at rt for other 2 h. The 
reaction mixture was diluted with 50 mL of water and extracted with CH2Cl2 (2 x 60 mL). The 
organic layers were combined and washed with water (40 mL) and brine (40 mL), dried on Na2SO4 
and evaporated under vaccuo. The crude product was purified by flash chromatography (silica gel, 
eluent: ethyl acetate/CH2Cl2 50/50) to afford trioxolane 6 (0.48 g, 70%) as a white solid.  
1H NMR (500 MHz, 313 K, CDCl3) δ: 3.64 (bs, 2H), 3.48 (bs, 2H), 2.39 (bs, 4H), 2.23 (d, J = 6.9 
Hz, 2H), 2.10-1.60 (m, 24H), 1.26 (dq, J = 13.2 Hz and 5.4 Hz, 2H), 0.93 (d, J = 6.6 Hz, 6H); 13C 
NMR (125 MHz, 313 K, CDCl3) δ: 170.38, 111.09, 108.64, 66.69, 53.85, 53.28, 45.82, 41.64, 
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39.14, 36.85, 36.46, 34.82, 34.09, 33.40, 30.30, 26.93, 26.55, 25.41, 20.78; HRMS calculated for 
C26H43N2O4 [M+H]+: 447.3223; found: 447.3221.  
 
Preparation of cis-adamantane-2-spiro-3'-8'-[1-methyl-4-(4-piperidino)piperazino]-1',2',4'-
trioxaspiro[4.5]decane (7): To a solution of cis-adamantane-2-spiro-3’-8’-(carboxymethyl)-1’,2’,4’-
trioxaspiro[4.5]decane (1.5 g, 4.65 mmol) in dry CH2Cl2 (150 mL) at 0°C, were added Et3N (1.32 
mL, 9.30 mmol, 2 equiv.) and methyl chloroformate (0.36 mL, 4.65 mmol, 1 equiv.) under N2. The 
mixture was stirred at 0°C for 1 h and 1-methyl-4-(4-piperidino)piperazine was added (860 mg, 
4.69 mmol, 1 equiv.). The reaction mixture was stirred at 0°C for 30 min and at rt for other 2 h. The 
reaction mixture was diluted with 150 mL of water and extracted with CH2Cl2 (3 x 100 mL). The 
organic layers were combined and washed with water (100 mL) and brine (100 mL), dried on 
Na2SO4 and evaporated under vaccuo. The crude product was purified by flash chromatography 
(silica gel, eluent: CHCl3/methanol 100/0 to 90/10) to afford trioxolane 7 (418 mg, 20%) as a white 
solid.  
1H NMR (500 MHz, 313 K, CDCl3) δ: 4.65 (bd, J = 12.8 Hz, 2H, CH2), 3.92 (bd, J = 13.3 Hz, 2H, 
CH2), 3.01 (t, J = 12.8 Hz, 2H), 2.70-2.39 (m, 7H, CH/CH2), 2.31 (s, 3H, NCH3), 2.23 (d, J = 6.9 
Hz, 2H), 2.03-1.25 (m, 27H, CH/CH2); 13C NMR (125 MHz, 313 K, CDCl3) δ: 170.21, 111.28, 
108.65, 61.66, 55.40, 49.03, 45.88, 45.09, 41.06, 39.20, 36.85, 36.45, 34.81, 34.09, 33.41, 30.30, 
29.18, 28.25, 26.93, 56.55; HRMS calculated for C28H46N3O4 [M+H]+: 488.3488; found: 488.3487. 
 
 
General procedure for the reaction of tetraoxanes with Fe2+ and TEMPO 
A solution of tetraoxane (0.5 mmol), FeSO4 or FeBr2 (2 equiv.), TEMPO (2 equiv.) in THF or 
CH2Cl2/ CH3CN 50:50 (10mL) was stirred at ambient temperature under nitrogen atmosphere for 
24 h and concentrated. The crude product was dissolved in ethyl acetate, washed with water and 
brine, dried over MgSO4, filtered and concentrated. The crude product was analyzed by LC-MS and 
TEMPO adducts were identified in all cases.  
General procedure for the reaction of antimalarial peroxides with ferrous sulfate:  
Stock solution of peroxide (10 mM in absolute ethanol) and ferrous sulfate (100 mM in water) were 
freshly prepared and degassed prior to use.  
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A solution of ferrous sulfate (1.0 mL, 18.2 mM) was added to a solution of peroxide (1.0 mL, 1 
mM) in ACN/H2O 1:1 (final volume 5.5 mL). The reactions were allowed to stir at room 
temperature under nitrogen with LC-MS monitoring.   
LC-MS analysis: Compounds were eluted using a ternary solvent system consisting of 50% MeOH, 
35% acetonitrile and 15% 0.1 M ammonium acetate, in isocratic mode (flow rate: 0.5 mL/min). 
Reaction of antimalarial peroxides with FeSO4 and PC: 
Stock solutions of PC, FeSO4 and peroxides were degassed prior to use. To a solution of PC in 
water (500 µL, 0.83 µmol) were added an aqueous solution of ferrous sulfate (500 µL, 7.2 µmol, 
8.7 equiv.) and a solution of peroxide in absolute ethanol (500 µL, 6.81 µmol, 8.2 equiv.). For 
control reaction, the peroxide solution was replaced by absolute ethanol (500 µL). The cloudy 
mixtures were stirred at 38°C for 24 h under a nitrogen atmosphere. An aliquot of each crude 
mixture was taken for ESI/MS analysis before reactions were quenched with 50% phytic acid 
solution (10 µL), and a trace of BHT, according to the procedure reported by Kumura et al. The 
reaction mixtures were extracted with CHCl3/CH3OH (1:2, 1 mL) and the chloroform layers were 
analyzed by ESI/MS. 
General procedure for the reaction of antimalarial peroxides with heme: 
Hemin stock solution (10 mM in 0.1 M NaOH) was freshly prepared and degassed with acetonitrile 
prior to use. Hemin solution (2.0 mL, 0.02 mmol) was added to a solution of peroxide (0.02 mmol, 
1 equiv.) and dithionite (41 mg, 0.20 mmol, 10 equiv.) in acetonitrile (2.0 mL) under argon. The 
mixture was stirred at room temperature and monitored by LC-MS. 
LC-MS analysis: Compounds were eluted using a binary gradient solvent system consisting of 
MeOH, 1% TFA (solvent A) and H2O, 1% TFA (solvent B). The gradient used was 70% to 80% of 
solvent A over 10 min (flow rate: 0.5 mL/min). Retention times were 3.24 min for heme and 5.39 to 
8.15 min for the heme-tetraoxane adducts. 
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Résumé de la publication : 
The antimalarial trioxaquine DU1301 alkylates 
heme in malaria­infected mice 
F. Bousejra-El Garah, C. Claparols, F. Benoit-Vical, B. Meunier, A. Robert, Antimicrobial Agents 
and Chemotherapy 2008, 52, 2966-2969. 
La trioxaquine DU1301 alkyle l’hème chez la souris impaludée 
Les trioxaquines ont été conçues de façon à être des alkylants potentiels de l’hème grâce à la 
réactivité du cycle 1,2,4-trioxane. La capacité alkylante de la trioxaquine prototype DU1301 avait 
été mise en évidence chimiquement avec la caractérisation des adduits hème-DU1301.[1] Nous nous 
sommes intéressés ici à la réactivité de cette trioxaquine vis-à-vis de l’hème in vivo, et au lien 
possible entre son caractère alkylant et son activité antipaludique. Pour cela, nous avons évalué les 
propriétés alkylantes de la DU1301 chez la souris infectée par Plasmodium, en recherchant les 
adduits covalents heme-trioxaquine dans les organes et fluides biologiques. 
 
Des souris infectées par la souche P.vinckei petteri ont été traitées par voie orale, avec une dose 
efficace de trioxaquine DU1301 (lot 1, dose : 100 mg/kg/100 µL DMSO).  
A titre de contrôle,  
 des souris non infectées ont été traitées avec DU1301 dans les mêmes conditions que les 
souris impaludées (lot 2). 
 des souris infectées ont été « traitées » au DMSO pur (lot 3). 
Les souris ont été sacrifiées 2 h après le traitement ; les organes ont été broyés et extraits à la 
pyridine. L’analyse par LC-MS des extraits de rate de souris impaludées et traitées à la DU1301, a 
permis de mettre en évidence la présence des adduits hème-trioxaquine 1 (m/z 1101.1) et 2 (m/z 
949.2). Ces adduits, présents dans les rates de toutes les souris du lot 1, ont été détectés avec des 
temps de rétention identiques à ceux des adduits préparés chimiquement. De plus, les figures 
isotopiques des deux ions m/z 1101.1 et 949.2 (figure ci-dessous) sont caractéristiques de la 
présence d’un atome de fer et de chlore.  
Les adduits hème-trioxaquine n’ont pas été détectés dans les rates de souris saines traitées dans les 
mêmes conditions (lot 2), ni dans les rates de souris impaludées non traitées (lot 3), ce qui montre 
que la réactivité alkylante de la trioxaquine in vivo est induite par la présence du parasite. 
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Adduit hème-trioxaquine 2 
m/z 949.2 M+ 
Adduit hème-trioxaquine 1 
m/z 1101.1 M+ 
Figures isotopiques des ions m/z 1101.1 et 949.2, correspondant aux adduits hème-trioxaquine 1 et 2, 
respectivement 
 
C’est également dans la rate que les adduits entre l’hème et l’artémisinine avaient été détectés.[2] En 
effet, la rate étant le principal organe d’élimination des érythrocytes infectés, il est normal que l’on 
y retrouve les adduits hème-drogue, eux-mêmes formés dans ces érythrocytes malades.  
 
Lors de la recherche d’adduits hème-artémisinine chez la souris impaludée, des adduits glucuro-
conjugués avaient été détectés dans l’urine. Dans le cas présent, les adduits n’ont pas pu être 
détectés dans les reins, ni l’urine. Ceci peut être dû à deux raisons : 1) une concentration des adduits 
inférieure à la limite de détection ou 2) la métabolisation des adduits étant un processus dynamique, 
ils n’ont peut-être pas encore atteint les reins pour être éliminés dans l’urine.  
Conclusion 
La trioxaquine DU1301 est un alkylant efficace de l’hème chez la souris impaludée. La mise en 
évidence des adduits hème-drogue montre que la réactivité des trioxaquines vis-à-vis de l’hème in 
vivo est similaire à celle de l’artémisinine. Cette propriété d’alkylation pourrait être liée à leur haute 
efficacité antipaludique, d’autant plus que ces deux molécules ont montré des moments d’action sur 
le cycle du parasite identiques.[3] 
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The in vivo alkylation of heme by the antimalarial trioxaquine DU1301 afforded covalent heme-drug adducts
that were detected in the spleens of Plasmodium sp.-infected mice. This result indicates that the alkylation
capacities of trioxaquines in mammals infected with Plasmodium strains are similar to that of artemisinin, a
natural antimalarial trioxane-containing drug.
Artemisinin and its derivatives have emerged as antimalarial
drugs over the past three decades. With a pharmacophore
based on a 1,2,4-trioxane, these drugs are highly active against
multidrug-resistant Plasmodium strains and are nontoxic, even
for children and pregnant women. In addition, no clinically
relevant parasite resistance has been reported so far (7, 24, 25).
Many synthetic peroxides have been synthesized as artemisinin
models in the last 15 to 20 years (for recent reviews, see
reference 8, references therein, and references 15 and 22).
Among them, trioxaquines have a unique structure, containing
both an aminoquinoline moiety (as in chloroquine) and a syn-
thetic 1,2,4-trioxane entity (as an artemisinin mimic) (2, 4). As
previously described (4), trioxaquine DU1301 has been ob-
tained by convergent synthesis from 7-chloro-4-(2-aminoethyl-
amino)quinoline and a 1,2,4-trioxane derived from ascaridole
(20, 10). Trioxaquines are able to cure Plasmodium-infected
mice treated orally at 15 to 20 mg/kg of body weight/day for 4
days (as demonstrated by the “4-day suppressive test”) (see
reference 16). Trioxaquines are being developed by Palumed,
and one of them (PA1103-SAR116242) is currently under reg-
ulatory preclinical development with Sanofi-Aventis (reference
13 and references therein).
The mechanism of action of antimalarial 1,2,4-trioxanes has
been intensively studied during the last two decades. The cru-
cial role of heme digestion-aggregation processes in infected
erythrocytes has led to investigations of the possible interac-
tion of heme with artemisinin. In the initial work, it was re-
ported that heme-catalyzed peroxide cleavage is responsible
for the alkylation of heme and specific parasite proteins (1, 6).
Such iron(II)-mediated cleavage of the endoperoxide function
generates, in particular, an alkyl radical centered at position
C-4 of artemisinin or synthetic trioxanes (9, 17). The concen-
tration of free iron ions in living cells is close to zero, whereas
the hemoglobin concentration in red blood cells is 5 mM (cor-
responding to a heme concentration of 20 mM). In addition,
the extensive ingestion of host hemoglobin into the food vacu-
oles of Plasmodium parasites leads to vacuolar heme concen-
trations of about 400 mM (21). Bearing in mind the important
role of free heme in infected erythrocytes, we reported previ-
ously that artemisinin is efficiently activated by heme in vitro
and also in vivo, leading to the alkylation of the heme macro-
cycle (18, 19). Covalent heme-drug adducts resulting from al-
kylation by the drug were detected in spleens and urine sam-
ples from Plasmodium-infected mice (18). Yet, the exact role
of heme-artemisinin adducts in the death of the parasite will
probably remain a matter of debate. Nevertheless, it is now
well established that artemisinin alkylates heme with its C-4-
centered radical, and as underlined in a recent publication,
free heme or hemoglobin heme alkylations are “possibly the
only malaria-parasite-relevant fully characterized alkylation re-
actions reported so far for [artemisinin]” (23).
Trioxaquine DU1301 was designed as a potential heme-
alkylating agent, and such an alkylating ability has been evi-
denced previously in vitro (11). To confirm that the formation
of heme-trioxaquine adducts is a biologically relevant process,
we examined the in vivo alkylating ability of DU1301, a rep-
resentative member of this new class of antimalarial drugs, in
parasite-infected mice.
To address the question of the in vivo alkylating properties
of trioxaquines, Plasmodium vinckei petteri-infected mice were
treated orally with DU1301, a trioxaquine prototype (Fig. 1). A
set of three Swiss female albino mice (25 to 30 g) were intra-
peritoneally inoculated with erythrocytes parasitized by P.
vinckei petteri. When the level of parasitemia (evaluated mi-
croscopically on Giemsa-stained thin blood smears) was higher
than 40% (after 3 days), mice were treated orally with a single
dose of trioxaquine DU1301 (2.5 mg diluted in 100 l of
dimethyl sulfoxide [DMSO], corresponding to a dose of 100
mg/kg). As control experiments, a set of three healthy mice
received the same dose of DU1301 and a set of infected mice
received pure DMSO (no treatment). Mice were sacrificed 2 h
after treatment, and organs (spleens, livers, and kidneys) were
collected.
The detection of heme-DU1301 adducts in mouse organ
extracts first required the efficient extraction of these hydro-
* Corresponding author. Mailing address: Laboratoire de Chimie de
Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse
Cedex 4, France. Phone: 33 5 61 33 31 26. Fax: 33 5 61 55 30 03. E-mail:
anne.robert@lcc-toulouse.fr.
 Published ahead of print on 16 June 2008.
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phobic compounds from biological tissues. Each organ was
crushed with sand in a mortar. Heme-DU1301 adducts are
poorly soluble in common aqueous and organic solvents, and
the stacking of heme with quinoline moieties may account for
this low solubility (11). Strong - interactions between heme
and the quinoline ring of antimalarials has been evidenced
previously by nuclear magnetic resonance analyses (14). Be-
cause of the low solubilities of these heme-DU1301 adducts,
pyridine (1.0 to 1.5 ml) was found to be the best solvent for
their extraction (by subjecting the tissues to a vortex for 20
min). The organ extracts were analyzed by liquid chromatog-
raphy-mass spectrometry (LC-MS) without any additional
treatment.
The characterization of small amounts of poorly soluble
hydrophobic adducts in biological extracts was much more
complicated than the usual in vitro characterization of adducts
prepared on the bench on a 10- to 100-mg scale (11). Because
of the difficulties with the organ extracts, it was essential to
optimize the analytical conditions by using chemically pre-
pared adducts (11) in order to have reliable, accurate, and
sensitive detection of the in vivo adducts. Analytical separa-
tions were performed on a 5-m C18 Modulo-Cart QS Upti-
sphere column (250 by 4.6 mm) equipped with a precolumn
containing the same packing material. Compounds were eluted
under the following conditions: solvent A consisted of metha-
nol-H2O-trifluoroacetic acid, 70/30/0.05; solvent B consisted of
methanol-trifluoroacetic acid, 100/0.05; the gradient from an
A/B ratio of 100/0 to an A/B ratio of 0/100 over 25 min was
followed by 10 min at an A/B ratio of 0/100; the elution rate
was 0.5 ml/min; and UV-visible light detection was performed
at 340 and 400 nm by using a diode array detector. The volume
of pyridine extract injected was 100 l. Positive-ion electros-
pray MS was performed on a Q-Trap AB Sciex quadrupole
instrument (Fig. 2).
The LC-MS analyses of spleen extracts from a Plasmodium-
infected mouse treated with trioxaquine DU1301 (100 mg/kg in
100 l of DMSO administered per os) are summarized in Fig.
3a to c. Currents of ions with m/z 1,101.0 and 949.2, which
correspond to adducts 1 and 2, respectively, were detected with
retention times of 18.5 to 21.7 min, along with heme (retention
time, 16.5 min). Retention times and mass spectra were con-
sistent with those observed with chemically prepared adducts
(Fig. 2) (11). Furthermore, the isotopic patterns of signals at
m/z 1,101.1 and 949.2 clearly showed the presence of both one
iron atom (M  2 due to 54Fe) and one chlorine atom (M 
2 due to 37Cl) (Fig. 3). This result is fully consistent with the
reductive activation of the peroxide bond of trioxaquine
DU1301 by iron(II)-heme within infected erythrocytes. This
reaction leads to the formation of an oxygen-centered radical
that rapidly rearranges to give an alkyl radical (Fig. 1) able to
alkylate heme at meso positions, giving rise to the “complete”
covalent adduct heme-DU1301, adduct 1. Heme-drug adduct
2, generated by hydrolysis and the loss of the terpene moiety,
probably in the spectrometer, was also detected.
Adducts 1 and 2 were both detected in all infected mice
FIG. 1. Reductive activation of trioxaquine DU1301 by iron(II)-heme, leading to the covalent heme-drug adducts 1 and 2. Quin stands for the
aminoquinoline fragment, and FeIIIPPIX stands for ferriprotoporphyrin IX.
FIG. 2. LC-MS analyses of chemically prepared heme-trioxaquine
adducts. (a) UV-visible (vis.) trace at 400 nm; (b and c) extracted ionic
current (XIC) traces for the indicated m/z.
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treated with DU1301. In the control experiments, these heme-
trioxaquine adducts were undetectable in all spleen extracts
from healthy mice treated under the same conditions as in-
fected mice (Fig. 3d and e) and in all spleen extracts from
untreated Plasmodium-infected mice (which received only ex-
cipient) (data not shown).
Heme-DU1301 adducts remained below detectable levels in
the kidneys and urine samples from Plasmodium-infected mice
that had been treated with trioxaquine. However, it should be
considered that the spleen, an organ devoted to the elimina-
tion of damaged red blood cells, is the first candidate for the
accumulation of heme-drug adducts. Further metabolism of
these adducts is a dynamic process, whereas their distribution
may be responsible for the fact that they remained below the
detection limit in kidneys and urine samples.
The alkylation of heme by DU1301 occurred only in infected
mice treated at pharmacologically relevant doses. The pres-
ence of these heme-drug adducts should therefore be consid-
ered as evidence of the alkylating capacities of these trioxane-
containing drugs triggered by the presence of the parasite in
mice. The detection of heme-DU1301 adducts within a Plas-
modium-infected mammal indicates that heme alkylation by
DU1301 is an efficient reaction that occurs in vivo and may be
considered to be a key element concerning the mechanism of
action of this antimalarial agent. This result underlines the
importance of the alkylating abilities of trioxane-based anti-
malarial drugs and also confirms that artemisinin and trioxa-
quines share the same heme-alkylating properties. In addition,
since artemisinin and the citrate salt of DU1301 are active
against the same stages of synchronized P. falciparum parasites
(ring, trophozoite, and gametocyte stages) (2), these pharma-
cological features strongly suggest that this common alkylating
reactivity may be one of the key factors of their antimalarial
activities.
In addition, aminoquinolines (such as chloroquine) are con-
sidered to inhibit the formation of hemozoin by - stacking
(21, 3, 5). It has been reported recently that trioxaquine
DU1301 efficiently prevents the in vitro formation of -hema-
tin at a lower concentration than chloroquine itself, whereas
the synthetic trioxane precursor of DU1301 does not inhibit
the dimerization of hemin (12). On the other hand, heme-
artemisinin adducts also inhibit -hematin dimerization and
are themselves unable to dimerize (12). These results suggest
that, besides the alkylating ability of the peroxide moiety, tri-
oxaquines may have the ability to prevent heme aggregation
within the parasite either (i) by the stacking of their quinoline
fragment with heme or (ii) by the formation of unpolymeriz-
able heme-drug adducts. Thus, trioxaquines should be consid-
ered as hybrid antimalarial molecules with a dual mode of
action: heme alkylation and the inhibition of heme polymer-
ization.
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Résumé de la publication : 
Docking study of structurally diverse antimalarial 
drugs targeting PfATP6: No correlation between in 
silico binding affinity and in vitro antimalarial 
activity 
F. Bousejra-El Garah, J.-L. Stigliani, F. Coslédan, B. Meunier, A. Robert. ChemMedChem 2009, 
4(9), 1469-1479. 
Calcul  d’interaction  entre  divers  antipaludiques  et  la  protéine 
parasitaire PfATP6 : Absence de  corrélation entre  l’affinité  calculée et 
l’activité antipaludique 
L’un des mécanismes envisagés pour l’artémisinine 1 repose sur l’inhibition de PfATP6, une 
protéine de type SERCA (sarco/endoplasmic reticulum Ca2+-ATPase) de Plasmodium 
falciparum. En effet, Krishna et ses collaborateurs ont montré que l’artémisinine pouvait inhiber 
l’activité de PfATP6 surexprimée dans des ovocytes de xenopes.[1] Cette interaction de 
l’artémisinine avec PfATP6 serait antagoniste de celle de la thapsigargine (TG), inhibiteur 
naturel des SERCA de mammifères. Cependant, on peut noter que les deux molécules présentent 
des structures très différentes, une des principales différences étant que TG est dépourvue de la 
fonction peroxyde nécessaire à l’activité antipaludique de l’artémisinine. TG n’est d’ailleurs pas 
active sur Plasmodium. 
 
Structures de l’artémisinine et de la thapsigargine 
 
Depuis la publication de cette étude, PfATP6 est considérée par certains auteurs comme la cible 
responsable de l’activité de l’artémisinine et de ses dérivés hémi-synthétiques. Dans le but de 
mieux comprendre le possible rôle de cette protéine dans le mécanisme d’action de 
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l’artémisinine, nous avons réalisé une étude de docking entre un modèle de PfATP6 et 
différentes molécules antipaludiques de structures variées. L’objectif de ce travail est de savoir 
s’il existe une corrélation significative entre l’affinité de ces molécules pour PfATP6, prédite 
par le logiciel AutoDock, et leur activité antipaludique mesurée in vitro.  
1. Modélisation par homologie. Validation du modèle et du protocole de docking 
La séquence d’acides aminés de PfATP6 étant connue, nous avons reconstitué sa structure 
tertiaire par homologie avec une SERCA de mammifère, protéine dont la séquence est la plus 
proche de celle de PfATP6 (SERCA1a, référence pdb de la structure cristalline utilisée : 2DQS). 
Dans la structure 2DQS, la protéine a été co-cristallisée avec la thapsigargine. La construction 
du modèle de PfATP6 a donc été faite en plusieurs étapes, en utilisant plusieurs outils de 
modélisation moléculaire : 1) alignement des séquences avec le logiciel ClustalW, 2) 
construction en 3D de la protéine avec le logiciel Modeller et 3) vérification de sa qualité 
stéréochimique avec Procheck. Enfin, la superposition de la structure cristalline de la SERCA1a 
et de notre modèle PfATP6 montre un arrangement très proche des hélices M1 à M10, où est 
localisé le site d’inhibition de TG.  
 
Superposition de PfATP6 (bleu) et 2DQS (vert) avec TG (rose) dans son site 
Nous avons ensuite utilisé le logiciel AutoDock4 pour calculer l’affinité de diverses molécules 
antipaludiques pour la protéine PfATP6.  
La validation préalable de la construction du modèle de PfATP6 et du protocole de docking par 
l’utilisation des inhibiteurs connus de SERCA1a est également décrite ci-après. 
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2. Etude de docking de molécules antipaludiques et leurs dérivés avec la protéine 
PfATP6 
Les molécules antipaludiques étudiées ici peuvent être divisées en deux groupes principaux : 
celles comportant une liaison peroxyde (artémisinine et ses dérivés, trioxolanes, tétraoxanes) et 
celles comportant un noyau quinoléine (chloroquine, quinine, méfloquine). Les trioxaquines, 
contenant à la fois un trioxane et une 4-aminoquinoléine, appartiennent à ces deux groupes. A 
titre de contrôle, nous avons également considéré des analogues inactifs de certaines molécules 
antipaludiques (figure ci-dessous).  
Pour l’analyse des résultats, nous nous sommes intéressés à l’énergie d’association (Ebind, 
kcal/mol) et à la constante d’affinité (Ki, µM) de chaque drogue pour PfATP6. Une différence 
d’énergie d’association a été considérée comme significative à partir de 2.0 à 2.5 kcal/mol.[2] 
L’affinité des molécules testées a été corrélée avec leur activité in vitro sur Plasmodium 
falciparum. 
 
Quelques structures utilisées pour l’étude de docking avec PfATP6 
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Artémisinine et dérivés 
L’étude de docking de l’artémisinine 1, ainsi que de ses dérivés 2 à 5, avec la protéine PfATP6 
indique que ces molécules se positionnent préférentiellement dans le site de TG. Les dérivés de 
l’artémisinine, dont la deoxyartémisinine (5) qui ne possède pas de peroxyde, ont tous la même 
localisation et adoptent des orientations très similaires. Par ailleurs, l’af
la protéine est essentiellement basée sur une interaction de type 
hydrophobe, quelle que soit la structure du composé. Aucune 
corrélation n’a pu être établie entre l’affinité prédite pour 
PfATP6 et l’activité in vitro des dérivés étudiés. En particulier, 
la deoxyartémisinine (5, Ebind -6.9 kcal/mol), molécule 
dépourvue d’activité antipaludique, présente la même affinité 
que celle prédite pour l’artémisone (3, Ebind -6.7 kcal/mol), l’un 
des dérivés les plus actifs de l’artémisinine.    
Il est également intéressa
finité de ces dérivés pour 
nt de noter que l’affinité de l’artémisinine et de ses dérivés pour 
oquine (15), dans leurs différents états de 
) et le tétraoxane RKA216 (9), deux peroxydes synthétiques très 
 comparable à celle de 
Superposition de l’artémisinine 
et de la déoxyartémisinine (en 
clair) dans le site de TG
PfATP6 est significativement moins importante que celle de TG (Ebind -10.0 kcal/mol).  
Antipaludiques comportant un noyau quinoléine 
La chloroquine (13), la quinine (14) et la méfl
protonation, présentent une affinité pour la protéine qui est du même ordre que celle de 
l’artémisinine (Ebind -7.0 à -8.3 kcal/mol). Ce résultat est assez inattendu, dans la mesure où 
PfATP6 n’est pas impliquée dans leur mécanisme d’action antipaludique. L’interaction de ces 
molécules dans le site de TG est principalement de type hydrophobe. 
Peroxydes synthétiques 
Le trioxolane OZ277 (7
efficaces, ont été conçus dans le but de mimer l’activité de l’artémisinine.[3,4] C’est la raison 
pour laquelle nous les avons inclus dans notre étude de docking.  
Le trioxolane OZ277, en particulier, présente une activité in vitro
l’artémisinine (IC50 2.7 et 11 nM, respectivement). L’étude de docking montre que OZ277 
présente une énergie de liaison avec PfATP6 très proche de celle de l’artémisinine (-7.9 
kcal/mol). Par contre, OZ277 n’inhibe pas PfATP6 lorsque celle-ci est surexprimée dans des 
ovocytes.[5] Il n’y a donc pas de corrélation entre l’affinité prédite de OZ277 pour la protéine et 
l’inhibition mesurée dans les ovocytes.  
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Trioxaquines  
Selon la position relative du peroxyde et de l’amine par rapport au plan moyen du cyclohexane, 
la trioxaquine PA1103 existe sous la forme de deux diastéréo-isomères séparables (cis ou trans). 
La même diastéréo-isomérie existe pour la trioxaquine DU1301 : dans l’isomère cis, la liaison 
peroxyde se trouve en position axiale et l’amine se trouve en position équatoriale. Dans 
l’isomère trans, ils sont tous les deux en positions équatoriales. Chaque diastéréo-isomère de la 
trioxaquine DU1301 se présente sous la forme d’un couple d’énantiomères, en fonction de la 
configuration des atomes de carbone de jonction des cycles trioxanes et cyclohexene ((RS ou 
SR)). Les diastéréo-isomères de PA1103 et DU1301 ont été séparés et ont montré la même 
activité in vitro.[6,7]  
L’énergie de liaison calculée pour les diastéréo-isomères cis et trans de la trioxaquine DU1301 
(10a et 10b) est de -9.9 et -9.3 kcal/mol, respectivement. Ces énergies sont très proches de celle 
de TG (-10.0 kcal/mol) et significativement plus importantes que celle de l’artémisinine (-7.6 
kcal/mol). 
Les deux diastéréo-isomères de la trioxaquine PA1103, qui ont la même activité in vitro, 
adoptent des conformations très différentes dans le site de TG (figure ci-dessous). Dans le cas 
de la cis-PA1103, le noyau quinoléine se trouve à l’emplacement de l’artémisinine et le trioxane 
à l’extérieur du site ; pour la trans-PA1103, c’est le trioxane qui occupe la cavité intérieure et le 
noyau quinoléine est totalement sorti de la protéine.  
 
Conformations prédites par AutoDock4 pour la trioxaquine cis-PA1103 (gauche) et la trans-PA1103 (droite) 
Les résultats de docking obtenus pour les trioxaquines ne sont pas corrélés pas à leur activité 
antipaludique mesurée in vitro. Cette étude laisse penser qu’une protéine avec un site stéréo-
spécifique telle que PfATP6 n’est pas une cible pour les trioxaquines. 
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3. Conclusion  
Notre étude ne confirme pas l’existence d’une corrélation entre l’affinité calculée pour la 
protéine PfATP6 et l’activité in vitro des molécules testées. De plus, les constantes d’inhibition 
mesurées dans les ovocytes, en particulier en ce qui concerne l’artémisinine et ses dérivés, ne 
peuvent être reliées à l’affinité pour PfATP6 calculée par AutoDock4. 
 
L’inhibition de PfATP6 par l’artémisinine a été présentée dans la littérature comme dépendante 
du fer.[1] D’autres travaux décrivant des coupures oxydantes de SERCA1a en présence de fer et 
de H2O2 ont été publiés.[8] Sur cette base, une étude de docking prenant en compte le rôle du fer 
dans l’inhibition de PfATP6 pourrait être envisagée. 
 
Toutefois, afin de valider PfATP6 comme cible de l’artémisinine et de ses dérivés, les résultats 
obtenus dans les membranes d’ovocytes de xenopes, qui constituent un milieu mal défini et 
difficilement reproductible, devraient être confirmés par des mesures d’inhibition sur la protéine 
isolée et purifiée. 
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Docking Studies of Structurally Diverse Antimalarial Drugs
Targeting PfATP6: No Correlation between in silico Binding
Affinity and in vitro Antimalarial Activity.
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Introduction
Artemisinin (1), a 1,2,4-trioxane-derived antimalarial drug ex-
tracted from the Chinese herb Artemisia annua, is highly active
against both chloroquine-sensitive and chloroquine-resistant
strains of Plasmodium falciparum (Pf), the most virulent species
of Plasmodium that causes malaria in humans.[1,2] In order to
delay the emergence of drug resistances, and to interrupt the
transmission of P. falciparum, a drug regime using artemisinin
derivatives, artesunate or artemether, in combination with
more slowly eliminated antimalarial drugs is now recommend-
ed (artemisinin combination therapy, ACT).[3, 4] In spite of these
efforts, recent clinical and molecular studies suggest the emer-
gence of ACT-resistant P. falciparum infections.[5]
Although the antimalarial mechanism of action of artemisi-
nin (1) and related synthetic peroxides is still a matter of
debate, it was established that the peroxide bond of artemisi-
nin is essential for its activity.[1, 2] In the 1990s, it was shown
that iron(II) ions catalyze the reductive cleavage of the perox-
ide bond, leading to the formation of oxy radicals that rapidly
rearrange to more stable carbon-centered radicals.[6,7] These
more stable radicals were thought to covalently bind heme, a
product of host cell hemoglobin digestion.[8]
Supporting this hypothesis, covalent heme–artemisinin ad-
ducts have been isolated and characterized.[9,10] The involve-
ment of iron(II) heme in the mode of action of artemisinin was
further supported by in vivo studies. Heme–artemisinin ad-
ducts were identified in the spleen and urine of P. vinckei in-
fected mice orally treated with artemisinin, however, these ad-
ducts were absent in the spleen and urine of healthy mice
treated with artemisinin under the same condition.[11] Addition-
ally, heme–artemisinin adducts are able to inhibit in vitro heme
polymerization and are themselves unable to polymerize,[12] a
process that also contributes to parasite death. These results
confirm the importance of the alkylating ability of peroxide-
based antimalarial drugs. Artemisinin (1) also interacts with
specific parasite proteins,[13] however, protein–drug coupling
products have yet to be characterized.
In addition to heme alkylation, an alternative mechanism of
action for artemisinin has been suggested. It involves PfATP6, a
Pf-sarco/endoplasmic reticulum calcium ATPase, homologous
to mammalian sarco/endoplasmic reticulum calcium ATPase
(SERCA1a). Krishna and co-workers reported that artemisinin
inhibits PfATP6 overexpressed in Xenopus oocytes.[14] An antag-
onistic interaction was also reported between artemisinin and
thapsigargin (TG), a specific SERCA inhibitor,[14] however, these
results were not confirmed by a more recent publication.[15]
Additional studies in Xenopus oocytes suggest that mutations
in position 263 can modulate the affinity of artemisinin for
PfATP6.[16] Mutation S796N was also proposed to be related to
decreased sensitivity of the parasite to artemether, an artemisi-
nin derivative.[17] However, a genetic analysis indicated the ab-
sence of mutation in atp6 genes of artemisinin-resistant P. falci-
parum and P. chabaudi, thus contradicting this assumption.[18]
In order to provide information on the possible role of the
PfATP6 calcium pump in the mechanism of action of artemisi-
nin and related compounds, we performed a docking study of
a series of structurally different antimalarial drugs into the
thapsigargin-binding cleft of a PfATP6 model. In contrast to a
recent report,[19] our study was not limited to artemisinin deriv-
atives, but included other peroxide- and quinoline-based anti-
malarial agents. The mechanism of action of the latter class of
antimalarial drugs does not involve PfATP6 inhibition, because
PfATP6, a calcium-dependent ATPase of Plasmodium falcipa-
rum, is considered the putative target of the antimalarial drug
artemisinin and its derivatives. Herein, the 3D structure of
PfATP6 was modeled on the basis of the crystal structure of
SERCA1a, the mammalian homologue. Model validation was
achieved using protein structure checking tools. AutoDock4
was used to predict the binding affinities of artemisinin (and
analogues) and various other antimalarial agents for PfATP6,
for which in vitro activity is also reported. No correlation was
found between the affinity of the compounds for PfATP6 pre-
dicted by AutoDock4 and their antimalarial activity.
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quinoline derivatives interact with heme, thus preventing he-
mozoin formation.[12,20,21] Our objective was to determine
whether the binding affinity of the studied drugs to PfATP6
can be significantly correlated to their in vitro antiplasmodial
activity.
Herein, we report the construction of a PfATP6 model from a
mammalian SERCA1a X-ray crystal structure, and the results of
the docking study of structurally different antimalarial agents
with this PfATP6 model.
Results and Discussion
Homology modeling
The peptide sequence of PfATP6 is known (1228 amino acids)
and available from the PlasmoDB website,[22] but no crystal
structure has been obtained so far. PfATP6 presents the high-
est sequence homology with mammalian SERCAs (43.5%). The
tertiary structure of PfATP6 was therefore modeled using the
crystal structure of the SERCA1a homologue, extracted from
rabbit skeletal muscle (PDB:2DQS, resolution 2.5#). [23] In the
2DQS structure, the protein was co-crystallized with thapsigar-
gin (TG), a sesquiterpene lactone extracted from the plant spe-
cies Thapsia garganica, which is a highly specific inhibitor of
Ca2+-dependent pumps.[24,25] SERCA proteins actively transport
Ca2+ ions from the cytosol to the sarco/endoplasmic reticulum
against a large concentration gradient.[26] SERCA1a contains
994 amino acids, organized in ten transmembrane helices (M1
to M10) and three cytosolic domains.
In SERCA1a, a thapsigargin-binding site was identified as a
cavity located in the transmembrane region and formed by
the M3, M5 and M7 helices. During its catalytic cycle, SERCA
undergoes significant conformational changes that involveACHTUNGTRENNUNGinterconversion between the two conformations E1 and E2.[26]
In the E1 conformation, the ATPase presents two high-affinity
binding sites for two Ca2+ ions. These two sites are associated
with protons in the E2 conformation. Thapsigargin inhibits the
Ca2+ ATPase by locking the E2 conformation,[27] predominantly
through hydrophobic interactions.[28]
The sequences of PfATP6 and the rabbit muscle SERCA1a
were aligned using ClustalW 2.0.1.[29] The 3D reconstruction of
PfATP6 was performed using Modeller 9 (version 2).[30,31] The
quality of the refined PfATP6 model was assessed with PRO-
CHECK.[32] The distribution of the Psi/Phi torsion angles of the
best model is represented by a Ramachandran plot, which
shows 87.0% of residues in most favored regions, 10.0% in ad-
ditional allowed regions, 1.6% (18) in tolerated regions and
1.4% (15) in disallowed regions (Figure 1). The calculated Ram-
achandran Z-score is !0.168, meaning that there is a good
agreement between the PfATP6 model and the SERCA1a tem-
plate. Superposition of the PfATP6 model with the SERCA1a
crystal structure (PDB:2DQS) gave an root mean square devia-
tion (RMSD) of 0.67 # for the 3880 Ca atoms, indicating highly
similar arrangements of the M1 to M10 helices, where the TG
site is located (Figure 2).
Model and docking protocol validation
Both the validity of the model construction and the accuracy
of the docking protocol was determined by assessing how
closely the lowest predicted energy conformation resembles
the crystal-binding mode. In a first assay, AutoDock4[33] suc-
cessfully found the TG-binding site in PfATP6 and was able to
generate positions and conformations closely related to the
TG-binding pose observed in the 2DQS crystal structure. How-
ever, because of deviations in the orientation of the octyl side
chain of TG, the lowest energy conformation of TG docked in
PfATP6 did not exactly match the TG crystallographic position
in the TG–SERCA1a complex. However, this result can be
Figure 1. Ramachandran plot of PfATP6 model (PROCHECK). Red, mostACHTUNGTRENNUNGfavored regions; yellow, allowed regions, beige, tolerated regions; white,ACHTUNGTRENNUNGdisallowed regions.
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ACHTUNGTRENNUNGexplained; AutoDock4 is known to fail when ligands contain
more than 15–20 degrees of freedom, since TG contains 19ACHTUNGTRENNUNGrotatable bonds the lack of correlation is not surprising.[33]
To circumvent this difficulty, TG was docked using a two-
step procedure. In a first calculation, a TG derivative lacking
the octyl chain was docked (nine degrees of freedom). In a
second step, the octyl chain was added with full flexibility to
the best ranked pose previously found (11 rotatable bonds, in-
cluding 8 in the side chain). This method led to a TG confor-
mation very close to the X-ray structure of TG in SERCA1a
(RMSD=1.68# ). From the result, AutoDock4 local minimiza-
tion option was then applied for overall relaxation of the TG
ligand in the cavity of PfATP6 (Figure 3a). The polycyclic skele-
ton of TG is located in a cavity in PfATP6, while the propylacyl-
oxy and 2-buten-2-acyloxy substituents are deeply buried in
channels. No H bond was detected between TG and the pro-
tein, but interactions closer than 3 # are possible between the
polycyclic skeleton of the drug and many hydrophobic amino
acids: Ile261, Leu263, Phe264, and Leu268 on one side, and
Ile973, Ile977, Ile981, Leu1040, Ile1041, Leu1046, Ile1050 on
the other side.
AutoDock4 local minimization of TG in the binding cleft of
SERCA1a was also performed. The predicted inhibition con-
stants (Ki) of TG against PfATP6 and SERCA1a were in the same
range: 50 and 24 nm, respectively. The same procedure of cal-
culating the docking conformation followed by local minimiza-
tion was used to allow comparison of results with all com-
pounds tested.
In order to validate our model and docking protocol, we
also docked cyclopiazonic acid (CPA) and ouabain (OUA) into
the TG site of PfATP6. CPA, a secondary metabolite found in
certain fungi, is also a Ca2+ ATPase inhibitor, but the CPA-bind-
ing site is different to that of TG.[34] OUA is a highly polar ste-
roid derivative and a specific Na+/K+ ATPase inhibitor.[35] CPA
and OUA interaction in the TG site can therefore be considered
negative controls. As expected, docking results showed that
CPA and OUA exhibit low binding affinities for PfATP6 and
SERCA1a. Their predicted Ki values were more than three
orders of magnitude higher than that of TG against PfATP6
(CPA, Ki=99 mm; OUA, 512 mm) and SERCA1a (CPA, 124 mm;
OUA, 2.4 mm). These preliminary results with TG, CPA and OUA
support the validity of both the constructed PfATP6 model and
the docking protocol.
Docking studies with antimalarial drugs
Despite very high antimalarial activities of artemisinin and its
semisynthetic derivatives, their half-lives in plasma are short,
and combination therapy with an antimalarial drug that is
eliminated slowly is required to maximize cure rates.[2b] To cir-
cumvent the drawbacks of artemisinin, many research groups
have designed and prepared fully synthetic peroxide-contain-
ing analogues. Some of these compounds are highly potent
antimalarial agents; among them are the trioxaquines,[36–38]
1,2,4-trioxolanes, such as OZ277,[39,40] and 1,2,4,5-tetraox-
anes.[41,42] As these compounds were designed to mimic arte-
misinin reactivity, we studied their interaction with PfATP6.
The compounds used in this study can be divided into two
major groups based on their chemical structures and theirACHTUNGTRENNUNGreactivities toward iron: peroxide-containing drugs (1,2,4-tri-ACHTUNGTRENNUNGoxane, 1,2,4-trioxolane and 1,2,4,5-tetraoxane derivatives) con-
sidered as artemisinin mimics, and quinoline-based drugs. Tri-
oxaquines DU1301 (10), DU1302 (11) and PA1103 (12) are
hybrid molecules with a dual antimalarial mode of action, con-
taining both a 1,2,4-trioxane and a 4-aminoquinoline moiety.[43]
Inactive analogues of antimalarial drugs, such as deoxyartemi-
sinin (5) or carbaOZ277[44] (8), were also studied for compari-
son. For amine-containing drugs, we considered both the free
base and protonated forms, which are the major species at
physiological pH.
Figure 2. Superimposition of PfATP6 model (blue), SERCA1a (pink) with TG
in its binding site.
Figure 3. a) Best ranked docked conformation of TG in its binding site in
PfATP6; b) Best-ranked docked conformation of artemisinin in TG site of
PfATP6; c) The lipophylic aminoacids surrounding artemisinin in PfATP6.
H bond is depicted as a green dashed line.
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The predicted binding affinities of these compounds with
PfATP6 and SERCA1a were evaluated using their binding free
energies (Ebind, kcalmol
!1) and inhibition constants (Ki, mm). We
considered the binding free energy of the best ranked confor-
mations as the main parameter for analysis of AutoDock4ACHTUNGTRENNUNGresults. A difference of 2.0–2.5 kcalmol!1 was considered signif-
icant.[33] Data are reported in Table 1. The affinity values were
correlated with the in vitro antimalarial activity of the drugs,
evaluated on FcM29, a chloroquine-resistant strain of P. falci-
parum.
Artemisinin and derivatives
Docking of artemisinin (1) to the PfATP6 model indicated that
the drug binds the protein preferentially in the TG-binding site
(Figure 3b). However, as artemisinin is a smaller molecule than
TG, it occupies only a small portion of the TG site. Four semi-
synthetic artemisinin derivatives (2–5) were also docked in the
PfATP6 model. Three of these derivatives are active against Pf:
dihydroartemisinin (2),[45] which is the biological metabolite of
artemether and artesunate, artemisone (3), a highly active
second-generation derivative currently under clinical develop-
ment,[46, 47] and MP118 (4), a C10-substituted aryl artemisinin
derivative with a good antimalarial activity.[48] Deoxyartemisinin
(5), which lacks the crucial peroxide bond, is inactive.[1]
The docking studies with artemisinin and its derivatives 2–5
(a single cluster) gave protein binding in exactly the same loca-
tion and with consensus orientations. An extensive network of
hydrophobic interactions was observed between artemisinin
and the protein TG site (Figure 3c). The C4 of artemisinin was
close to NH of Ile1041 (2.8# ), while the C8 and C9 methyl
group were close to the Cg of Ile977 (3.1 and 3.3# , respective-
ly). C8 was also close to Phe264 (3.1# ). The distance between
the C9 methyl group and Ca of Ile977 was 2.8# . The distances
between C6 methyl group of artemisinin and the methyl
groups of Ile261 and Leu1040 were 3.2 and 3.5# , respectively.
The C5 of artemisinin was in the vicinity of the hydrophobic
side chains (methylene groups) of Asn1039 and Lys260 (3.5
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and 3.1# , respectively, from Cb). The distance between the O1
and O2 and one of the Leu1046 methyl groups were 3.2 #and
3.7# , respectively, while O3 was 3.0 # from the Leu263 methyl
group. In addition, an H bond was proposed between the O1
of the peroxide function of artemisinin and the NH of Ile1041.
All the tested artemisinin derivatives, including the inactive de-
oxyartemisinin (5), were predicted by AutoDock4 to interact
with PfATP6 in a similar manner to artemisinin. The peroxide
bond in compounds 1–4 is orientated toward the inner part of
the cavity. Superimposition of docked conformations shows
that the ether oxygen atom of deoxyartemisinin (5) is located
between the two oxygen atoms of the artemisinin peroxide
bond (Figure 4).
As predicted by AutoDock4, artemisinin (1) interacts with
PfATP6 with a binding energy of !7.6 kcalmol!1 and an inhibi-
tion constant of 2.66 mm (Table 1, line 2). The affinities of arte-
misinin (1) for PfATP6 and SERCA1a were compared (for clarity,
affinity parameters for SERCA1a are not shown in Table 1). No-
tably, the binding energy of artemisinin for SERCA1a was
found to be !7.2 kcalmol!1, which is not significantly different
than the energy calculated for PfATP6 (!7.6 kcalmol!1), al-
though artemisinin reportedly does not inhibit SERCA1a.[14]
Artemisinin (1) was found to exhibit a binding affinity for
PfATP6 higher than that of artemisone (3) (1, Ki=2.66 mm; 3,
Ki=11.78 mm, Table 1, line 4), although the latter is more active
against the FcM29 strain of P. falciparum (1, IC50=11 nm; 3,
IC50=0.7 nm). It has also been reported that artemisone (3) is
more efficient than artemisinin (1) at inhibiting PfATP6 over ex-
pressed in Xenopus oocytes (1, Ki=170 nm; 3, Ki=1.7 nm).
[49]
Interestingly, AutoDock4 data suggest similar binding energies
of artemisone (3) and deoxyartemisinin (5) (3, Ebind=
!6.7 kcalmol!1; 5, Ebind=!6.9 kcalmol!1), without significant
difference from artemisinin (1) (Ebind=!7.6 kcalmol!1), despite
the fact that derivative 3 is highly active against Plasmodium,
and derivative 5 is totally inactive.
An artemisinin linked to an acridine moiety at the C10 posi-
tion (compound 6) was used to image the distribution of arte-
misinin in infected erythrocytes.[14] In attempt to evaluate the
relevance of such an acridine-labeled fluorescent derivative,
we included the monoprotonated form of this artemisinin–acri-
dine conjugate 6H in the present study (the alkylamine func-
tion should indeed be protonated at physiological pH). The
top ranked conformations of artemisinin–acridine conjugate
6H exhibited a binding affinity for the protein very close to
that of thapsigargin itself (Ki=0.06 cf. 0.05 mm, Ebind=!9.8 cf.
!10.0 kcalmol!1, for 6H and TG, respectively, Table 1, lines 1
and 7), and significantly higher than that of artemisinin (1, Ki=
2.66 mm, and Ebind=!7.6), despite the fact that artemisinin and
artemisinin–acridine conjugate exhibit similar in vitro antima-
larial activities.[50] Note that the docking results obtained for
6H were rather scattered (high number of clusters) due to the
high degree of freedom in the molecule. However, in all cases,
the artemisinin fragment of 6H was located in the TG site in a
highly conserved position, and in an environment similar to
that of the parent artemisinin, i.e. close to Leu263, Phe264,
Leu1040 and Ile1041. The top-ranked conformations of 6H ex-
hibited hydrophobic interactions between the acridine moiety
with Ile977 and Ile981, Gly1043, Leu1046, and Leu1047 closer
than 4# . In clusters with a lower affinity (Ebind~
!9.5 kcalmol!1), the acridine moiety of 6H was shifted and the
surrounding environment consisted of Ile275, Ile981, Gly982,
Figure 4. Superimposition of docked artemisinin (dark grey) and deoxyarte-
misinin (light grey).
Table 1. IC50 values against the FcM29 P. falciparum strain and AutoDock4
predicted binding affinities and inhibition constants for the PfATP6 mod-
els.[a]
in vitro antimalarial activity AutoDock4 results
Drug IC50 [nm] PfATP6
ligand[b]
Ebind
[kcalmol!1]
Predicted
Ki [mm]
1 Thapsigargin 4300 TG !10.0 0.05
2 Artemisinin 11 1 !7.6 2.66
3 Dihydroartemisinin 2.4[c] 2 !7.1 6.4
4 Artemisone 0.7 3 !6.7 11.78
5 MP118 25[d] 4 !7.4 3.72
6 Deoxyartemisinin 5000–
10000
5 !6.9 8.71
7 Artemisinin–acridine 8–20[e] 6H !9.8 0.06
8 OZ277 2.7[f] 7 !7.9 1.56
9 OZ277·mesylate 2 7H !8.2 1.04
10 carbaOZ277 6400[g] 8 !7.7 2.21
11 RKA216 5.2[h] 9 !8.3 0.89
12 cis-DU1301 8 10a !9.9 0.06
13 trans-DU1301 8 10b !9.3 0.16
14 cis-DU1302·citrate 8 11a !9.6 0.09
15 trans-DU1302·citrate 8 11b !9.8 0.07
16 cis-PA1103 12 12a !7.9 1.7
17 trans-PA1103 8 12b !7.6 2.7
18 Chloroquine 420[i] 13 !8.3 0.83
19 Chloroquine·diphosphate 518 13H !7.0 7.0
20 13H2 !6.1 33.9
21 Quinine 14 !7.7 2.40
22 Quinine·chlorhydrate 217 14H !7.5 3.26
23 Mefloquine 15 !7.0 7.2
24 Mefloquine·chlorhydrate 6[j] 15H !7.6 2.73
[a] Unless noted, IC50 values were evaluated in the present study on the
chloroquine-resistant FcM29-Cameroon P. falciparum strain. [b] For a
given ligand, for example 13, 13H, and 13H2 stand for the free base, mo-
noprotonated, and diprotonated species, respectively. [c] Measured on
W2-Indochina cloroquine resistant strain.[44b] [d] Pf strain not given.[14]
[e] Reference [49] .[f] Measured on K1-Thailand chloroquine resistant
strain.[39] [g] Measured on K1-Thailand chloroquine resistant strain.[44]
[h] Measured on 3D7 chloroquine sensitive strain.[41] [i] Measured for the
racemic drug.
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Val984 and Ala985, which are amino acids located at the sur-
face of the protein.
It should be noted that in one predicted conformation of
6H that had binding energy and inhibition constant values
close to artemisinin (Ebind=!7.6 kcalmol!1, Ki=2.76 mm), the
acridine moiety was located completely outside the protein,
and had no significant interactions with amino acids. Thus, the
hydrophobic interaction of the acridine residue with the
PfATP6 amino acids seems to be the main reason for the high-
est binding energy of !9.8 kcalmol!1 for the protonated arte-
misinin–acridine conjugate 6H.[51] This result indicates that
using an acridine probe to localize a small molecule such as ar-
temisinin may not be appropriate, and may provide biased
data concerning the interaction of an antimalarial drug with a
biological target.
The affinities of artemisinin derivatives 1–6H for PfATP6, as
calculated using AutoDock4, clearly does not correlate with
the antimalarial activities of these drugs.
Quinoline-based antimalarial drugs
Chloroquine is clinically used as a racemate (R & S). Mefloquine,
which contains two stereogenic centers, is also used as a race-
mic mixture (11S,12R & 11R,12S). This is possible as both enan-
tiomers of quinoline antimalarial drugs have the same antima-
larial activity within the limits of experimental variability.[52] The
S enantiomer of chloroquine, and the (11R,12S)-mefloquineACHTUNGTRENNUNGenantiomer in which the C-OH is in the R configuration as inACHTUNGTRENNUNGquinine (14), were selected for docking studies.
The dibasic drug, chloroquine, was tested as the free base
(13), monoprotonated on the tertiary alkyl amine (13H, pKa=
10.2) and diprotonated (13H2, 4-aminoquinoline group pKa=
8.2). Chloroquine (13) exhibits a predicted binding energy to
PfATP6 of !8.3 kcalmol!1, comparable to that of artemisinin
(Table 1, line 18). There is good shape complementarity be-
tween the TG site and the top-ranked conformation; the quin-
oline moiety, stacked with Phe264, occupies the cavity where
artemisinin (1) was previously found. The C7 chloro group is in
the place of C6 methyl group of artemisinin close to Ile261.
The diethylamino chain of chloroquine interacts with the hy-
drophobic channel where the octyl chain of TG is located.
Minimized binding energies obtained with 13H and 13H2 are
!7.0 and !6.1 kcalmol!1, respectively, indicating a slight but
probably significant decrease in affinity of chloroquine for the
protein induced by protonation. Ki values of 0.83, 7.0, and
33.0 mm for 13, 13H and 13H2, respectively, support this analy-
sis.
Docking conformations for the quinine free base (14) and its
quinuclidine-protonated derivative 14H were found to be su-
perimposable. As in the case of chloroquine (13), the quinoline
moiety of quinine resides between the two channels of the
TG-binding site, while the quinuclidine residue is located deep
in the cavity. No H bond was identified. Calculated binding en-
ergies were !7.7 and !7.5 kcalmol!1, respectively, and Ki
values were 2.40 and 3.26 mm for 14 and 14H, respectively.
Calculated binding conformations of neutral mefloquine (15)
and its protonated piperidine form (15H) were totally superim-
posable with binding values of !7.0 and !7.6 kcalmol!1, re-
spectively. Unlike quinine, the hydroxy group of derivative 15
and 15H forms an H bond with the carbonyl of Ile1041. Calcu-
lated binding energies were !7.0 and !7.6 kcalmol!1, and Ki
values were 7.20 and 2.73 mm for 15 and 15H, respectively.
In summary, all quinoline drugs, either in the base or mo-
noprotonated form, exhibit similar binding affinity values for
the protein (Ebind=!7.0 to !8.3 kcalmol!1), with predominant
hydrophobic interactions. Surprisingly, these affinity values
were not significantly different to that of artemisinin (1, Ebind=
!7.6 kcalmol!1) despite the fact that antimalarial quinolines do
not target PfATP6. Indeed, it is accepted that this class of com-
pounds exert their activity by interacting with heme, prevent-
ing hemozoin formation.[12,53]
Synthetic peroxide-containing drugs
Among synthetic peroxides, OZ277 (7) is a highly potent anti-
malarial agent. The pharmacophore of this drug is a 1,2,4-triox-
olane, rather than the 1,2,4-trioxane ring of artemisinin (1).[39]
In our study, no significant difference was found between
the conformation of OZ277 (7), and its protonated derivative
7H. Both drugs were predicted to interact with PfATP6 in the
TG-binding pocket, predominantly through hydrophobic inter-
actions (no H bond were identified), with the adamantane
moiety located in the artemisinin site. In contrast to artemisi-
nin derivatives, the peroxide bond of 7 is directed towards the
binding site opening. As reported in Table 1 (lines 2, 8 and 9),
docking with PfATP6 gave close binding energies for both neu-
tral (7) and protonated (7H) forms of the trioxolane (7, Ebind=
!7.9 kcalmol!1; 7H, Ebind=!8.2 kcalmol!1). Again, the binding
value is similar to that of artemisinin. However, OZ277 showed
poor inhibition of PfATP6 over expressed in Xenopus oocytes
(7, Ki=7700 nm; 1, Ki=80–170 nm).
[54]
As the peroxide bond of OZ277 was shown to be crucial for
its antiplasmodial activity, we also docked its inactive ana-
logue, 1,3-dioxolane carbaOZ277 (8), in which one of the two
oxygen atoms of the peroxide bond was replaced by a carbon
atom.[44] The adamantane and 5-membered ring are closely su-
perimposed, whereas the p-substituted cyclohexane residue
adopts a slightly different orientation compared with those in
7 and 7H. The binding energies of OZ277 (7) and carbaOZ277
(8) are similar (7, Ebind=!7.9 kcalmol!1; 8, Ebind=
!7.7 kcalmol!1). Again, the binding affinity for the PfATP6 pro-
tein does not correlate with the antimalarial activity of OZ277.
The 1,2,4,5-tetraoxane moiety has also received attention re-
cently as an interesting pharmacophore for antimalarial agents.
One such derivative, RKA216 (9), has in vitro and in vivo activi-
ty similar to that of artemisinin (1).[41] RKA216 (9) was docked
with PfATP6; the results gave a binding affinity close to that of
artemisinin (1, Ebind=!8.3 kcalmol!1; 9, Ebind=!7.6 kcalmol!1,
Table 1, line 11). On the other hand, the affinity of RKA216 is
also in the same range as that of OZ277 (7, Ebind=
!7.9 kcalmol!1). Interestingly, RKA216 has a spiroadamantane
residue adjacent to the peroxide bond, as is the case in OZ277.
In both cases, the hydrophobic adamantane occupies the
same location in the binding site (Figure 5).
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Trioxaquines
The same docking protocol was used to predict the binding af-
finities of trioxaquines DU1301 (10) and PA1103 (12) for
PfATP6, which are highly active against all erythrocytic stages
of both sensitive and resistant strains of P. falciparum, and are
able to cure orally treated infected mice.[36–38,55] DU1302 (11),
which is the monoprotonated derivative of DU1301, was also
docked with PfATP6 for comparison. Trioxaquines are synthetic
hybrid molecules built with both a 1,2,4-trioxane ring and an
aminoquinoline residue.[43] It should be noted that compounds
10–12 exist as cis (10a–12a) and trans (10b–12b) diastereo-
isomers, the amine and the peroxide substituents being either
on the same side or on the opposite side of the cyclohexane
mean plane. For all trioxaquines, the two diastereoisomers a
and b have the same in vitro activity against Plasmodium
strains.[37,38,55] Furthermore, the four stereoisomers of DU1301
(10), two enantiomers of 10a and two enantiomers of 10b,
were also tested separately and they were shown to exhibit
the same activity in vitro.[55]
Note that each diastereoisomer of DU1301 (10) and DU1302
(11), may in principle exist as two conformers, depending on
whether the peroxide and the amine are axial or equatorial
with respect to the cyclohexane ring. Docking studies of cis-
DU1301 and cis-DU1302 were carried on the conformers with
the peroxide in the axial position and the amine equatorial,
while docking of trans-DU1301 and trans-DU1302 were carried
on the conformers with both amine and peroxide in equatorial
positions.[37] Similarly, the conformer with the axial peroxide
and equatorial amine was considered for cis-PA1103 (12), and
the conformer with both amine and peroxide in equatorialACHTUNGTRENNUNGpositions was considered for trans-PA1103. Notably, the 1,4-di-ACHTUNGTRENNUNGaminocyclohexane moiety of PA1103 has a trans configuration
with the two amines in equatorial positions.[38]
Calculated binding energies of the best-ranked conforma-
tions of the free bases cis- and trans-DU1301 (10) and the mo-
noprotonated forms cis- and trans-DU1302 (11) were in the
range of Ebind=!9.3 to !9.9 kcalmol!1 (Table 1, lines 12–15),
close to that of TG (Ebind=!10.0 kcalmol!1) and significantly
higher than artemisinin (Ebind=!7.6 kcalmol!1). Moreover, the
Ki values were 0.06 and 0.16 mm for the cis- and trans- isomers
of DU1301, respectively, compared to 2.66 mm for artemisinin
(1), confirming that the affinity of these drugs for PfATP6 is
higher than the affinity of artemisinin.
In the best-ranked conformation, the fused trioxane and cy-
clohexene moieties of trans-DU1301 (10b) are located in the
part of the TG site that is occupied by artemisinin (1), while
the quinoline moiety is outside of the TG cavity. While no
H bonds were seen, close hydrophobic interactions between
the quinoline ring and methylene residues of the side chains
of Gln267 and Leu268, two amino acids located at the periph-
ery of the TG site, were observed. However, several clusters are
found with very close Ebind values, corresponding to conserved
conformations of the trioxane moiety, but different positions
of the quinoline residue, due to a possible rotation around the
!NH!ACHTUNGTRENNUNG(CH2)2!NH! tether. The conformation of the protonated
derivative 11b is similar to that of 10b.
The overall conformation of lowest binding energy of cis-
DU1301 (10a) is similar to that of the trans stereoisomer 10b.
In both cases, the positions of the trioxane ring are close al-
though the peroxide bond of the cis isomer 10a was turned
towards the outside the cavity, while that of the trans isomer
10b was located deeper inside the pocket. The C7 chloro
group of derivative 10a is 3.6 # from the Ca of Ala313, and
the quinoline is retained in the hydrophobic cage of Leu268,
Ile271 and Ile981 (where the acridine of compound 6H wasACHTUNGTRENNUNGlocated), whereas the quinoline of compound 10b comes out
Figure 5. Best ranked docked conformation of a) OZ277 (7) and b) RKA216
(9) in the TG-binding site.
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of the binding pocket (Figure 6). The conformation of the pro-
tonated cis-DU1302 (11a) is very similar to 10a.
Both diastereoisomers of PA1103 (12) were tested. Binding
parameters to PfATP6 were Ebind=!7.9 and !7.6 kcalmol!1
and Ki=1.7 and 2.7 mm for 12a and 12b, respectively. These
results are very close to those of artemisinin (1). In contrast to
derivative 10a, the best-ranked conformation of 12a indicates
quinoline, and not trioxane, binding in the same location as ar-
temisinin (1) in the TG site. There is a H bond between the car-
bonyl group of Leu1046 and the cyclohexyl-NH-cyclohexyl of
12a, while the trioxane residue is directed out of the binding
site (Figure 7a).
In the lowest energy cluster for trioxaquine 12b, the quino-
line ring is found in the same region of artemisinin (1). The
methyl substituents of the trioxane are at 3.1 and 3.7 #from
Lys270 Cb and Ile271 Ca, respectively, and O2 is close to the
Gln267 carbonyl group (3.0# ). However, for both 12a and
12b, other clusters corresponding to very different conforma-
tions, that have the trioxane in the artemisinin-binding site, are
also found. These clusters, which correspond to a molecule
that is turned head to tail, have a binding energy value close
to that of the best-ranked conformation (12b, DEbind=0.2–
0.3 kcalmol!1; 12a, DEbind=0.6–0.8 kcalmol
!1). Two different
poses of 12b are depicted in Figure 8. Compound 12 adopts
completely different poses in PfATP6 with close binding
energy values; this same ability was not found for trioxaquine
10a. It occurred to a much lower extent for derivative 10b
(DEbind "2 kcalmol!1). This feature may be due to the in-
creased rigidity and hindrance of the 1,4-diaminocyclohexane
linker of 12 compared to the 1,2-diaminoethane of 10. Trioxa-
quine 10 may thus adopt more suitable poses, with lower
binding energies.
Figure 6. Best-ranked docked conformation of a) cis-DU1301 (10a) and
b) trans-DU1301 (10b) in the TG-binding site.
Figure 7. Best-ranked docked conformation of a) cis-PA1103 (12a) and
b) trans-PA1103 (12b) in the TG-binding site.
Figure 8. Two different poses of 12b into the TG site of PfATP6.
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Notably, the binding affinities of compounds 10–12 for
PfATP6 could not be correlated with their stereochemistry. This
supports the proposal of binding driven mainly by hydropho-
bic interactions and not correlated with stereospecific interac-
tions with a chiral protein pocket. Indeed, all the stereoisomers
of each trioxaquine have the same in vitro and in vivo anti-ACHTUNGTRENNUNGmalarial activity.[37,55]
Trioxaquines, containing a 1,2,4-trioxane (like artemisinin
and artemisone) and a 4 aminoquinoline (like chloroquine), are
designed to kill the Plasmodium parasite via a dual mode of
action. The endoperoxide bond of the trioxane cycle is cleaved
by an iron(II)-catalyzed reduction, generating oxy-radicals that
further rearrange into alkyl radicals able to efficiently alkylate
heme.[56] Heme–trioxaquine adducts were detected in the
spleen of malaria infected mice, orally treated with DU1301 or
PA1103.[38,57] This in vivo reactivity is a feature shared with arte-
misinin (1)[11] that underlines the relevance of heme alkylation
in the mechanism of action of these 1,2,4-trioxane-containing
antimalarial drugs. In addition, it has also been reported that,
like chloroquine, DU1301 and PA1103 prevent b-hematin for-
mation, thus being able to interfere with the heme detoxifica-
tion process.[12,38]
Conclusions
In the present work, we generated a model of PfATP6, a sarco/
endoplasmic reticulum ATPase of P. falciparum, by homology
modeling. This model was used in docking calculations with a
set of structurally diverse antimalarial agents. Most notably, the
predicted binding affinities of these compounds for PfATP6 do
not correlate with either their antimalarial activity or the re-
ported inhibition of the protein overexpressed in Xenopus
laevis oocytes.
Artemisinin (1) and artemisone (3) are known to react with
heme to form covalent heme–drug adducts, which is another
possible mode of action for these agents.[58] Alkylation of
heme by OZ277 (7) and other 1,2,4-trioxolanes has also been
correlated with antimalarial activity, suggesting that heme alky-
lation could play a significant role in the mechanism of action
of these peroxide antimalarial agent.[59] Since their capacity to
alkylate heme in infected mammals has been demonstrated,
the importance of this process for the biological activity of
drugs remains a credible hypothesis.
It should be noted that the PfATP6 inhibition by artemisinin
in Xenopus oocytes was reported by Krishna et al. to be iron
dependent, although the role of iron was not investigated in
the report.[14] Results presented here deal with the affinity of
these drugs for PfATP6, however, these results do not take into
account the possible iron(II)-induced reaction of peroxide-
containing drugs with PfATP6.
When discussing the role of iron in Ca2+ pump inhibition,
Karlish and co-workers carried out the iron(II)-catalyzed oxida-
tive cleavage of a mammalian SERCA by the Fenton reac-
tion.[60,61] Analysis of the degradation patterns provided evi-
dence for two iron ion sites, one being located in the trans-
membrane region, near the TG-binding site. Taking into ac-
count these results, a future docking study should include a
possible iron site in the protein structure. Work is in progress
to investigate more precisely the role of iron in the putativeACHTUNGTRENNUNGinhibition of PfATP6 by artemisinin and artemisone.
Experimental Section
Artemisinin, thapsigargin, chloroquine diphosphate, quinine chlor-ACHTUNGTRENNUNGhydrate, mefloquine chlorhydrate, cyclopiazonic acid and ouabain
were purchased from Sigma–Aldrich. Trioxaquines DU1301 and
PA1103, deoxyartemisinin and artemisone were prepared according
to published methods.[37,38, 58,62] The synthesis of trioxolane OZ277
was reported in Reference [63].
Antimalarial cell-based assay
Chloroquine-resistant P. falciparum strain FcM29-Cameroon was
chosen for this study. The parasites were cultured using the modi-
fied Trager’s method,[64] in 5% CO2 humid atmosphere at 37 8C,
and maintained in vitro in human red blood cells (O#) that were
diluted to 2% hematocrit in RPMI 1640 complemented with 5%
human AB mixed serum.
The antiplasmodial activities of the test compounds were evaluat-
ed by the radioactive microdilution method described by Desjar-
dins et al.[65] Drug dilutions were tested in triplicate in 96-well
plates containing cultures of various P. falciparum strains at various
stages of 1% parasitemia and 2% hematocrit. For each test, plates
of parasite culture were incubated with drugs at a fixed concentra-
tion for 48 h in 5% CO2 humid atmosphere at 37 8C, and radioac-
tive hypoxanthine was added to the medium 24 h after incubation
commenced. Artemisinin or artesunate were used as reference
drug. Stock solutions of artemisinin and tested compounds were
prepared in DMSO. All the dilutions were done in DMSO except
the last one (1/50), which used RPMI 1640 complemented with 5%
human serum at 37 8C. Diluted solutions were added to 96-well
plates containing P. falciparum cultures. Parasite growth was esti-
mated by [3H]hypoxanthine incorporation compared to the para-
site growth without drug (=100%). Each drug dilution was tested
in three separate wells on the same 96-well plate.
Based on data obtained using the scintillation spectrometer, the
following formula was used to calculate the inhibitory effect (%):
Inhibition (%)=100!( X!BnCo!Bn )$100
where X=cpm (counts per minute) for one well with the drug,
Bn=background noise, Co=control (cpm for one well without
drug). The concentration that inhibited 50% parasite growth (IC50)
was determined by plotting the drug concentration versus the per-
centage of parasite growth inhibition at 48 h of incubation using
GraphPad Prism 4 software.[66]
Computational method
Resources : Docking calculations were performed on a SGI
Altix 3700 cluster at the Toulouse University Computer Center
(France)
Protein modeling and refinement : The PfATP6 sequence was ob-
tained from PlasmoDB.[22] The BLAST server[67] was used to search
the closest sequence of PfATP6 in the RCSB Protein Data Bank. The
high degree of primary sequence identity between the target
PfATP6 and mammalian SERCA1a (43.5% homology) indicates that
crystal structures of the latter are good models, usable as tem-
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plates (SERCA1a, EC 3.6.3.8). The SERCA1a 3D structure (in the E2
conformation) was obtained from the RCSB Protein Data Bank
(PDB: 2DQS).[23] The sequence alignment of PfATP6 with SERCA1a
as a reference was performed using ClustalW 2.0.1, applying the
default parameters.[29] Protein reconstruction was achieved with
Modeller 9 (version 2) on the entire PfATP6 sequence.[30,31] The re-
finement was made with the loopmodel class. To maintain good
complementarity between the protein and the ligands, both thap-
sigargin and the ACP cofactor, included in the 2DQS PDB file, were
retained during the refinement using the “env.io.hetatm=True”
keyword. The quality of each Modeller refined model was evaluat-
ed with PROCHECK (version 3.5.4).[32, 68] The final model was chosen
from both the PROCHECK results and the Modeller energy score.
Hydrogen atoms were added and the PfATP6 structure was mini-
mized using the Amber (PARM99) force field.
Ligand preparation : When available, the coordinates of antimalarial
compounds were obtained from the Cambridge Structural Data-
base (CSD), otherwise they were built and energy minimized using
the AMMP force field[69] implemented on the VEGA ZZ molecular
modeling package.[70] Prior to docking, all the drugs were energy
minimized using the semiempirical PM6 hamiltonian[71] and calcu-
lated partial charges. Structures were placed inside the grid box
for the docking studies.
Docking protocol : Thapsigargin, SERCA inhibitors and antimalarial
drugs were docked into the TG-binding site of the homology-mod-
eled PfATP6 using AutoDock4.0.[33] The graphical interface Auto-
Dock Tools[72] was used to keep polar hydrogens and add partial
charges for protein using the Gasteiger United charges. The grid
maps for each atom type found in the ligand structures were cal-
culated using the auxiliary program AutoGrid4.0. The grid size was
set to 80$80$80 points with 0.375 # spacing, and the grid box
was centered on the TG-binding site. The Lamarckian genetic algo-
rithm (LGA) was selected for ligand conformational searching. De-
fault parameters were used, except for the number of energy eval-
uations and docking runs, which were set to 25,000,000 and 100,
respectively. The resulting docked conformations were clustered
into families of similar conformations, with a RMSD clustering toler-
ance of 2# . Flexible torsion angles in the ligands were assigned
with Autotors, an auxiliary module of AutoDock Tools. The top
ranked conformation was extracted and redocked using the Auto-
Dock4 local minimization option.
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Conclusion  
This thesis project was part of the Antimal European Programme and involved close 
collaboration with Palumed S.A.  
In a first review, we introduced the importance of heme for Plasmodium and presented 
quinoline drugs, which have been the mainstay of malaria treatment for the last 6 decades. We 
underlined the problem of chemo-resistance, particularly important with chloroquine, and 
introduced two very promising quinoline-based drug candidates: N-tert-butyl Isoquine and 
Ferroquine.  
Artemisinin, a natural peroxide from the traditional Chinese medicine, and its derivatives have 
become essential for malaria treatment. They are highly active on both early erythrocytic stages 
and gametocytes of Plasmodium. Moreover, they are fast-acting and have proven to be safe. 
However, one of the major issues of artemisinin derivatives is their short and variable supply.  
The design of fully synthetic peroxides requires a good knowledge of artemisinin mode of 
activation. Extensive work in the early 90’s on iron-mediated reactivity of artemisinin has 
clearly demonstrated the formation of C-centered radicals. Significant progress has also been 
made in the identification of potential biological targets and artemisinin-derived radicals 
revealed to be powerful alkylating agents of both heme and parasite proteins. In particular, 
alkylation of heme by the artemisinin-derived radicals may be directly involved in the parasite 
death through the accumulation of non-dimerizable redox-active heme adducts. 
This knowledge of the molecular mechanism of artemisinin activation has contributed to the 
rational design of new synthetic antimalarial peroxide-containing drugs, including trioxolanes, 
trioxaquines and tetraoxanes, which exhibit outstanding antimalarial activity and improved 
DMPK and toxicological profiles. 
 
In the present work, we studied the two main mechanisms proposed in the literature for 
artemisinin, namely heme alkylation and PfATP6 inhibition. In addition, we also explored a 
new hypothesis by studying the possible bio-activation of artemisinin by copper enzymes.   
 
In the second chapter, we reported the heme-mediated reactivity of artemisone, an artemisinin 
derivative, substituted at the C-10α position by a thiomorpholine-1,1-dioxide residue. The 
characterization of heme-artemisone adducts confirmed that substitution at the C-10α position 
does not prevent the reductive activation of the peroxide bond nor the alkylation of heme. 
147 
 
Conclusion    
Artemisone, as all the other active artemisinin derivatives (artemether, artesunate, ...) is a very 
efficient alkylating agent. 
 
After iron, copper is the second biological metal in Plasmodium. In the third chapter, we 
studied the reactivity of artemisinin with copper-complexes as models for protein active sites. 
As expected, artemisinin can be activated by copper(I) complexes, in the same way than with 
iron(II). We could characterize covalent coupling products and confirm the alkylating 
properties of artemisinin with non-iron complexes. However, the reactivity with copper being 
much more sluggish than with iron, this alternative mechanism is probably not significant for 
artemisinin activation in vivo. 
 
We next turned our attention to the heme-mediated reactivity of synthetic peroxides. 
Hybrid trioxaquines have been shown to alkylate heme in vitro. In collaboration with Dr F. 
Benoit-Vical (Inserm, LCC, Toulouse) and Dr C. Claparols (LCC, Toulouse), we confirmed 
that the heme alkylation reaction by the trioxaquine DU1301 occurs in vivo. We could 
characterize heme-drug adducts in the spleen of malaria-infected mice, while they were not 
detected in non-infected mice, treated in the same conditions. This result confirmed that heme-
alkylation does not only occur in vitro, but is also relevant in vivo. Trioxaquine and artemisinin 
share a common reactivity toward heme in vivo, which may be related to the high activity of 
the two drugs.  
 
The work reported in Chapter 4 was done in the group of Pr P. O’Neill, in the University of 
Liverpool, in collaboration with Dr R. Amewu. LC-MS analysis was done in collaboration 
with Dr S. Muangnoicharoen, in the Liverpool School of Tropical Medicine (LSTM). During 
this stay, we confirmed the formation of carbon-centered radicals by Fe-mediated activation of 
potent antimalarial tetraoxanes. We went further and characterized covalent coupling products, 
both with heme, and tetraphenylporphyrins of iron and manganese. Modeling studies would be 
useful to see whether the regioselectivity of the reaction toward the formation of the secondary 
radical can be predicted. We also studied the reactivity of two potent tetraoxanes in presence of 
a phospholipid model and confirmed the formation of phospholipid oxidation products. This 
reactivity is common with trioxolanes analogues, but not with artemisinin. This work might 
need to be confirmed with other tetraoxanes.  
 
Overall, our results with heme confirmed that the alkylating properties of artemisinin, in 
particular in malaria-infected mice, are not limited to this natural compound, but are shared 
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with other potent endoperoxide-containing drugs. Indeed, all the potent antimalarial peroxides 
used in this study are also efficient heme-alkylating agents. It is likely that heme alkylation 
plays a very important role in their antiplasmodial mechanism of action. 
 
In this work, we also considered an alternative mechanism of action for artemisinin, based on 
the inhibition of PfATP6. We generated a model of PfATP6 by homology modeling from its 
SERCA1a homologue crystal structure and used this model in docking calculations with 
structurally diverse antimalarials. The main result is that the predicted binding affinity of the 
tested compounds does not correlate with their in vitro antiplasmodial activity. However, 
PfATP6 inhibition by artemisinin in Xenopus oocytes has been shown to be iron-dependent. 
Keeping this in mind, further docking studies that include an iron site in the protein might be 
considered.  
Working on the PfATP6 project was the good opportunity to gain useful experience in 
homology modeling and docking calculation tools. 
 
The precise mechanism of parasite killing process by artemisinin and antimalarial peroxides 
will probably remain for a long time a matter of debates. Nevertheless, a good understanding of 
the key features of its mode of action could help to develop efficient synthetic antimalarial 
drugs.  
As the alkylating ability is probably required for the antimalarial activity of this class of drugs, 
the extent of the alkylation reaction could be a way of screening the potential antimalarial 
activity of new compounds, before in vivo testing. 
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Quinine is a challenging synthetic target: it is an alkaloid with a 
complicated, multi-ring structure that has four stereogenic centers (and 
thus 15 other stereoisomers). In this appendix, we report the key events 
of quinine total synthesis, reported in the very complete review of 
Kaufman and Rùveda.[1] 
 1817: Pelletier and Caventou isolated quinine from cinchona tree.  
 1853: Pasteur obtained erization of quinine. 
 
Figure 1: Formation of d-quinotoxine by acid-catalyzed degradation of quinin . Adapted from[2] 
 
 1908: Rabe, a German chemist, suggested the first correct connectivity of quinine  
ce for the 
d-quinotoxine (2) by acid-catalized isom
e

 1918: In a very brief publication, Rabe and Kindler reported a synthetic sequen
reconstruction of quinine (and quinidine) from d-quinotoxine (figure 2). This three-step sequence 
involved the construction of the C8-N bond (C8-N approach) and started with addition of sodium 
hypobromite to d-quinotoxine to give the N-bromoquinotoxine. This intermediate was oxidized with 
sodium ethoxide in ethanol to give quininone, which interconverts with quinidinone via the 
formation of an enol intermediate in basic conditions. In the third step the ketone group is reduced 
with aluminum powder and sodium ethoxide in ethanol. Quinine (12%) and quinidinine (6%) were 
identified as major products.[3] 
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Figure 2: Rabe and Kindler three-step convertion of d-quinotoxine to (R-C8, S-C9) quinine and (S-C8, R-C9) 
quinidine. Adapted from[1]  
This transformation was the first major step towards the synthesis of quinine. However, perhaps 
because of wartime pressures, Rabe’s procedure was not cautiously reviewed and the key procedure 
for the reduction of quininone to quinine was detailed 14 years later, by the reduction of 
dihydrocinchoninone to dihydrocincho-nine.[1] 
 1943: Prostenik and Prelog made a notable step forward when they degraded the natural 
product cinchotoxine to optically active homomeroquinene (4), and used 4 to prepare d-quinotoxine 
(2). The sequence included a key condensation with ethyl quininate (6). 
 
Figure 3: Degradation and reconstitution of quinotoxine by Prostenik and Prelog. Adapted from[1] 
 
 1944/1945: Woodward and Doering (Harvard University) published the “formal” Total 
Synthesis of Quinine.[4,5] In the 1940s, the synthesis of quinine became urgent when the war in 
southeast Asia cut off supplies of the drug, thus causing thousands of soldiers to die after becoming 
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infected with malaria during the campaigns in Africa and the Pacific. Moreover, the cinchona 
plantations established in Java by the Dutch were the major sources of the European reserves of 
quinine, which were stored in Amsterdam. However, the German capture of Holland in 1940 and 
the Japanese military invasion of Java in 1942 abruptly cut these vital supplies.[1]  
Woodward ingeniously visualized that the basic homomeroquinene skeleton could be accessed 
from an isoquinoline. His synthesis included transformation of 3-hydroxybenzaldehyde (8) into 
isoquinolin-7-ol (10) via Schiff base 9 (figure 4). This starting isoquinoline was converted into its 
8-methyl derivative 12 through the intermediacy of piperidine 11. In turn, 12 was partially 
catalytically hydrogenated to the tetrahydroisoquinoline 13, which was isolated as its N-acetyl 
derivative 14, while a second catalytic hydrogenation furnished 15, as a complex diastereomeric 
mixture. This mixture was simplified by oxidation to the related ketones, with concomitant 
epimerization of the tertiary carbon center next to the carbonyl group. Separation of the 
diastereomers was aided by the formation of the hydrate of compound 16 with a cis ring junction.[1] 
 
Figure 4: Preparation of the homomeroquinene derivative by Woodward and Doering.[1] Reagents and conditions: 
a) H2NCH(OEt)2 (94%); b) 1. 80% H2SO4 ; 2. NaOH, crystallization then H+ (64%); c) piperidine, HCHO, EtOH (61%); 
d) NaOMe, MeOH, 220°C, 16 h (65%); e) H2, Pt, AcOH; f) Ac2O (95%); g) H2, Raney nickel, EtOH, 150°C, 205 bar, 16 
h [1:1 cis(crystalline)/trans(oil)]; h) H2Cr2O7, AcOH; Et2O/H2O, diastereomer separation (28 %). 
Ring opening of 16 through preferential nitrosation of the tertiary carbon atom next to the carbonyl 
group furnished the oxime 17 (figure 5). Conservation of the crucial cis geometry of the substituents 
on the piperidine ring in 17 marked the success of the strategy for building both adjacent side chains. 
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Reduction of 17 provided amine 18. Exhaustive methylation of 18 afforded 19 and then a Hofmann 
elimination was employed to install the vinyl moiety and generate the intermediate product protected 
as a uramido derivative (20) to facilitate its isolation. The derivative 20 was finally subjected to an 
acid hydrolysis to regenerate homomeroquinene (4).  
 
Figure 5: Completion of the synthesis.[1] Reagents and conditions: a) EtO-N=O, NaOEt, EtOH (68%); b) H2, Pt, 
AcOH, 1–3 bar; c) MeI, K2CO3 (91% overall); d) 1. 60% KOH, 180°C, 1 h; 2. KCNO (40%); e) 1. dilute HCl, EtOH, 
reflux (100%); f) PhCOCl, K2CO3 (96%); g) ethyl quininate (19), NaOEt, 80°C; h) 1. 6N HCl, reflux (50%); 2. 
resolution with d-dibenzoyl tartrate (11 %). Bz = benzoyl. 
However, homomeroquinene (4) prepared by Woodward was racemic, thus prompting to go one step 
further and include a resolution in his synthesis. After protection of 4 and a Rabe condensation using 
the readily available ethyl quininate (6), hydrolysis and decarboxylation of the resultant β-ketoester 
20 gave dl-quinotoxine Bz-derivative 34, which was hydrolyzed to dl-quinotoxine and the latter 
carefully resolved with d-dibenzoyl tartaric acid. Finally, after little over a year, on April 11th 1944, 
Woodward and Doering obtained synthetic d-quinotoxine (2) and assumed that the Rabe’s part of the 
sequence to quinine was reliable.[6] The next year, they published their “formal” total synthesis of 
quinine, without repeating Rabe’s protocol.[4,5]  
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The synthesis was plagued by low yields, did not allow control of the stereochemistry, and could not 
have afforded commercial quantities. Indeed, in spite of wishful thinking surrounding the synthesis, 
commercial production of quinine by the newly devised strategy 
would have cost approximately 200 times more than its natural 
equivalent.[1]  
 
Nevertheless, the synthesis was viewed as a scientific milestone 
and was the beginning of a successful carrier for Woodward, 
who won the  Nobel Prize in Chemistry in1965 for "his 
outstanding achievements in the art of organic synthesis”.  
 
F
igure 6: Robert Woodward (left) and William 
Doering (right) 
 
 2001: Several synthesis of quinine were proposed since Woodward and Doering publication 
(reviewed in ref[1]). In 2001, Stork et al. (Columbia University) published the first stereoselective 
synthesis of quinine – using the C6-N approach - and questioned the validity of the 
Woodward/Doering strategy,[7] which is called “a widely believed myth”.[8] 
 2008: Smith and Williams reproduced the Rabe/Kindler protocol, and showed that the contentious 
‘missing step’ in Woodward and Doering’s synthesis, but previously reported by Rabe and Kindler 
in 1918, is indeed possible under the conditions sketchily described in that early work.[9] By 
validating the Rabe and Kindler route, Smith and Williams wrote the last chapter of the quinine 
saga, at least for now … 
 
Thus, taken together, the total synthesis of d-quinotoxine by Woodward and Doering in 1944 with 
the previously reported synthesis of homomeroquinene by Prostenik and Prelog, and the conversion 
of d-quinotoxine into quinine by Rabe and Kindler in 1918 constitute the Woodward-
Doering/Prostenik-Prelog/Rabe-Kindler total synthesis of quinine (or Rabe-Kindler/Prostenik-
Prelog/Woodward-Doering depending if we consider the chemical order or the chronological order). 
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Figure 7: The Woodward-Doering / Prostenik-Prelog / Rabe-Kindler total synthesis of quinine. Adapted from[2] 
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Artemisinin 1 is an extract of the Chinese wormwood Artemisia 
annua and has been used since ancient times to treat malaria.[1] 
Today, semi-synthetic derivatives artesunate 2 and artemether 3 are 
used clinically in drug combinations (ACT).[2].  However, first 
generation analogues (eg. 2 and 3) have a limited availability,[3] high 
cost[4] and poor oral bioavailability (Figure 1a).[5] In addition to 
these drawbacks there have been recent reports of high failure rates 
associated with ACTs suggesting the possibility of clinical 
artemisinin resistance along the Thai–Cambodian border.[6] In the 
light of these observations there is an urgent need to develop 
alternative endoperoxide based therapies.[7]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. a. Artemisinin and its semi-synthetic analogues, b. 
Comparison of tetraoxanes with trioxolane based antimalarials. 
  The crucial structural functionality within artemisinin and 
synthetic 1,2,4-trioxanes [8] is the endoperoxide-bridge. Recently a 
series of molecules based on an ozonide structure were developed 
from which a candidate OZ277[9] was shown to have impressive 
antimalarial activity profiles in vitro and in rodent models of 
malaria. However, the recent development of OZ 277 has been 
hampered as this molecule was found to be unstable in the plasma of 
malaria patients during a Phase II dose ranging study. This 
instability stems from the inherent reactivity of the 1,2,4-trioxolane 
core structure in the presence of iron released during malaria 
infection.[10a, 10b] 
 In our hands, studies of endoperoxide stability have shown 
that 1,2,4,5-tetraoxanes (eg. 6) have significantly higher stability 
than their 1,2,4-trioxolane (4) or 1,2,4-trioxane counterparts.[11] To 
exemplify further the chemical and biological differences between 
these two heterocycles it has been noted that the simple dispiro 
1,2,4-trioxolane 4 is antimalarially inactive and unstable whereas the 
close chemically stable tetraoxane analogue 6 expresses antimalarial 
activity in the nanomolar range (IC50 = 25nM) (Figure 1b). For good 
levels of antimalarial activity in the ozonide series fusion of the 
1,2,4-trioxolane-ring system to an adamantane core (see for example 
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5, Figure 1)) was found to be essential.[9] Given the foregoing 
observations we reasoned that similar substitution of the cylohexyl 
group in antimalarially active analogue 6 would generate a new 
series of molecules with improved stability profiles and improved 
oral and PK profiles through optimization of the side chain in 
generic structure 7 (R = polar water-solubilising group). 
Identification of the optimal, metabolically stable polar side chain to 
counterbalance the lipophilicity of the adamantane functional group 
was the primary focus of the medicinal chemistry optimization. 
 
Figure 2. Tetraoxane candidate development and SAR. [13] 
 
 In order to candidate select a 1,2,4,5 tetraoxane we set a 
rigorous target product profile from the onset of our medicinal 
chemistry optimisation and for the candidate selection of RKA 182 
(15) over 150 novel 1,2,4,5-tetraoxanes were synthesised and 
screened from two independent hit series (Figure 2). After extensive 
in vitro/in vivo and DMPK studies on Hit Series 1 this template was 
selected over series 2 for lead optimisation which ultimately led to 
the synthesis, profiling and selection of RKA 182 15 (vide infra) as 
the development candidate.  
Synthesis of lead tetraoxanes (Hit series 1) is depicted in 
Scheme 1. The synthetic route is high yielding, only 5 steps and 
divergent in the last step making expedient parallel synthesis 
possible. (supporting information)[12a]. In vitro and in vivo data of 
the most potent compounds synthesised in Hit Series 1 can be seen 
in Table 1. These molecules exhibit an IC50 of less than 6 nM 
against both chloroquine sensitive 3D7 and chloroquine resistant K1 
strains of P.falciparum with the lowest IC50 being 0.8 nM (Table S1, 
supporting information).[14] Tetraoxane analogues also have 
ED50/ED90 values of less than 3.5/9.5 mg/Kg, with the lowest values 
being ED50/ED90 = 0.99/1.41 mg/Kg (tetraoxane 17) when tested in 
mice infected with the P.berghei ANKA parasite.  The activity of 17, 
in terms of ED50 and ED90 in the 4-day test,[15] surpasses that of any 
synthetic endoperoxide reported in the literature to date after oral 
administration. Piperidinyl piperazine functionalised tetraoxane 15, 
when formulated as a tosylate salt, has outstanding in vitro activity 
(< 1nM) and in vivo activity with an ED50/ED90 of 1.33/4.18 mg/Kg 
which is superior to artemether, artesunate and comparable to 
Artemisone, the leading next generation semi-synthetic artemisinin 
which is currently undergoing Phase 2 clinical trials.[16] In studies 
conducted on mouse survival, mice treated at 3 x 10 mg/kg per day 
with 15 survived 22 days in comparison with only 9 days for 
artesunate. (Supporting information) 
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Scheme 1. Synthesis of polar tetraoxane derivatives 12-18.  
Table 1. In vitro and in vivo15 data for tetraoxanes 12-18 and Pharmocokinetic parameters after a single intravenous (1mg/kg) and single oral 
(10 mg/kg) administration. 
IC50 (nM) Compound 
3D7 K1 
% 
Inhibition  
30 mg/Kga 
ED50 
(mg/Kg) 
ED90 
(mg/Kg) 
1 mg/kg 
(iv) 
T1/2 (h) 
10mg/kg 
(po) 
T1/2 (h) 
Fb 
(%) 
12 1.4 0.9 100 3.47 5.40 0.39 1.64 9 
13 5.2 0.8 100 3.18 3.88 1.16 5.89 11 
14 2.5 2.8 99.7 3.02 9.25 0.54 1.72 9 
15 4.9 1.9 100 1.82 8.38 0.61 3.53 24 
15 (tosylate salt) 0.87 1.1 100 1.33 4.18 0.80 2.38 38 
16 6.0 1.5 100 2.23 5.12 0.64 NC 36 
17 1.2 0.9 100 0.99 1.41 0.57 1.08 9 
18 1.2 0.9 100 1.60 2.91 0.40 1.23 23 
Artesunate 1.8 1.6 100 3.96 11.72 0.26 NC NC 
Artemether 7.8 3.2 100 3.80 12.24  ND 1.4d 
Chloroquineb 12.5 250.0 100 2 4.5 - - - 
 
[a] Parasitaemia was determined by microscopic examination of Giemsa stained blood films taken on day 4. Microscopic counts of blood films 
from each mouse were processed using spreadsheet (Microsoft Corp.) and expressed as percentage of inhibition from the arithmetic mean 
parasitaemias of each group in relation to the untreated group. [b] indicates F(oral bioavailability) calculated using AUC0-t and actual doses (see 
supporting online information). [d] Data taken from Vennerstrom et al.9 NC = Not calculable. ND = Not determined 
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Pharmacokinetic parameters and oral bioavailability were 
determined after intravenous (1mg/kg) and oral administration (10 
mg/kg) in Sprague-Dawley rats (Table 1) (For in vitro metabolism 
data see supporting information). The most significant observation 
from this study is that tetraoxanes 15, 16 and 18 have oral 
bioavailabilities of greater than 20%, superior to OZ277 which had 
an oral bioavailability of less than 10% in the comparator arm 
(Table S2 and S3, supporting information).  Taking this information 
together with the antimalarial activity data it was clear that although 
the activity of 12 and 17 in the 4-day test was very good, the poor 
bioavailability of 17 and 12’s complicated in vivo metabolic profile 
meant that these molecules were not considered further. Compounds 
13 and 18 were also ruled out at this point due to relatively poor 
bioavailability and a very short half-life predicted for the latter 
tetraoxane. Based on the outstanding in vitro and in vivo 
antimalarial activity and pharmacokinetic profile 15 was selected as 
the lead candidate. Formulation work on 15 delivered the compound 
as a di-tosylate salt which had improved oral bioavailability of 38% 
in the rat (Table S4, supporting information).  
Having selected 15 as the drug candidate a scalable, industrial 
synthesis was sought. The industrial synthesis (Carbogen AMCIS) 
of 15 is only four steps (due to the synthesis of 8 in one step from 
direct hydrogenation of phenol ester 19) involving a single 
chromatography step and has a projected low cost of goods.  The 
key step in the scale up of this potentially hazardous chemistry 
involved the in situ generation of the keto ester 10 without isolation 
of the gem dihydroperoxide precursor followed by hydrolysis (of the 
ester function) to provide the acid 11 in acceptable yields on a 1.2 
kg scale.  The application of Dussault procedure (employing Re2O7 
as a mild Lewis acid)12b for the key tetraoxane ring-forming step 
was also crucial to the scale-up of this chemistry.  
As a part of our preclinical development 15 was also tested 
against eleven different South East Asian isolates from patients who 
had failed ACT combination chemotherapy (Figure 3) and clearly 
demonstrated superiority over mefloquine, artesunate and 
artemisinin with all measured IC50’s below 5nM. 
To assess the speed of action a single oral dose of 30 mg/kg 15 
was administered to mice infected with 4 x 106 P. berghei ANKA 
infected red cells two days post-infection (Figure 4).  Parasitaemias 
rapidly decreased to undetectable levels 24h after treatment with 
RKA-182 (15) whereas treatment with the same dose of artesunate 
(ASN) reduced parasitaemias up to 5% 8h post-treatment increasing 
rapidly thereafter.  
 
 
Figure 3. IC50 data for 15 (RKA182) compared with other 
antimalarials 
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Scheme 2. Industrial synthesis of tetraoxane 15 (RKA182).  
 
 
Figure 4. Speed of action of 15 (RKA 182) following a single oral 
dose of 30mg/kg. 
To demonstrate the remarkable stability of tetraoxane 15 in 
both non-infected and infected red blood cells, in vitro studies were 
carried out to assess the percentage recovery of drug at set time 
points in non-infected and infected blood (Figure 5). It can be seen 
from this data that OZ277 rapidly degrades in infected blood cells 
giving no recovery of drug after only 35 minutes. In sharp contrast, 
RKA182 (15) shows 79% recovery after 4 hours in infected blood. 
In vivo pharmacokinetic analysis was also performed to demonstrate 
the impact of infection on the exposure profile of 15 in non-infected 
mice and mice infected with P.berghei (Table S6 in supporting 
information) and the data clearly demonstrates equivalent exposure 
(AUC) in both infected and non-infected mice. Taken together, 
these data suggests 15 is significantly more stable than OZ277 in 
which malaria infection was associated with a significant reduction 
in drug plasma concentrations in Phase II trials. [17]  
In order to characterise the potential mediators of the 
antimalarial activity of RKA182 we performed mechanistic studies 
with ferrous (II) bromide in THF in the presence of the spin-
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trapping agent 2,2,6,6-tetramethyl-1-piperidine-1-oxyl (TEMPO).  
From these studies, we were able to intercept both the primary and 
secondary carbon centred radicals to produce two TEMPO adducts 
A and B (Scheme 3).  
 
Figure 5:  Stability of 15 in non-infected and infected red blood cells 
in comparison with OZ277. 
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Scheme 3. TEMPO spin-trapping of C-radical intermediates 
generated following from 12 Fe(II) Activation . (R = 
N(CH2CH2)2NCH2iPr)  
 
The behavior of the tetraoxanes reported here is distinct from 
1,2,4,-trioxolanes since only the secondary carbon centered radical 
species has been characterized from OZ277 and other 1,2,4-
trioxolanes. [9] Since heme alkylation is believed to play a vital role 
in the mechanism of action of endoperoxide antimalarials [17] 
(Scheme 4) we examined the reactivity of 12 with ferrous heme LC-
MS analysis confirmed an m/z 782.3 Da for three adducts 
(maximum absorption of the Soret band at 430 nm) that result from 
the covalent bonding of the tetraoxane-derived secondary C-
centered radical and the heme porphyrin ; this process may play an 
important role in the molecular mechanism of action of these 
derivatives. 
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Scheme 4. Proposed mechanism of the heme alkylation reaction with 
tetraoxane 12 (RKA099). For clarity, only the δ–regioisomer of the 
adduct is shown. 12 was allowed to react with iron(III)-hemin, in 
presence of an excess of dithionite to generate iron(II)-heme in situ, in 
ACN/NaOH 0.1 M (50/50) 
 
In conclusion, we have identified the first water soluble 
1,2,4,5-tetraoxane drug candidate that has outstanding antimalarial 
activity, stability, low toxicity (see supporting information) and 
ADME properties that overcome most of the problems encountered 
previously with the synthetic and semi-synthetic antimalarial 
endoperoxide drugs that have progressed into pre-clinical 
development. This work firmly establishes the potential of this class 
of tetraoxane to provide the next generation of synthetic drugs for 
deployment in the control and eradication of malaria as a component 
of combination chemotherapy.  
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Supplementary Tables 
Table S1: In Vitro Antimalarial Activities versus Chloroquine Sensitive and Resistant Strain of P. falciparum and Multidrug 
Resistant Cancer Cell-line for all analogues. 
 
Compound 3D7 (nM) K1(nM) KB(nM) ClogP 
12 1.4 - - 4.21 (± 0.85) 
13 5.2 nd nd 3.47 (± 0.77) 
14 2.5 2.8 72018.7 3.98 (± 0.82) 
15 4.9 1.9 30458.8 3.99 (± 0.98) 
16 6.0 1.5 21284.8 3.99 (± 0.88) 
17 7.7 nd nd 4.09 (± 0.76) 
18 1.2 0.9 111446.4 4.81 (± 0.94) 
Chloroquine 12.5 250.0 nd - 
Artemether 2.6 nd nd - 
POD nd nd 15.9 - 
                 nd = Not determined 
Table S2: Pharmocokinetic Parameters after a single Intravenous (1mg/kg) Administration. 
 
Analyte Actual 
Dose 
(mg/kg) 
C0 
(ng/mL) 
AUC0-t 
(ng.h/mL) 
AUC0-∞ 
(ng.h/mL) 
T½ 
(h) 
CL 
(mL/h/kg) 
Rsq 
12 1.124 280 144.1 147.9 0.39 7601 1.00 
13 0.984 418 201.3 204.3 1.16 4816 0.96 
14 1.093 262 140.6 149.8 0.54 7298 1.00 
15 1.094 138 83.87 92.53 0.61 11820 0.98 
16 1.047 60.7 31.85 35.17 0.64 29770 0.97 
17 1.087 37 552.0 558.1 0.57 14793 1.00 
18 1.032 66.1 39.09 40.26 0.40 25640 1.00 
OZ277 0.721 52.1 32.16 32.59 0.32 22130 0.99 
 
Table S3: Pharmocokinetic Parameters after a single Oral (10mg/kg) Administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* indicates F calculated using AUC0-t and actual doses, NC = not calculable. 
 
Table S4: In vivo Pharmacokinetic parameters of RKA 182 (tosylate salt) after p.o and i.v administrations (n=3). 
  
i.v 
(1 mg/kg) 
p.o. 
(10 mg/kg) 
Compound Parameter 
Mean SE Mean SE 
F (%) 
15 
(tosylate salt) 
AUC  (min*µg/mL) 7.37 0.29 27.9 1.83 37.9 
 AUC 0-6h (min*µg/mL) 7.34 0.3 20.5 3.4  
 cmax (µg/mL) 0.11 0.01 0.09 0.02  
 tmax (min) 15 0 200 80  
 t½ (min) 48.2 2.11 143 54.5  
 CL/F (mL/min/kg) 136 5.3 360 23.6  
 CL (mL/min/kg) 136 5.3 136 8.93  
 Vd/F (L/kg) 9.48 0.69 76 33.2  
Analyte 
Actual 
Dose 
(mg/kg) 
Cmax(obs) 
(ng/mL) 
Tmax(obs) 
(h) 
AUC0-t 
(ng.h/mL) 
AUC0-∞ 
(ng.h/mL) 
T½ 
(h) 
CL/F 
(mL/h/kg) F
* Rsq 
12 8.912 34.2 1.00 103.4 113.5 1.64 78550 0.09 0.99 
13 8.826 74.9 0.50 200.9 370.2 5.89 23840 0.11 0.80 
14 9.797 29.5 2.00 116.7 131.3 1.72 74630 0.09 0.97 
15 8.792 38.0 2.00 159.6 247.9 3.53 35470 0.24 0.94 
16 7.360 20.5 4.00 79.69 NC NC NC 0.36 NC 
17 8.981 82.0 0.25 636.1 645.1 2.77 3900 0.09 0.99 
18 9.257 21.2 2.00 80.30 84.23 1.23 110100 0.23 0.90 
OZ277 6.113 2.75 2.00 12.68 15.49 2.33 394600 0.05 0.78 
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 Vd (L/kg) 9.48 0.69 28.8 12.6  
 MRT (min) 46.6 3.97 248 79.2  
SE = standard error 
 
Table S5: Average Survival and Percentage Inhibition of Mice Infected With P. berghei ANKA in a Single Oral Dose of 1 x 
30 mg/kg and an Oral Dose of 3 x 10mg/kg. 
 
Comp. Avg. Survival (days) 
post-infection  
(3 x10 mg/kg) 
% of 
inhibition 
at day 4 
post-
infection 
Avg. Survival (days) 
post-infection  
(1 x 30 mg/kg) 
13 nd nd 7.6 (7, 7, 7, 8, 9) 
14 15.4 (14, 14, 21, 14, 14) 99.99 9.4 (8, 8, 15, 8, 8) 
15 21.8 (20, 21, 23, 22, 23) 99.99 12.4 (21, 7, 6, 22, 6) 
16 27.6 (30, 30, 20, 30, 28) 99.98 11.4 (15, 14, 7, 7, 14) 
17 nd nd 7.6 (7, 7, 8, 8, 8) 
Artesunate 9.0 (7, 7, 7, 14, 10) 99.09 6.8 (6, 7, 7, 7, 7) 
OZ277 25.2 (18, 30, 18, 30, 30) 99.98 10.2 (8, 10, 8, 10, 15) 
No Drug 4.0 (4, 4, 4, 4, 4) 0 3.0 (3, 3, 3, 3, 3) 
nd = not determined 
 
Table S6: In vivo phamacokinetic analysis - impact of infection on exposure profile.  
 
 Cmax 
(ng/mL) 
Tmax 
(h) 
AUCtot 
(h)*(ng/mL) 
T 1/2 
(h ) 
Clearance 
(L/h) 
Vz  
(L) 
Vss 
(L) 
1 Control 80.48 1 291.34 1.85446 80.3186 214.885 257.938 
2 Control 173 1 299.317 1.33499 78.1779 150.57 204.841 
3 Control 64.85 1 147.257 1.44923 158.906 332.241 393.892 
mean 106.11 1 245.97 1.54 105.33 232.5 285.55 
        
1 Berg 76.66 2 364.987 2.38413 64.112 220.518 306.167 
2 Berg 58.73 1 244.207 2.72154 95.8204 376.224 442.388 
3 Berg 95.02 2 262.468 1.25088 89.1536 160.89 250.662 
Mean 76.80 1.66 290.55 2.11 83.02 252.53 333.07 
Mice dosed orally with 0.75 mg RKA182 (salt) in water (16 mg/kg) at time 0     
Blood sample centrifuged and plasma sample collected and frozen     
Control = RKA mice received drug only 
Berg  = RKA mice were infected with P.berghei at approximately 4% parasitemia 
 
 
Supplementary Figures 
 
Figure S1: Main metabolic pathways in the amide tetraoxanes  
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Supplementay Data 
 
X-Ray Data for 15 (RKA182) 
CCDC 757528. C28H45N3O5, M = 503.67, colourless prism, 0.33 x 0.27 x 0.15 mm3, monoclinic, P21/c (No. 14), a = 20.387(4) 
b = 6.1810(1), c = 20.945(4) Å, β= 106.617(4)°, V = 2587.4(9) Å3, Z = 4, Dc = 1.293 g/cm3, T = 100(2)K, 17914 reflections 
collected, 6876 unique, Rint = 0.0435, Final GooF = 0.984, R1 = 0.0467, R2 = 0.1099,328 parameters, 0 restraints, µ  = 0.088 
mm-1 
 
Supplementary Materials and Methods Chemistry 
 
Preparation of ethyl 2-(4-oxocyclohexyl)acetate 8 
 
A solution of ethyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate (13 mmol) in 1M HCl (30 ml) was stirred at room temperature for 
2-4 hr.  The aqueous solution was neutralised with sodium bicarbonate and extracted with dichloromethane (3 × 15 ml).  The 
combined organic extracts were washed with brine (10 ml), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a colourless liquid.  Purification by flash column chromatography gave 8 in 94%. 1HNMR (400MHz, CDCl3) 
δH, 1.28 (t, 3H, J = 7.1 Hz, CH3), 1.43-1.56 (m, 2H, CH2), 2.06-2.13 (m, 2H, CH2), 2.32 (s, 2H, CH2CO), 2.36-2.42 ( m, 5H, 
CH2/CH), 4.15(q, 2H, J = 7.1 Hz, OCH2),  13CNMR (100MHz, CDCl3), δC 14.6, 32.7, 33.4, 40.5, 40.9, 60.7, 172.8, 211.7 MS 
(CI), [M + NH4] + (100), 202.1. 
 
Preparation of ethyl 2-(4,4-dihydroperoxycyclohexyl)acetate 9 
 
50% aq. Hydrogen peroxide (4 ml) was added to a stirring solution of 8 (6.31 mmol) in formic acid (8 ml) and acetonitrile (8 
ml) at 0 °C.  The solution was allowed to warm to room temperature and stirred for 15 min.  The solution was diluted with 
dichloromethane (30 ml) and washed with water (10 ml), saturated aq. NaHCO3 (10 ml) and brine (10 ml).  The organic phase 
was dried over MgSO4, filtered and concentrated to give 9 1HNMR (400MHz, CDCl3) δH, 1.26(t, 3H, J = 7.15Hz, CH3), 1.62(m, 
2H, cyclohexyl),1.78(m, 4H, cyclohexyl), 1.92(m, 2H, cyclohexyl),  2.22 (d, 2H, J = 13.51Hz, CH2CO), 2.4 (m, 1H, CH), 4.14 
(q, 2H, J = 7.15Hz, OCH2), 8.55 (bs, 2H, OH). 13CNMR (100MHz, CDCl3), δC 14.20, 24.78, 28.19, 41.76, 60.67, 109.58. MS 
(ES+), [M + Na] + (100), 389.1 [2M + Na] + 257.3 
 
Preparation of ethyl dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-ylacetate 10 
 
A solution of 9 in DCM (10mL) was added to a stirring solution of 2-adamantanone (9.46 mmol) and rhenium (VII) oxide 
(0.13 mmol)  in DCM (10 mL) at 0 °C.  The solution was allowed to warm to room temperature and stirred for 45 min before 
being filtered through a plug of silica and the filtrate was concentrated under reduced pressure to give a white solid.  
Purification by flash chromatography on silica gel (10/90 ethyl acetate/n-hexane) gave 10 as a white solid in 48% yield. Mpt. 
60-62oC Vmax (CHCl3)/cm-1 1446.8, 1718.5, 2858.9, 2922.3, 3003.8 1HNMR (400MHz, CDCl3) δ H, 1.25(t, 3H, J = 7.31Hz, 
CH3), 1.28-1.37(m, 2H, CH2), 1.48-1.79(m, 10H, CH2), 1.87(bs, 2H, CH2), 1.91-2.20(m, 9H, CH2/CH), 2.23(d, 2H, J = 6.83Hz, 
CH2CO), 4.13(q, 2H, J = 7.21Hz, CH2)13CNMR (100MHz, CDCl3), δC 14.62, 27.48, 27.87, 34.10, 36.72, 37.37, 39.65, 41.12, 
47.38, 60.62, 107.99, 110.78, 173.00 MS (ES+), [M + Na] + (100), 389.1 [2M + Na] + 755.2 HRMS calculated for 389.1940 
C20H30O6Na found, 389.1954. 
 
Preparation of dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-ylacetic acid 11 
 
A solution of 10 (3.06 mmol) in 10% w/v potassium hydroxide/methanol (10 ml) was stirred at reflux for 90 min.  The solution 
was allowed to cool to room temperature and concentrated under reduced pressure.  The resulting residue was taken up in 
water (15 ml) and washed with diethyl ether (3 × 10 ml).  The aqueous layer was acidified with concentrated hydrochloric acid 
and a white precipitate formed.  Diethyl ether (15 ml) was added to dissolve the precipitate and the aqueous phase extracted 
with diethyl ether (2 × 10 ml).  The combined organic phases were washed with brine (10 ml), dried over Na2SO4, filtered and 
concentrated under reduced pressure to give a white solid.  Recrystallisation from ethanol gave 11 as a white solid in 94% 
yield. Vmax (CHCl3)/cm-1 991.8, 1057.5, 1446.7, 1694.3, 2844.0, 2924.8, 3005.7 3355.7. 1HNMR (400MHz, CDCl3) δH, 1.22-
1.46(m, 2H, CH2), 1.50-1.90(m, 12H, CH2), 1.01-2.05(m, 4H, CH2), 2.06-2.15(m, 5H, CH), 2.29(d, 2H, J = 6.83Hz, CH2CO). 
13CNMR (100MHz, CDCl3), δ C 27.47, 27.84, 33.52, 33.86, 36.69, 37.35, 39.65, 40.75, 47.34, 108.89, 110.79, 178.23. MS 
(ES+), [M - H] + (100), 337.2 HRMS calculated for 337.1651 C18H25O6 found, 337.1663. 
 
Preparation of amide tetraoxanes 12-18 
General procedure 
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To a solution of the acid 11 (0.89 mmol) in dry DCM (20 mL), with added triethylamine (1.34mmol, 1.5 eq) and 
ethylchloroformate (0.89mmol, 1.0 eq). The reaction was stirred for 60 minutes at 0oC. (0.89 mmol, 1.0 eq) of the required 
amine was added, and after 30 minutes of stirring the reaction mixture was warmed to room temperature. After 90 minutes, it 
was diluted with water and extracted with DCM. The organic extracts were washed with brine, dried over anhydrous Na2SO4. 
The crude products were purified by flash column chromatography.  
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)-1-(4-
isobutylpiperazin-1-yl)ethanone 12 
The general procedure above was followed to give 12 as a white solid in 87% yield. 1H NMR (400MHz, CDCl3) δH, 0.89 (m, 
6H, J = 6.46Hz, CH3), 1.17-1.36 (m, 2H, adamantylidene), 1.50-1.84 (m, 14H, adamantylidene/CH2), 1.86 bs, 2H, CH2), 1.90-
2.04 (m, 6H, CH), 2.08 (d, 2H, J = 7.40Hz, CH2CO), 2.20-2.27 (m, 2H, NCH2), 2.35 (t, 4H, CH2N), 3.45(t, 2H, J = 4.74Hz, 
NCH2), 3.62(t, 2H, J = 4.74Hz, NCH2). 13C NMR (100MHz, CDCl3), δC 21.2, 25.8, 27.4, 33.5, 34.4, 37.3, 39.4, 42.1, 46.3, 
53.7, 54.2, 67.2, 108.2, 110.8, 170.7. MS (ES+), [M + Na] + (100), 463.3 HRMS calculated for 463.3172 C26H43O5N2Na, found 
4632.3187. Elemental analysis C: 67.62, H: 9.18, N: 6.09 (required values C: 67.50, H: 9.15, N: 6.06). 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan] 
-4-yl)-1-(morpholin-4-yl)ethanone 13 
The general procedure above was followed to give 13 as a white solid in 81% yield. Mpt. 139-140 oC υmax (CHCl3)/cm-1 1442.3, 
1632.5, 2858.9, 2913.2, 3003.8 1H NMR (400MHz, CDCl3) δH, 1.11-1.38 (m, 2H, CH2), 1.50-1.82 (m, 12H, CH2), 1.85 (bs, 2H, 
CH2), 1.90-2.18 (m, 5H, CH), 2.30 (d, 2H, J = 7.0 Hz, CH2CO), 3.46 (t, 2H, J = 4.6 Hz, NCH2), 3.60-3.69 (m, 6H, 
NCH2/CH2O) 13C NMR (100MHz, CDCl3), δC 27.5, 28.9, 33.5, 33.6, 34.3, 37.4, 39.2, 42.4, 46.6, 67.3, 108.1, 110.8, 170.9 MS 
(ES+), [M + Na] + (100), 430.2 [2M + Na] +, 837.4 HRMS calculated for 430.2206 C22H33O6NNa, found 430.2213. Elemental 
analysis C: 65.10, H: 8.18, N: 3.39 (required values C: 64.84, H: 8.16, N: 3.44) 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)-1-[4-(morpholin-4-
yl)piperidin-1-yl]ethanone 14 
The general procedure above was followed to give 14 as a white solid in 88% yield. 1H NMR (400MHz, CDCl3) δH 1.20-2.03 
(m, 20H, CH2), 2.24 (bs, 2H, CH2), 2.40 (m, 1H, CH), 2.56 (bs, 6H, CH2), 2.78 (m, 1H, CH), 3.01 (t, 2H, J = 11.5 Hz, CH2), 
3.72 (t, 6H, J = 4.6 Hz, CH2), 3.91 (d, 2H, J = 13.6 Hz, CH2), 4.65 (d, 2H, J = 11.4 Hz, CH2) 13C NMR (100MHz, CDCl3), δC  
27.5, 28.5, 29.4, 33.5, 34.4, 37.4, 39.4, 41.3, 45.4, 50.2, 62.3, 67.5, 108.2, 110.8, 170.6 MS (ES+), [M + H ] + (100) 491.3 
HRMS calculated for 491.3121C28H42O6N2, found 491.3127. Elemental analysis C: 65.96, H: 8.55, N: 5.67 (required values C: 
66.10, H: 8.63, N: 5.71). 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)-1-[4-(4-
methylpiperazin-1-yl)piperidin-1-yl]ethanone 15 
The general procedure above was followed to give 15 as a white solid in 86% yield. Mpt. 128-130 oC. 1H NMR (400MHz, 
CDCl3) δH 1.20-2.07 (m, 27H, CH/CH2), 2.23 (bs, 2H, CH2), 2.28 (s, 3H, NCH3), 2.36-2.68 (m, 7H, CH/CH2), 3.00 (t, 2H, J = 
11.1 Hz, CH2), 3.90 (d, 2H, J = 11.0 Hz, CH2), 4.65 (d, 2H, J = 13.4 Hz, CH2). 13C NMR (100MHz, CDCl3), δC 27.5, 28.6, 29.6, 
33.5, 34.4, 37.3, 39.4, 41.5, 45.5, 46.4, 49.5, 55.7, 62.1, 108.2, 110.8, 170.5. MS (ES+), [M + H ] + (100) 504.4 HRMS 
calculated for 504.3437 C28H46O5N3, found 504.3426. Elemental analysis C: 66.44, H: 9.06, N: 8.34 (required values C: 66.77, 
H: 9.04, N: 8.30). 
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Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)-1-[4-(1-
methylpiperidin-4-yl)piperazin-1-yl]ethanone 16 
The general procedure above was followed to give 16 as a white solid in 88% yield. 1H NMR (400MHz, CDCl3) δH 1.26 (bs, 
2H, adamantylidene), 1.52-2.07 (m, 27H, CH/CH2), 2.26 (bs, 6H, CH/CH2), 2.56 (t, 4H, J = 4.5Hz, CH2), 2.90 (d, 2H, J = 11.9 
Hz, CH2), 3.46 ( t, 2H, J = 3.8 Hz, CH2), 3.62 (t, 2H, J = 3.8 Hz, CH2) 13C NMR (100MHz, CDCl3), δC  27.5, 28.5, 33.5, 34.3, 
37.3, 39.3, 42.3, 46.5, 49.4, 49.7, 55.7, 61.9, 108.2, 110.8, 170.6 MS (ES+), [M +H ] + (100) 504.3 HRMS calculated for 
504.3437 C28H46O5, found 504.3462. Elemental analysis C: 66.68, H: 9.03, N: 8.33 (required values C: 66.77, H: 9.04, N: 
8.30). 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan] 
-4-yl)-N-[2-(pyrrolidin-1-yl)ethyl]acetamide 17 
The general procedure above was followed to give 17 as a white solid in 76% yield. Mpt. 142-144oC. Vmax (CHCl3)/cm-1 
1446.7, 1559.9, 1641.1, 2859.1, 2931.2, 2937.7, 3260.8 1HNMR (400MHz, CDCl3) δH 1.19-1.35(m, 2H, CH2), 1.50-1.83(m, 
14H, CH2), 1.83-1.89(m, 4H, CH2), 1.90-2.04(m, 5H, CH), 2.12(d, 2H, J = 7.02Hz, CH2CO), 2.50-2.67(m, 6H, NCH2/CH2N), 
3.31(q, 4H, J = 5.50Hz, CH2), 6.55(bs, 1H, NH). 13CNMR (100MHz, CDCl3), δ C 23.81, 23.83, 27.47, 27.85, 28.61, 33.52, 
33.53, 34.45, 36.69, 37.35, 37.95, 39.64, 39.80, 43.51, 47.36, 50.89, 54.29, 55.33, 55.57, 61.06, 108.12, 110.74, 172.53. MS 
(ES+), [M + Na] + (100), 457.2 [2M + Na] +, 891.3 HRMS calculated for 457.2678 C24H38O5N2Na found, 457.2680. Elemental 
analysis C: 66.29, H: 8.80, N: 6.44 (required values C: 66.33, H: 8.81, N: 6.45). 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)-1-[4-(pyrrolidin-1-
yl)piperidin-1-yl]ethanone 18 
 
The general procedure above was followed to give 18 as a white solid in 82% yield. 1H NMR (400MHz, CDCl3) δH 1.20-1.36 
(m, 4H, adamantylidene), 1.42-1.80 (m, 14H, admantylidene/CH2), 1.81-1.89 (m, 8H, CH2), 1.90-2.04 (m, 5H, 
adamantylidene/CH),  2.24 (d, 2H, J = 7.22 Hz, CH2CO), 2.62-2.73 (m, 4H, NCH2), 3.05 (t, 1H, J = 11.6 Hz, NH), 3.85 (t, 2H, 
J = 13.5 Hz, NCH2), 4.56 (t, 2H, J = 13.5 Hz, NCH2). 13C NMR (100MHz, CDCl3), δC 23.7, 27.5, 31.0, 32.0, 33.6, 34.4, 37.4, 
39.4, 40.7, 44.8, 51.7, 62.1, 108.2, 110.8, 170.5. MS (ES+), [M + Na] + (100), 475.3 HRMS calculated for 475.3172 
C27H43O5N2Na, found 475.3163. Elemental analysis C: 68.22, H: 8.90, N: 5.91 (required values C: 68.32, H: 8.92, N: 5.90). 
General procedure for the reaction of tetraoxanes with heme:  
Hemin stock solution (10 mM in 0.1 M NaOH) and acetonitrile were freshly degassed prior to use. Hemin solution (2.0 mL, 
0.02 mmol) was added to a suspension of tetraoxane RKA099 (10.0 mg, 0.02 mmol, 1 equiv.) and dithionite (41 mg, 0.20 
mmol, 10 equiv.) in acetonitrile (2.0 mL) under argon. The mixture was stirred at room temperature. TLC monitoring showed 
that all the starting peroxide was consumed within 20 min. the crude mixture was analyzed by RP-HPLC. 
HPLC analysis conditions: Column: C18-Reversed phase preparative column; Gradient: From 70% MeOH/0.1% TFA to 100% 
MeOH/0.1% TFA over 60 min; Flow rate: 0.5 mL/min ; Wavelength: 430 nm. 
 
In Vitro Antimalarial Screening 
 
Cultures were grown in flasks containing human erythrocytes (2-5%) with parasitemia in the range of 1% to 10% suspended in 
RPMI 1640 medium supplemented with 25 mM HEPES and 32 mM NaHCO3, and 10% human serum (complete medium). 
Cultures were gassed with a mixture of 3% O2, 4% CO2 and 93% N2. Antimalarial activity was assessed with an adaption of 
the 48-h sensitivity assay of Desjardins et al. using [H]-hypoxanthine incorporation as an assessment of parasite growth.1 Stock 
drug solutions were prepared in 100% dimethylsulphoxide (DMSO) and diluted to the appropriate concentration using 
complete medium. Assays were performed in sterile 96-well microtitre plates, each plate contained 200 µl of parasite culture 
(2% parasitemia, 0.5% haematocrit) with or without 10 µl drug dilutions. Each drug was tested in triplicate and parasite growth 
compared to control wells (which consituted 100 % parasite growth). After 24-h incubation at 37oC, 0.5 µCi hypoxanthine was 
added to each well. Cultures were incubated for a further 24 h before they were harvested onto filter-mats, dried for 1 h at 
55oC and counted using a Wallac 1450 Microbeta Trilux Liquid scintillation and luminescence counter. IC50 values were 
calculated by interpolation of the probit transformation of the log dose - response curve. 
 
In vivo Antimalarial Screening 
 
In vivo data was determined using 30 mg/kg oral (po) and subcutaneous (sc) doses in a 4–days Peter’s test.2 For subcutaneous 
administration, compounds were dissolved in 10% dimethylsulfoxide (DMSO) 0.05% Tween 80 (Sigma, Dorset, UK) in 
distilled water. For oral admistration, compounds were dissolved in standard suspending formula (SSV) [0.5% sodium 
carboxymethylcellulose, 0.5% benzyl alcohol, 0.4% Tween 80, 0.9% NaCl (all Sigma)]. Subcutaneous (s.c) or oral (p.o) 
treatment was done with 0.2ml of a solution of the test compound two hours (day 0) and on days 1, 2, and 3 post infections. 
Parasitaemia was determined by microscopic examination of Giemsa stained blood films taken on day 4. Microscopic counts 
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of blood films from each mouse were processed using MICROSOFT@EXCELL spreadsheet (Microsoft Corp.) and expressed 
as percentage of inhibition from the arithmetic mean parasitaemias of each group in relation to the untreated group. 
Experiments described in Table S5 were generated at the Swiss Tropical and Public Health Institute with a slightly modified 
methodology. NMRI mice were infected intravenously on day 0 with the Plasmodium berghei GFP ANKA malaria strain (2 × 
107 parasitized erythrocytes, donation from AP Waters and CJ Janse, Leiden University). The mice were treated orally with 
either three doses (24, 48, and 72 h post-infection) or a single dose (24 h post-infection) of compound with a volume of 10 
mL/kg. Blood parasitemia levels were determined by FACS analysis. 
 
In vivo pharmacokinetic methods 
 
Dimethylsulphoxide (DMSO) was obtained from Fisher (UK).  Tetraglycol was obtained from Sigma-Aldrich (UK).  Ethanol 
was obtained from Hayman (UK) and sterile saline (0.9%, w/v) was obtained from Baxter (UK).All other chemicals used on 
this study were reagent grade or higher and were obtained from standard commercial suppliers. 
Seventy-eight male Sprague Dawley rats, aged 8-12 weeks, were supplied by Charles River (UK) Limited and surgically 
prepared with an indwelling femoral vein cannula.  After a post-surgery recovery period of at least 5 days and prior to dose 
administration, a pre-study health evaluation was conducted on these animals and the results were found to be satisfactory.A 
standard laboratory diet and mains tap water were available ad libitum to the animals.Clinical signs were monitored at regular 
intervals throughout the study in order to assess any reaction to treatment. 
 
Intravenous Dose Formulation and Administration 
For intravenous administration, the test items were formulated as solutions in 5% DMSO, 5% ethanol, 50% tetraglycol and 
40% sterile saline (v/v/v/v) to achieve the intravenous target concentrations of 1 mg/mL.  The weight of each formulation was 
recorded in order to determine the theoretical dose concentration.  Each intravenous formulation was administered to a group 
of three animals as a slow bolus over ca 30s via a tail vein at a target dose volume of 1 mL/kg to achieve a target dose level of 
1 mg/kg.  The dose volume administered was calculated according to the body weight of the animals on the day prior to 
administration. Three aliquots of each formulation (100 µL) were taken on completion of dose preparation and stored at ca -
80°C. 
 
Oral Dose Formulation and Administration 
For oral administration, the test items were formulated as solutions in 5% DMSO, 5% ethanol and 90% tetraglycol (v/v/v) to 
achieve final target concentrations of 10 mg/mL.  The weight of each formulation was recorded in order to determine the 
theoretical dose concentration.Each oral formulation was administered to a group of three animals via gastric gavage at a target 
dose volume of 1 mL/kg to achieve a target dose level of 10 mg/kg.  The dose volume administered was calculated according 
to the body weight of the animals on the day prior to administration.  Three aliquots of each formulation (100 µL) were taken 
on completion of dose preparation and stored at ca -80°C. 
All blood samples (ca 0.5 mL) were collected into glass tubes containing lithium heparin as an anti-coagulant from each 
animal via the femoral vein cannula at the following sampling times post dose: 0.25, 0.5, 1, 2 and 6 h post intravenous dose 
and 0.5, 1, 2, 4 and 6 h post oral dose. As soon as practically possible, each sample was centrifuged at 3000 r.p.m. for 10 min 
at ca 4°C.  Plasma was separated and transferred into glass tubes.  Plasma samples were stored frozen at ca -80°C prior to 
analysis.For each analysis batch, a calibration series of samples containing the test item (analyte) of interest were prepared 
using 50 µL of control plasma to give a range of concentrations generally 1 to 1000 ng/mL. The standards were prepared and 
analysed in batches along with freshly prepared blank samples. Plasma (50 µL) samples and standards were analysed and 
prepared for each analyte using a method based upon protein precipitation with acetonitrile containing and internal standard, 
Nifedipine (added at a matrix concentration of 100 ng/mL).  An aliquot of the supernatant was analysed by reverse phase LC-
MS/MS using a heat assisted electrospray interface in negative ion mode.  The intravenous and oral pharmacokinetics of each 
test item in male rats were characterised using mean plasma concentration vs time data.  The pharmacokinetic parameters C0, 
Cmax(obs), Tmax(obs), AUC(0-t), AUC(0-∞), T½, CL, CL/F and F were estimated using WinNonLin v4.1 pharmacokinetic software. 
 
Speed of action  
Swiss outbred 18-20g male CD-1 mice (Charles Rivers, UK) were kept in specific pathogen-free conditions and fed ad libitum. 
Mice were infected intravenously with 4 x 106 P. berghei NY infected red cells obtained from donor mice, randomized and 
divided in groups of five mice (day 0).  RKA182 or artesunate (ASN) were dissolved in standard suspending formula (SSV) 
[0.5% sodium carboxymethylcellulose, 0.5% benzyl alcohol, 0.4% Tween 80, 0.9% NaCl (all Sigma)] and administered by 
oral gavage in a single oral dose on day two post-infection. Parasitaemias were determined by microscopic examination of 
Giemsa stained thin blood films at 0, 0.5h, 1h, 2h, 2.5h, 6h, 8h, 24h, 48h post-treatment and the microscopic counts for each 
mouse processed using MICROSOFT ® EXCEL, and plotted as the arithmetic mean parasitaemia versus time.  
 
Additional Information 
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A full toxicological profile has been carried out on tetraoxane 15. The compound recorded no positive responses in the Ames 
test showing no mutagenicity in strains of Salmonella typhimurium and Escherichai coli, was found not to be clastogenic when 
tested with Chinese hamster ovary cells in vitro and demonstrated no potential to induce forward mutation in mouse lymphoma 
cells. Single dose oral toxicity experiments in Sprague-Dawley rats gave a maximum tolerated dose of 400 mg/kg. The cardiac 
toxicity (QT interval prolongation) was also evaluated by the conventional whole-cell patch-clamp technique by recording 
outward potassium currents [human Ether-a-Go-go related gene (hERG)] from single cells of HEK-293. An IC50 of greater 
than 10 uM was observed and testing of 15 against the multidrug resistant cancer cell line KB gave an IC50 of greater than 21 
mM giving the compound a therapeutic index (TI) of greater than 14,000 (See Table S2). Compound 15 also did not inhibit 
any of the major human cytochrome P450’s with all IC50s greater than 20 mM and most above 100 mM.  
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Identification of the First 1,2,4,5-
Antimalarial Tetraoxane Drug-
Development Candidate (RKA 182) 
with Superior Properties to the Semi-
Synthetic Artemisinins 
 
 
From a library of over 150 1,2,4,5-tetraoxanes we have candidate selected a 
molecule, RKA182, for full formal preclinical development. RKA182 has outstanding 
in vitro activity against sensitive and resistant strains of P.falciparum (IC50=1.1 nM 
(K1), 0.8 nM (3D7)) and retains this level of activity against South East Asian 
isolates that failed ACT combination chemotherapy.  The drug candidate has a fast 
rate of parasite kill, superior in vivo activity to artesunate (ED50=1.33 mg/kg and 
ED90=4.18 mg/kg) in rodent models of malaria and improved DMPK characteristics 
and stability in the presence of infected red blood cells when compared to synthetic 
ozonides or semi-synthetic artemisinins.   
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Abstract: 
The 1,2,4‐trioxane core structure of artemisinin is essential for its activity. It was shown 
that iron(II) catalyses the reductive cleavage of the peroxide bond of the drug, leading to 
the  formation of C‐centered radicals. These  radicals are able  to alkylate heme resulting 
from host  cell  hemoglobin digestion,  and parasitic  proteins. These alkylation processes 
are believed to induce parasite death.  
In the present work, we studied the two main mechanisms proposed in the literature for 
artemisinin, namely heme alkylation and PfATP6 inhibition. In addition, we also explored 
the possible bio‐activation of artemisinin by copper enzymes.   
We  report  our  investigation  into  the  reactivity  of  metal  salts  and  complexes,  such  as 
heme,  toward highly active antimalarial peroxide‐containing drugs, namely artemisone, 
trioxaquines, trioxolanes, and tetraoxanes. 
Overall, our results with heme confirmed that the alkylating properties of artemisinin, in 
particular  in  malaria‐infected  mice,  are  not  limited  to  this  natural  compound,  but  are 
shared with other potent peroxide‐containing drugs. It is likely that heme alkylation plays 
a very important role in their anti‐plasmodial mechanism of action. 
In  this  work,  we  also  considered  an  alternative  mechanism  of  action  for  artemisinin, 
based on the inhibition of PfATP6. The main result is that the predicted binding affinity of 
the tested compounds does not correlate with their in vitro antimalarial activity. 
 
Key words: Malaria / Treatment / Antimalarial peroxides / Artemisinin / Trioxaquines / 
Tetraoxanes / Heme / Alkylation / PfATP6 / Modelling 
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Résumé : 
Le cycle 1,2,4‐trioxane de l’artémisinine est essentiel pour son activité antipaludique. Le 
fer(II) peut catalyser la réaction de réduction de la liaison peroxyde de l’artémisinine et 
conduire  à  la  formation  de  radicaux.  Ces  radicaux  alkylent  l’hème  libéré  lors  de  la 
dégradation  de  l’hémoglobine  par  Plasmodium  pour  former  des  produits  de  couplage 
appelés adduits hème‐artémisinine. Ce processus d’alkylation pourrait être directement 
ou  indirectement  responsable  de  la  mort  du  parasite.  La  connaissance  du  mécanisme 
d’action de l’artémisinine est le point de départ de ce projet de thèse qui se divise en deux 
parties distinctes. La première partie consiste à étudier le rôle de complexes métalliques, 
l’hème  en  particulier,  dans  le  mécanisme  d’action  in  vitro  et  in  vivo  de  nouveaux 
peroxydes  synthétiques  ou  hémi‐synthétiques  (artémisone,  trioxaquines,  trioxolanes  et 
tétraoxanes).  Nous  avons  caractérisé  des  adduits  hème‐drogue  dans  tous  les  cas,  et 
econfirmé l’importance de l’hème dans l’activité antipaludique d  ces molécules. 
Une  étude  de  docking  a  également  été  réalisée  entre  ces  molécules  et  la  protéine 
parasitaire PfATP6 présentée dans la littérature comme une autre cible de l’artémisinine. 
Les  principaux  résultats  de  notre  étude  montrent  qu’il  n’y  a  pas  de  corrélation  entre 
l’affinité pour la protéine PfATP6 et l’activité in vitro des molécules testées. 
 
Mots clés : Paludisme / Traitement / Peroxydes antipaludiques / Artémisinine  / 
Trioxaquine  Alkylation / PfATP6 / Modélisation s / Tétraoxanes / Hème /
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